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ABSTRACT  
 
Skin cancer is the one of the most diagnosed cancers in the United States with increasing 
incidence of 6% every year. In 2015, it is estimated 73,870 new cases of melanoma will 
be identified and 9,480 individuals will die of their disease. While melanoma only 
accounts for approximately 2.4% of all cancer related deaths and is the 5th leading 
diagnosed cancer (US) it is the one of the most common cancers in young adults, age 25-
29, particularly for young women. Of particular importance, the mean survival rate of 
patients diagnosed with metastatic melanoma is six months, with five-year survival rates 
of less than 5%.   
 One reason for the increasing incidence in young adults may be due to the use of 
indoor tanning. UV exposure causes DNA damage and can induce the activation of a 
metabolic pathway called autophagy. Autophagy is activated by stress, including DNA 
damage, and melanoma risk is associated with UV exposure. 
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 Here I present three studies investigating oncogene differences in rates of 
autophagy as well as the relationship of UV exposure and genotypic variants to 
autophagy.  In this project, I determine whether oncogene status in melanoma 
differentially regulates apoptosis by modifying autophagic flux.  The central hypothesis 
of this project is that cutaneous malignant melanomas (CMM) with BRAF mutations may 
be autophagy-addicted while tumors with NRAS mutations may be less dependent on 
autophagy.  
 I found that BRAF/NRAS mutations differentially alter autophagic flux to suppress 
apoptosis in melanoma.  Our results show that oncogene status in melanoma correlates 
with differential regulation of autophagic flux and that inhibition of autophagy in BRAF 
mutant melanoma cells results in apoptosis. These data suggest that BRAF mutant 
melanoma cells suppress apoptosis by modifying autophagic flux and that these cells may 
be autophagy addicted in order to promote survival. 
 I also determined that proxy autophagy markers LC3 and Beclin1 are associated 
with UV exposure and clinical stage when evaluating tissue sections from melanoma 
patients and controls. Surprisingly, the NRAS wide-type sections had elevated LC3 levels 
when compared to the NRAS mutant tissue sections suggesting that autophagy may be 
inhibited NRAS in melanoma tumors. These results indicate that autophagic flux varies by 
tumor stage and is associated with UVR exposure.  
 Finally, I also determined that several SNPs in autophagy related genes are 
melanoma prognostic indictors.   Of note, one SNP that has previously been shown to be 
inversely associated with other diseases, with a functional variant which increases disease 
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susceptibility was inversely associated with Breslow thickness, the most important 
indicator of melanoma outcome. 
 The work from my study helps address the inconsistencies in the literature 
regarding autophagy’s impact on melanoma progression.  Furthermore, these studies 
provide a basis to investigate the role ATG gene SNPs, UV exposure and in autophagy 
and melanoma.   
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CHAPTER ONE: INTRODUCTION 
 
APOPTOSIS AND AUTOPHAGY: THE YIN-YANG OF HOMEOSTASIS IN CELL 
DEATH IN CANCER 
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1.1 ABSTRACT 
 Apoptosis and autophagy are physiologically necessary pathways which are vital 
for cell homeostasis. Apoptosis facilitates type I programmed cell death, while 
autophagic survival mechanism counteracts apoptosis. Dysregulation in the homeostatic 
balance between these two essential cellular pathways has been linked to various 
diseases. We review relevant Janus molecules and their interactomes, as well as 
lysosomes which play multiple roles in apoptosis and autophagy, and to discuss how 
targeted interventions can be used in cancer prevention and/or therapy. 
1.2 INTRODUCTION 
 Apoptosis and autophagy are both normal, genetically and biochemically 
regulated, and physiologically necessary pathways which are vital for cell homeostasis.  
Like two sides of a coin, apoptosis facilitates purposeful suicide by tightly controlled 
reactions followed by phagocytosis, while autophagy usually counteracts apoptosis and 
affords a survival mechanism for stressed cells until exaggerated stress or nutrition 
depletion forces the cells to compromise. Interestingly, compromised cells may use 
autophagy as a type II programmed cell death mechanism to die. Dysregulation in the 
balance between these two essential cellular pathways has been reported to be significant 
in the onset and pathogenesis of almost all diseases.  Work from my laboratory research 
and others has shown that inhibition of autophagy induces cell death in many cancer cell 
types and chemical and genetic inhibition of autophagy increases apoptotic cell death. 
Disrupted regulation of autophagy creates an environment that facilitates the initiation 
and progression of many diseases including cancer. In addition, this deregulation is 
associated with increased cancer risk, particularly for pancreatic, colorectal, and breast 
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cancer (Gukovsky et al., 2013). The goal of this article is twofold:  (1) to review relevant 
Janus molecules and their interactomes, as well as lysosomes which play multiple roles in 
apoptosis and autophagy, and (2) to discuss how targeted interventions can be used in 
cancer prevention and/or therapy. 
1.3 APOPTOSIS (THE YIN) 
 Apoptosis or type I programmed cell death is an ATP-dependent, multi-step 
process which occurs in response to both internal (intrinsic) and external (extrinsic) 
signals and as part of normal cell development and homeostasis (Figure 1) (Elmore, 
2007). Hallmark characteristics of apoptosis in the conserved, late stage include the 
appearance of phosphatidylserine (PS) on the outer leaflet of the cell membrane that is 
recognized by neighboring cells/macrophages which then rapidly phagocytose cells 
displaying PS (Li et al.,2003). Other key features of late-stage apoptosis include an intact 
membrane with signs of blebbing/membrane protrusions, cellular condensation, 
chromatin condensation, and site-specific DNA fragmentation (Coleman et al., 2001). In 
so processing, apoptosis does not result in inflammation and/or tissue damage as is 
typical of necrosis which is acute, unregulated, and accidental cell death.  The intrinsic 
apoptotic signaling pathway is dependent on the formation of apoptosome, an 
interactome of apoptotic protease activating factor 1 (Apaf-1), (pro-) caspase 9, 
cytochrome C and (d) ATP (Zou et al., 1997). While the extrinsic pathway utilizes 
transmembrane death receptors (for example FasR, tumor necrosis factor receptor 1 
(TNFR1), DR3, and DR4/DR5) (Bazzoni and Beutler, 1996), and their corresponding 
ligands (for example, FasL, TNF-α, Apo3L, and Apo2L) (Elmore, 2007). Apoptosis takes 
place in four sequential stages: stimulus, signaling, regulation, and execution. Stimulus 
 
 
4 
 
occurs in response to ligand-receptor interaction, which is extrinsic, or intracellular stress, 
which is intrinsic; an example of which is genomic toxicity. Subsequently, regulatory 
proteins, such as p53, Bcl-2, Inhibitors of APoptosis (IAPs), and signaling interactomes, 
such as apoptosome, fine tune this dynamic process, and then a group of Cysteine-
activated ASPartate-specific proteASES (Caspases) will be activated and used for 
cleaving critical proteins in cell structure, survival and proliferation. The inability to 
eliminate cells with genomic instability or aberrant proliferation through apoptotic 
mechanisms can eventually lead to the development of cancer. This inability to eliminate 
cells is often associated with the loss of function of p53, a tumor suppressor protein 
which is important in the signaling stage of apoptosis (Yu and Zhang, 2005). When p53 
gets activated, it prevents the cell from replicating by stalling the cell at the G1 and G2/M 
cell cycle checkpoints. Characteristic uncontrolled cellular proliferation, known as 
hyperplasia, and a lack of clearance of these cells leads to accumulation of genetic and/or 
epigenetic mutations, to transform proliferating cells into invasive, malignant cells.  
1.4 AUTOPHAGY (THE YANG) 
 Autophagy is a catabolic process, which utilizes lysosomal hydrolases to recycle 
and degrade cytosolic components, proteins, and other macromolecules and organelles in 
response to nutrient depletion and other stresses (Figures 2 and 3) (Rikiishi, 2012). The 
word autophagy literally means “eating of the self”; this process involves the cell 
digesting its own intracellular components to reallocate nutrients as a means of survival 
during nutritional deprivation. Autophagy is important during normal development as 
well as in response to environmental stimuli and is vital to the maintenance of cellular 
homeostasis and, unlike apoptosis, can be reversible. Autophagy rids the body of aged 
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and damaged organelles and can help in the elimination of pathogens. While autophagy 
references typically focus on macroautophagy, other types of autophagy, including 
microautophagy and chaperone-mediated autophagy, share the same lysosomal 
degradation mechanism but differ in the way that material is delivered to the lysosome 
(Mizushima, 2007; Sahu et al., 2011). 
Similar to apoptosis, autophagy has several characteristic features, including the 
formation of distinct cellular interactomes and structures (e.g., isolation 
membrane/phagophore, autophagic vesicles).  It has three major phases: initiation, 
elongation and completion.  Initiation involves the formation of a double membrane 
structure (from isolation membrane to autophagosome) which captures both the 
cytoplasm and organelles and then fuses with endosomes and lysosomes (becoming the 
amphisome and the autolysosome, respectively) which degrades the contents of the 
vesicle. The formation of this double membrane structure is a complex process involving 
many AuTophaGy-related proteins (Atgs) (Schmid and Münz, 2007). Currently, over 30 
genes encoding Atgs have been identified, including the microtubule-associated protein 
light-chain 3 (LC3). LC3, a homologue of yeast Atg8, is required for the formation of 
autophagosomal membranes. LC3 is recruited to the isolation membrane, which will 
ultimately develop into the autophagosome where cellular targets are sequestered in 
preparation for degradation. The autophagosome will then fuse with endosomes/ 
lysosomes to create the autolysosome where cellular targets are degraded (Hippert, 
2006). Under nutrient-deprived conditions, autophagy can be induced at the 
transcriptional and post-translational level. With regard to post-translational protein 
modifications, LC3, for example, exists in both a (normal) cytoplasmic and a 
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(autophagic) membrane-associated form (Kirisako et al., 1999). The process of 
incorporating LC3 to the membrane is accomplished through LC3 cleavage, lipidation 
and translocation. The LC3 designation is modified once cleavage has occurred as well as 
when the protein is localized to the membrane. Under this nomenclature, LC3-I refers to 
cytosolic localization following cleavage and LC3-II refers to a membrane bound LC3 
(Kirisako et al., 1999). Atg4, a specific cysteine protease belonging to the caspase family, 
initiates LC3 processing by post-translationally cleaving LC3’s C-terminal amino acid 
(arginine) (Ichimura et al., 2000). This cleavage generates LC3-I. The newly exposed C-
terminal glycine (Gly 116) is bound by phosphatidylethanolamine (PE), a lipid 
constituent of plasma membranes, lipidation occurs next resulting in the formation of 
LC3-II. Atg4 can also act by delipidating LC3 at the lysosomal fusion step and during 
apoptosis Atg4 is cleaved by caspase-3 becoming highly toxic (Betin et al., 2009).  
LC3-II associates with both the inner and outer membranes of the isolation membrane. 
Transient conjugation of LC3 to the autophagosomal membrane through an ubiquitin like 
system is essential for macroautophagy.  The conversion of LC3-I to LC3-II has been 
used as an indicator of autophagic state in in vitro model systems (Mizushima et al., 
2010). The biochemical reactions involved in LC3 cleavage, lipidation, and translocation 
to the isolation membrane are defining features of this type of autophagy. Autophagy 
uses two conjugation systems similar to the ubiquitin targeting system. For comparison, 
ubiquitin directs proteins targeted for degradation to the proteasome and is activated by 
an E1 enzyme. Following activation, E1 transfers the activated ubiquitin to E2 enzymes 
and then with E3 enzymes catalyzes the conjugation of ubiquitin to substrates. Important 
binding residues on LC3 can function in an ubiquitin-like fashion and LC3’s crystal 
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structure demonstrated folds similar to ubiquitin, illustrating the resemblance of these two 
proteins in structure (Sugawara et al., 2004; Suzuki et al., 2005). Therefore, terms 
ubiquitin-like, E1-like, E2-like and E3-like are applied to these autophagic ubiquitin-like 
systems that produce the conjugated proteins (LC3-II-PE and Atg5-Atg12-Atg16L), 
which play a role in autophagosome formation, elongation and completion. In brief, the 
LC3 targeting system works with LC3 acting as the ubiquitin-like protein that is 
transferred to phosphatidylethanolamine (PE), while Atg7 functions in the same manner 
as an E1 enzyme;  Atg3 like an E2 enzyme and the Atg12-Atg5-Atg16L complex like an 
E3 ligase for the LC3-II–PE complex (Figure 4).  Residues Phe 77 and Phe 79 are 
located on one surface of Atg8, and residues Tyr 49 and Leu 50 are on the opposite 
surface. Researchers have shown that Phe 77 and Phe 79 recognize Atg4, which can also 
act as a de-ubiquitination enzyme. Residues Tyr 49 and Leu 50 act downstream of 
lipidation (Amar et al., 2006) (Figure 5). In addition, these multi-complex interactions 
potentially facilitate the loading of large proteins into a developing autophagosome 
(Bjorkoy et al., 2005). Upstream of the LC3-II-PE linkage, Atg12 is conjugated to Atg5 
to form a stable Atg12-Atg5 conjunction. This process is mediated by Atg7, an E1-like 
activating enzyme, and Atg10, an E2-like conjugating enzyme. Atg16 then forms a 
complex with the Atg12–Atg5 conjugate (Mizushima et al., 2002). 
The isolation membrane structure serves as both a signaling platform and a compartment 
for holding targeted proteins. Autophagy requires precise signaling and sorting of cargo 
in order to transport the appropriate materials to the autophagosome for degradation and 
recycling. The induction of autophagy causes the translocation of proteins like LC3 to the 
isolation membrane from the cytosol. During the elongation of the isolation membrane, 
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the Atg5-Atg12-Atg16L complex localizes to the membrane to form a cup-shaped 
structure. LC3-II then localizes to the isolation membrane, while the Atg5-Atg12-Atg16L 
complex dissociates. Autophagosome formation occurs and finally the autophagosome’s 
outer membrane fuses with lysosomes to form the autolysosome which can then degrade 
targeted contents. LC3 is the only protein that remains associated with the completed 
autophagosome. Following autolysosomal formation, lysosomal hydrolases, including 
cathepsins, degrade the targeted proteins, while cathepsins degrade LC3-II on the inner 
autophagosomal surface.  Following target degradation, Atg4 is involved in separating 
outer membrane LC3-II from the autophagosome, although LC3-II is still present in late 
autophagic vesicles (Mizushima et al., 2010).  
 Derailed autophagy has been associated with many diseases including cancer, 
neurodegenerative disease, and cardiovascular disease (Shintani and Klionsky, 2004). 
Important crosstalk between apoptosis and autophagy has been identified in colorectal 
cancer with possible therapeutic implications including the use of a new class of 
anticancer agents, histone deacetylase (HDAC) inhibitors, which induce autophagy. 
Autophagy has been shown to be induced in hormone-sensitive prostate cancer cells 
either by incubation in androgen deficient medium or by treatment with an androgen 
inhibitor (Kaini et al., 2012). These findings suggest that autophagy protects prostate 
cancer cells during androgen deprivation allowing the cells to survive nutrient depletion. 
Conversely, investigators were able to show that induction of autophagy has a pro-death 
role in pancreatic cancer cells (Mujumdar and Saluja, 2010). Pancreatic tumors have been 
shown to have elevated autophagy under basal conditions and studies involving 
autophagy inhibition using either selective inhibitors (chloroquine) or RNA interference 
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of essential autophagy genes appear to influence sensitivity to chemotherapy. In addition, 
autophagy appears to play multiple roles in pancreatic cancer as a higher LC3 expression 
in pancreatic cancer tissue is associated with enhanced expression of the hypoxia marker 
carbonic anhydrase IX in the peripheral area, correlating with poor outcome and shorter 
disease-free period (Kang et al., 2012). Moreover, melanoma cell lines have also been 
shown to exhibit high basal levels of both p62 and LC3II (Xie et al., 2013) and cutaneous 
malignant melanoma cells display high overall levels of autophagy (Lazova et al., 2010) 
suggesting that autophagy may provide an active metabolic state for invasive melanoma 
tumors.  
1.5 P53 IN APOPTOSIS AND AUTOPHAGY 
 P53, a sequence-specific DNA binding protein, is a sensor of both DNA and 
cellular stress and is commonly called the guardian of the genome for its ability to 
regulate the cell cycle. The Janus or bi-functional role of p53 is illustrated by the ability 
of this protein to both trigger and inhibit apoptosis and autophagy based on its subcellular 
localization. Under normal low stress conditions, p53 is basally activated and promotes 
DNA repair and cell survival. However, under high stress conditions or in response to 
DNA damage, p53 is highly activated and upregulates cell cycle arrest and/or apoptosis. 
P53 directly affects the expression of two BH3-only proteins, Bad and (t)Bid, which are 
important regulators of both apoptosis as well as autophagy (Zhaorigetu et al., 2008).  
P53 also induces apoptosis through transcription independent mechanisms including the 
generation of reactive oxygen species (ROS) and through its direct associations with 
mitochondria. P53 interacts with several apoptogenic proteins including Bax and Fas and 
p53-dependent apoptosis typically follows the intrinsic apoptosis pathway. However, p53 
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can also influence cell death through the death receptors. P53 has the ability to activate 
the transcription of pro-apoptotic genes, including Bax, Noxa, and PUMA, and can also 
trigger apoptosis through the inhibition of anti-apoptotic genes including survivin (Mirza 
et al., 2002), which allows the activation of caspases. Conversely, in addition to its 
inhibitory characteristics, p53 also has the ability to upregulate several processes 
including the activation of the death domain receptor (DR5) for TRAIL (TNF-related 
apoptosis-inducing ligand), which is activated in response to DNA damage (Wu et al., 
1997) and induces apoptosis through caspase 8 activation. Once the TRAIL receptor 
binds its ligand, the receptor trimerizes facilitating the recruitment of pro-caspase 8 to the 
death domain as well as the Fas-associated death domain protein (FADD). These 
interactions cause the formation of a death inducing signaling complex or DISC which 
then assists in the cleavage of pro-caspase 8 into its active state (Sprick et al., 2000). An 
increase in p53 expression also enhances the levels of Fas on the cell surface by 
promoting its ability to translocate from the Golgi (Sionov and Haupt, 1999). In apoptosis 
p53 is important in the activation of the apoptosome. Upregulation of p53 is associated 
with an increase in Apaf-1 expression (Haupt et al., 2003), and can also trigger apoptosis 
through the upregulation of the pro-apoptotic Bcl-2 family members, such as Bax and 
PUMA (Fridman and Lowe, 2003). While p53 is a strong nuclear transcription factor it 
can also function in the cytoplasm where it increases mitochondrial permeability. In 
general, the basal level of cytosolic p53 is present and maintained through the ubiquitin 
proteasome pathway but at higher concentrations it may translocate into the 
mitochondria. Once in the mitochondria, p53 interacts with both Bcl-xL and Bcl-2, down 
regulating their ability to inhibit apoptosis (Tasdemir et al., 2008).  
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P53’s role in autophagy is also multifaceted. In the cytosol it operates at the 
mitochondrial level to suppress autophagy through its binding to Bcl-2 and Bax 
(Tasdemir et al., 2008), as well as potentially through its interactions with mTOR 
(Tasdemir et al., 2008). Nuclear p53 upregulates apolipoprotein L1 (ApoL1), a novel 
BH3-only, (phospho)lipid binding protein with high affinity for phosphatidic acid (PA), 
that directly interacts with mTOR to increase autophagy. P53 post transcriptionally 
down-regulates LC3 resulting in a reduction of autophagic flux (Figures 2 and 3). In 
tumors where p53 function is lost or altered through mutations, the accumulation of 
excessive LC3 may ultimately result in apoptosis. P53 helps sustain the viability of cells 
by helping to maintain homeostasis and adjusting the rate of autophagy to nutrient 
stimulus (Scherz-Shouval et al., 2010). Not only does the direct activation of p53 in cell 
lines induce autophagy but it also upregulates the expression of the Damage Regulated 
Autophagy Modulator (DRAM) gene. DRAM, a p53 target, encodes lysosomal proteins 
which upregulate autophagy (Zhaorigetu et al., 2008) (Figures 2 and 3). Chemical 
inhibition of p53 in cell lines results in the characteristic signs of autophagy including the 
depletion of p62, the presence of GFP-LC3 in the cytoplasmic vacuoles (puncta), and the 
presence of autophagosomes and autolysosomes (Tasdemir et al., 2008). In apoptosis, 
p53 can activate the pro-apoptotic proteins in a transcription-independent manner and 
DNA-damage leads to mitochondrial translocation of p53 and intrinsic pathway 
upregulation by increasing PUMA. P53 can bind directly to the Bcl-2 family member 
Bcl-xL and influence cytochrome c release through direct activation of Bax to upregulate 
apoptosis. P53 can release both pro-apoptotic multi-domain proteins and BH3-only 
proteins that are sequestered by Bcl-xL. Finally, the cross-talk between apoptosis and 
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autophagy is shown through the ability of p53 to post transcriptional inhibition LC3 by 
p53, which reduces the overall rate of autophagy ultimately causing excessive LC3 
accumulation resulting in apoptosis (Scherz-Shouval et al., 2010).  
 Targeting p53 in order to develop novel anti-cancer treatments has broad 
implications. The two major strategies include targeting of wildtype (wt.) p53 or mutant 
p53. With respect to wt. p53, drugs that activate endogenous p53 at protein or 
transcription levels through small molecules would be preferable. For example, 
Reactivation of p53 and Induction of Tumor cell Apoptosis (RITA), which binds to and 
activates p53 thereby inducing apoptosis, has shown promise in suppressing tumor 
growth in culture (Roh et al., 2010). CP-31398 was the first small molecule developed 
that increases expression of wt. p53 through the reduction of p53 ubiquitination.  In 
addition, small molecules which target p53 transcription may reduce the adverse effects 
of chemotherapy or radiation in normal proliferating cells. One such compound, Pifithrin, 
can reversibly inhibit p53 transcriptional activation, block p53 activation in normal cells, 
and thus reduce apoptosis. In targeting mutant p53, new compounds which re-activate wt. 
p53 activities through conformational changes of mutant p53 have been developed 
(Wang and Sun, 2010). For example, ellipticine, P53 Reactivation and Induction of 
Massive Apoptosis (PRIMA-1), and Mutant p53 reactivation and Induction of Rapid 
Apoptosis (MIRA-1) have been shown to induce a conformational change of mutant p53 
that revert the protein to wild type activity. Interestingly, UCN01, a bifunctional 
modulator of cyclin-dependent kinases, can arrest cancer cells harboring mutant p53 at 
the G2 checkpoint leading to cell death (Facchinetti et al., 2004). 
1.6 THE BCL-2 FAMILY MEMBERS IN APOPTOSIS AND AUTOPHAGY 
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 Bcl-2 (B cell lymphoma/leukemia type 2) is a member of a family of proteins, 
with the same name, that convey either pro- or anti-death signaling.  The interactions of 
the Bcl-2 proteins determine the fate of a cell tipping the homeostatic balance to favor 
apoptosis, or autophagic survival.   The anti-death Bcl-2 members (e.g. Bcl-2 and Bcl-
xL) suppress apoptosis and promote cell survival and mutations in the Bcl-2 gene have 
been shown to be associated with many cancers.  The BH3-only proteins which contain a 
single Bcl-2 homology (BH) domain can interact with the anti-death Bcl-2 family 
members to induce apoptosis (Tuffy et al., 2010).  These interactions also trigger 
downstream events which can ultimately permeabilize the mitochondrial membrane, 
resulting in the release of the cytochrome c and resulting in the activation of caspases 
(Figure 1) (Shintani and Klionsky, 2004). The BH3-only proteins can also propagate 
stress signals and indirectly activate Bax and Bak, the pro-death members, responsible for 
the induction of apoptosis and/or blockage of autophagy.  For example, ApoL6, a newly 
identified members of the BH3-only proteins, when overexpressed, induces apoptosis and 
blocks Beclin 1-mediated autophagy simultaneously (Liu et al., 2005; Zhaorigetu et al., 
2011) (Figures 1 and 3).  Interestingly, Beclin 1 has also been shown to be a bona fide 
BH3-only protein, however, when overexpressed, it does not induce apoptosis but rather 
autophagy (Fan et al.,2013).  On the other hand, Bcl-2 interferes with Bax or Bak 
function by forming heterodimers with them. When separated from Bcl-2, Bax or Bak 
forms homodimers or heterodimers which allow permeabilization of the mitochondrial 
membrane (Ruvolo et al., 2001). Interestingly, the interplay of Bcl-2 kinase and 
phosphatase allows for rapid and reversible regulation of Bcl-2’s activity in response to 
stress signals or damage (Ruvolo et al., 2001). Bcl-2 interacts either directly or indirectly 
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with siblings including Bik, Bid, Bim and PUMA (see below) to affect cell death and 
survival.  
 Bcl-2 also plays a Janus role regulating both apoptosis and autophagy through its 
interactions with their common proteins linking these pathways, allowing for a more 
responsive cell survival/ cell death switching mechanism. Bcl-2 inhibits both autophagy 
and apoptosis through direct binding to Beclin 1 (Jegga et al., 2011). Beclin 1 is a core 
component in the enzymatic complex phosphoinositides-3-kinase class III (PI3KC3) 
which initiates the formation of autophagosomes (Moscat and Diaz-MecoSee 2009). Bcl-
2 binding to Beclin 1 allows the survival of cells when they are deprived of their growth 
factors. Disruption of this interaction by pro-apoptotic proteins such as Bad and ApoL6 
induces autophagy (Zhaorigetu et al., 2008, Li et al., 2007). Under starvation conditions, 
the stress activated signaling molecule, c-Jun N-terminal protein kinase 1 (JNK1) 
mediates the induction of multisite phosphorylation of cellular Bcl-2. This 
phosphorylation results in the dissociation of Bcl-2 from Beclin 1 and the subsequent 
activation of autophagy (Wei et al., 2008). Other research has indicated that cells 
containing mutations in Beclin 1 inhibit its ability to bind Bcl-2 and induce autophagy 
related cell death (Pattingre et al., 2005).  
 Other findings implicate autophagy as a mechanism of resistance to anti-
angiogenic therapies in colon cancer cells supporting the importance of investigations 
into inhibitory approaches in the management of this disease (Selvakumaran et al., 2013). 
In addition, researchers have shown that autophagosomes are actively produced in 
colorectal cancer cells under nutrient starvation, and treatment with autolysosome 
inhibitors like 3-methyladenine, which inhibits autophagy by blocking autophagosome 
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formation through inhibition of PI3KC3, enhances apoptosis. Overall it appears that 
autophagy is activated in colorectal cancers both in vitro and in vivo, and may contribute 
to the cancer cell survival (Sato et al., 2007, Prabhudesai et al., 2007). Overexpression of 
the pro-survival Bcl-2 family members, for example, Bcl-2 and Bcl-xL, is associated with 
tumor progression, as well as resistance to chemotherapy. Bcl-2 small molecule inhibitors 
(Figure 1), including mimics of BH3-only proteins and Bcl-2 antagonists, induce 
activation of pro-apoptotic proteins and overcome chemoresistance in cancer cells. 
Inhibitors like ABT-263 (Navitoclax) and AT-101, both mimics of the BH3-only domain, 
have a broader range of targets binding to both Bcl-2 and Bcl-xL. On the other hand, 
inhibitors, like GX15-070 (Obatoclax), are antagonists against only Bcl-2 and lower the 
apoptotic threshold in tumor cells already damaged by chemotherapy. Functions of 
several Bcl-2 drugs are listed in Table 1 and shown on Figure 3. Please refer to other 
outstanding reviews and articles for details (Azmi et al., 2011; Bodur and. Basaga 2012; 
Kamal et al., 2014; Bai and Wang 2014). 
1.7 ATG PROTEINS IN AUTOPHAGY AND APOPTOSIS 
 Atgs are regulated in response to the availability of nutrients and growth factors 
including amino acids. These signals are generated through a serine/threonine kinase 
known as the mammalian/mechanistic target of rapamycin (mTOR) (Kamada et al., 
2004). MTOR is an important negative regulator of autophagy that exists in two distinct 
complexes, mTORC1 and mTORC2. MTORC1 is typically active and serves as a 
nutrient deprivation sensor. MTORC2 is a regulator of AKT phosphorylation, thus 
inhibition of mTORC2 results in G1 cell cycle arrest as a consequence of the inhibition of 
AKT phosphorylation (Feldman et al., 2009). Under normal conditions mTOR signaling 
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results in the hyper-phosphorylation of several Atgs which leads to inhibition of the 
autophagic process. For example, mTOR phosphorylates Atg13 and disrupts its binding 
to two orthologs of Atg1, ULK1 and ULK2, which are required for autophagy (Grasso et 
al., 2012). ULK1/2 is essential for both the initial construction of the autophagosome as 
well as acting as a nutrient sensing center in a complex with Atg13 and Atg17. Atg13 in 
conjunction with a second protein, FIP200, is critical for correct localization of ULK1 to 
the isolation membrane and for the stability of ULK1 protein. Interestingly, ULK1 also 
has bi-functionality that can be unregulated in response to activated p53, resulting in cell 
death (Gao et al., 2011). 
1.8 P62 IN APOPTOSIS AND AUTOPHAGY 
 Other proteins can facilitate the targeting of LC3. Initiation signals from 
autophagy can recruit p62, a multi-domain ubiquitin-binding, signaling adaptor protein 
also known as sequestosome 1 (47). P62 can assemble proteins that have been tagged by 
ubiquitin through its polymerization with other p62 molecules. This ability to aggregate 
permits p62 clusters to recognize, assemble, and deliver the targeted cargo into the 
autophagosomes via binding to LC3. P62 aggregates are often termed speckles due to 
their cytosolic visibility and these speckles act as organizing centers where p62 is able to 
interact with caspase 8 as well as other factors (Sanz et al., 2000). Inhibition of autophagy 
results in larger p62 speckles which appear experimentally to co-localize with poly 
ubiquitinated proteins that are normally degraded by autophagy (Komatsu et al., 2007). It 
is postulated that in addition to its autophagic role in aggregation p62 functions to 
compact toxic proteins (Moscat and Diaz-MecoSee 2009). P62 is also implicated in the 
activation of NF-κB, a transcription factor (Baldwin, 2012) that plays an important role in 
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the inhibition of apoptosis. These results indicate that p62 plays a role in the apoptosis 
pathway as well as in autophagy. Further experiments suggest that p62 is required for the 
extrinsic apoptosis pathway in particular for the proper functioning of the death receptors 
DR4 and DR5 also needs p62. These data imply that p62 speckles are signaling centers 
which determine either cell survival through autophagy, triggering the NF-κB pathway, 
or by aggregating caspase-8 to signal the cell to undergo apoptosis.  
 Research has identified two caspase cleavage sites in Beclin-1 that once cleaved 
result in fragments which are unable to induce autophagy.  The cleavage site at the c-
terminus of Beclin 1 sensitizes cells to apoptosis once cleaved was able to induce the 
release of proapoptotic factors. These findings point to a mechanism by which caspase -
dependent generation of a cleaved Beclin-1 enhances apoptosis. In addition, growth 
factor withdrawal in a murine pro-B cell line (Ba/F3) results in caspase mediated 
cleavage of both Beclin-1 and PI3K (Moscat and Diaz-MecoSee 2009). Finally, research 
has shown that increased ApoL6 expression has been shown to induce the degradation of 
Beclin 1, which results in p62 accumulation, as well as reducing LC3-II formation and 
translocation, ultimately hindering autophagy (Zhaorigetu et al., 2008). 
 1.9 THE LYSOSOME IN APOPTOSIS AND AUTOPHAGY 
 The lysosome is one of the required organelles of autophagy, as well as a way to 
distinguish three different types of autophagy which are partially defined by the way the 
lysosome interact with cargo (Hotchkiss et al., 2009).  In general, the term autophagy 
typically refers to macroautophagy, where the double membrane autophagosome 
envelops its cargo, fuses with lysosomes and forms the autolysosome. Microautophagy 
refers to the second mechanism where the lysosome appears to bring cargo in from the 
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cytosol. Lastly, chaperone-mediated autophagy utilizes heat shock proteins to deliver 
substrates to lysosomes for degradation (Hotchkiss et al., 2009).  
 The lysosome, a major depot of non-specific hydrolases within the cell, has a 
single lipid-bilayer membrane. Changes in lysosomal structure or damage to its 
membrane can lead to lysosomal destabilization. Factors including ROS, proteases, p53, 
and Bcl-2 family proteins which contribute to the permeabilization of the lysosomal 
membrane are similar to those which can affect apoptosis and autophagy. Lysosomal 
destabilization or lysosomal membrane permeabilization (LMP) can occur in response to 
cell death signals resulting in the leakage or release of the lysosomal cathepsins. The 
release of cathepsins regulates apoptosis signaling and LMP can be triggered by a wide 
range of apoptotic and autophagic signals including death receptor activation, ER stress, 
DNA damage, and growth factor starvation (Boya and  Kroemer, 2008; Chwieralski et 
al.,2006; Guicciardi et al.,2004; Stoka et al.,2007). The induction of apoptosis can be 
dependent on this early release of cathepsins, but it can also occur late in the apoptotic 
process and amplify the death signal. The cysteine cathepsins and the aspartic protease 
cathepsin D are both very abundant in the lysosome and are involved in apoptosis 
signaling (66-69). Excess ROS may destabilize the lysosomal membrane resulting in the 
rapid release of cathepsins to the cytosol (Werneburg et al., 2007).  Cell death by LMP 
has also been linked to the direct activation of caspases by lysosomal proteases (Ishisaka 
et al., 1998). In addition, pro-apoptotic Bax relocates to the lysosomes and co-localizes 
with Bim suggesting that this localization may result in Bax-mediated LMP and 
ultimately apoptosis. Bcl-2 family members may also regulate LMP through the 
mitochondria (Yuan et al., 2002). There is also evidence that LMP may occur in p53-
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induced apoptosis where p53 actually localizes to the lysosomes and triggers LMP (Li et 
al., 2007). It may also upregulate LMP and Bax-mediated mitochondrial permeabilization 
without translocating to the lysosome but rather through the upregulation of the gene p53 
up-regulated modulator of apoptosis (PUMA) and Noxa (Oda et al., 2000; Yu et al., 
2001; Nakano and Vousden, 2001). Noxa encodes a Bcl-2 homology 3 (BH3)-only 
member of the Bcl-2 family of proteins. When ectopically expressed, Noxa localizes to 
the mitochondria where it interacts with and suppresses the anti-apoptotic Bcl-2 family 
members and also results in the activation of caspase-9.  
 Following the activation of apoptosis, another protein called lysosome associated 
apoptosis inducing protein (LAPF) associates with lysosomes and is essential for DNA 
damage induced LMP  (Li et al., 2007, Chen et al., 2005). Downregulation of either p53 
or LAPF prevents the induction of LMP (48). LMP may also occur during other types of 
cell death, including autophagic cell death (Kroemer et al., 2005). Transcriptional 
analysis has established common binding sites both in autophagy and on lysosomal genes 
showing an additional association (46). ApoL1 localizes in the cytosol and lysosomes 
suggesting that ApoL1 regulated autophagy, may involve the lysosomes (Zhaorigetu et 
al., 2008). The lysosome is an extremely important structure in both homeostasis and cell 
death. 
 Targeting the lysosome by chemical inhibitors is typically accomplished using 
lysosomotropic agents. It is well known that intermittent use of the lysosomotropic weak 
bases like chloroquine or hydroxychloroquine can prevent cancer in mouse models. This 
data suggests that chemicals which target the lysosome may be effective in cancer 
prevention. Chloroquine, a weak base, functions through its preferential accumulation in 
 
 
20 
 
the lysosome where it becomes protonated and cannot diffuse out (Maclean et al., 2008). 
This accumulation results in the inactivation of lysosomal hydrolases, including 
cathepsins, which are necessary for lysosomal degradation.  
 Other drugs which target the lysosome include the macrolide antibiotic 
bafilomycins, particularly bafilomycin A1 (Baf-A1). This antibiotic derived from 
Streptomyces griseus is a specific inhibitor of vacuolar-type H+ ATPases (V-ATPase) 
and prevents maturation of autophagic vacuoles by preventing the fusion between 
autophagosomes and lysosomes (Yamamoto et al., 1989). Cancer cells overexpress V-
ATPase when compared to non-tumorigenic cells, and may be more sensitive to 
treatment with Baf-A1 or concanamycin A (ConA), another potent V-ATPase inhibitor 
(Figure 2; Morimura et al., 2008; Huss et al., 2002). Interestingly, am emerging drug, 
Concanavalin A (ConVA), induces lysosome- and mitochondria-mediated apoptosis. 
ConVA is a lectin or carbohydrate-binding protein which binds mannose displayed on 
cell surfaces. ConVA is then internalized preferentially to the mitochondria, although 
some endocytosed ConVA will accumulate in the lysosome and also changes the 
membrane permeability on the mitochondria and initiates apoptosis. Many tumors have 
increased expression of lectins on their plasma membrane, therefore ConVA 
preferentially binds to tumor cells (Alonso et al., 2006). Thus, through the identification 
of small molecules or chemical inhibitors that induce lysosomal permeabilization or 
increase lysosomal facilitated autophagy–associated cell death, targeting the lysosome 
may prove to be an effective strategy for treatment of cancer (Fehrenbacher and Jäättelä, 
2005; Figure 2; Table 1).  
1.10 PUMA IN APOPTOSIS AND AUTOPHAGY 
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 PUMA, which is a BH3-only protein (Nakano and Vousden, 2001), has an 
expression pattern consistent with a causative role in p53-dependent apoptosis. PUMA is 
a pro-apoptotic protein and rapidly induces apoptosis through a Bax- and mitochondria- 
dependent pathway (Han et al., 2001). PUMA can be directly activated p53 through p53-
responsive elements in its promoter region and can also be induced by the 
chemotherapeutic (e.g., Adriamycin/doxorubicin) in a p53-dependent fashion (Yu et al., 
2003). Protein isoforms encoded by PUMA have also been shown to localize in the 
mitochondria where they interact with Bcl-2 and Bcl-xL via the BH3 domain (Yu et al., 
2003). Structural analysis has shown that PUMA directly binds to these anti-apoptotic 
Bcl-2 family proteins (Day et al., 2008) and is essential for apoptosis induced by both 
exogenous and endogenous p53. In cancer cell lines PUMA has been shown to dissociate 
Bax and Bcl-xL to induce apoptosis (Ming et al., 2006). Following chemicals and/or 
genotoxic-induced DNA damage (Yu and Zhang, 2008), both p53 and PUMA are 
activated. Independent of p53, PUMA expression can also be induced by oncogenic stress 
(Fernandez et al., 2003; Maclean et al., 2003), growth factor withdrawal, inhibition of 
kinases including FOXO (Han et al., 2001, Maclean et al., 2003, You et al., 2006), ER 
stress and altered redox (Reimertz et al., 2003;, Ward et al., 2004), as well as infection 
(Castedo et al., 2004) all resulting in apoptosis upregulation. It have been shown that 
nuclear factor-kB (NF-kB) can assist in p53-dependent PUMA induction through 
recruitment to the PUMA promoter during response to DNA damage (Yu and Zhang, 
2008). Additionally, many tumors possess p53 mutations (Vogelstein and Kinzler, 2004) 
which prevent PUMA induction during DNA damage response (Yu and Zhang, 2005). 
PUMA induces apoptosis through the generation of both superoxide and hydrogen 
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peroxide in a Bax-dependent manner. Mitochondrial translocation and multimerization of 
Bax is a critical event in mitochondrial-mediated apoptosis (Nakano and Vousden, 2001). 
Interestingly, hypoxia results in metabolic changes which induce p53 to transcriptionally 
activate genes including PUMA. After its activation, PUMA will interact with all the 
anti-apoptotic Bcl-2 family members, releasing Bax or Bak which induce apoptosis in the 
mitochondria (Yu and Zhang, 2008). The induction of PUMA causes Bax to form 
multimers resulting in mitochondrial dependent cell death. PUMA has recently been 
shown to induce autophagy which appears to lead to targeting of the mitochondria for 
removal by autophagy, or mitophagy (Yee et al., 2009), mediated through Bax and Bak. 
This is interesting since PUMA also induces apoptosis in a Bax-dependent manner (Yu et 
al., 2003). In addition, the inhibition of PUMA- or of Bax-induced autophagy results in a 
reduction in apoptosis suggesting that targeting mitophagy could enhance apoptosis. 
Because of its role in both apoptosis and autophagy, PUMA is extremely interesting and 
may provide a vital link in the communication between these two programmed cell death 
pathways.  
1.11 INHIBITORS OF APOPTOSIS (IAPS) 
 Inhibitor of apoptosis proteins (IAPs) are a family of anti-apoptotic proteins that 
promote cancer cell survival. IAPs exert a range of biological activities that promote cell 
survival and proliferation. X chromosome-linked IAP (XIAP) is a direct inhibitor of 
caspases whereas cellular IAPs block the assembly of pro-apoptotic protein signaling 
complexes and mediate the expression of anti-apoptotic molecules. In general, expression 
and function of IAPs are deregulated in human cancer cells due to genetic aberrations, 
increase of their mRNA or protein expression levels, or loss of endogenous inhibitors, 
 
 
23 
 
such as second mitochondria-derived activator of caspase (SMAC). As IAPs are 
expressed at high levels in various types of cancer and have been linked to tumor 
progression, treatment failure and poor prognosis, IAPs are promising targets for cancer 
therapeutic intervention (Stern et al., 2012). Several therapeutic targeting strategies that 
have been designed to target IAPs thus far, such as small-molecule IAP antagonists and 
antisense oligonucleotides. Among them, the most common approach is based on 
mimicking the IAP-binding motif of SMAC, an endogenous IAP antagonist. These 
antagonists include AT-406, and YM155. It has been shown that AT-406 selectively 
inhibits the activity of XIAP, cellular IAPs 1 (c-IAP1) and 2 (c-IAP2), and melanoma 
inhibitor of apoptosis protein (ML-IAP). This inhibition results in the promotion of 
apoptosis (Brunckhorst et al., 2012). AEG35156, a XIAP antisense oligonucleotide, has 
been shown to sensitize malignant cells to chemotherapies both in vitro and murine in 
vivo models (Schimmer et al., 2009) (Table 1). Preclinical studies have indicated that the 
therapeutic potential of IAP antagonists might best be exploited in combination protocols, 
including conventional chemotherapeutic drugs, signal transduction modulators, death 
receptor agonists or radiation therapy (Fulda and Vucic, 2012). 
 In conclusion, the environment encountered by tumor cells requires adaption to 
low blood supply, low nutrients, and hypoxic conditions that contributes to the cell’s 
avoidance of multiple cell death pathways. The loss of homeostasis between apoptosis 
and autophagy has been postulated as both a causative factor in tumorigenesis as well as 
an area for therapeutic intervention. In general, the autophagic survival mechanism 
blocks apoptosis in most cancer types (Stern et al., 2012; Rubinsztein et al. 2012; Yao et 
al., 2011; Harhaji-Trajkovic et al., 2012). In designing therapies to eliminate cancer cells, 
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specifically through apoptosis rather than necrosis, one might consider (a). targeting the 
activation of the cytosolic pro-apoptotic p53 interactome as well as inactivating the pro-
autophagic p53 interactome; (b). inducing degradation of Beclin 1 and Atg5 for the 
generation of pro-apoptotic form of Beclin 1-C and Atg5N; (c). mobilization of Bcl-2 and 
Bcl-xL from Bax/Bak interactome to Beclin 1 interactome; and (d). activation of PUMA, 
ApoL6, or ApoL1 in a cancer cell specific manner.  Thus, the crosstalk between 
apoptosis and autophagy remains a highly investigated and promising area for the 
identification of novel therapeutics and research into the interactions which maintain 
molecular homeostasis between these two death pathways will continue to further our 
understanding of the dynamics between cell death and cancer etiology. 
1.12 ABBREVIATIONS: 
ApoL1, Apolipoprotein L1;   ApoL6, Apolipoprotein L6; AMPK, AMP-activated protein kinase; 
Apaf-1, apoptotic proteinase-activating factor-1; Atg, Autophagy-related gene; BAD, Bcl-2-
associated death promoter; Bcl-2, B-cell lymphoma 2; Beclin 1, Bcl-2 interacting protein 1; BH3, 
Bcl-2-homology-3 domain; BH, Bcl-2 homology; BID, BH3 interacting-domain death agonist; 
DISC, death-inducing signaling complex; DR5, the death domain receptor; DRAM, damage-
regulated modulator of autophagy; FADD, FAS-associated death domain protein; FLICE, FADD-
like IL-1 β-converting enzyme; FIP200，focal adhesion kinase -interacting protein FIP 200 
fragment; HDAC, histone deacetylase; IAPs, inhibitors of apoptosis proteins; JNK, c-Jun N-
terminal kinase; LC3, microtubule-associated protein 1 light chain 3; MAPK, mitogen-activated 
protein kinase; MOMP, mitochondrial outer membrane permeabilization; mTOR, mammalian 
(mechanistic) target of rapamycin; PA, phosphatidic acid; PCD, programmed cell death; PE, 
phosphatidylethanolamine; PI3K, phosphoinositide 3-kinase; ROS, reactive oxygen species; 
SMAC, second mitochondrial-derived activator of caspase; TNF-α, tumor necrosis factor-α; 
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TRAIL, tumor necrosis factor-related apoptosis inducing ligand; TSC1/2; tuberous sclerosis 
complex1/2; ULK1, unc-51-like kinase 1; TNFR1 tumor necrosis factor receptor 1; Vps34, 
vacuolar protein sorting-34. 
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 1.15 Chapter Table and Figures. 
1.15.1 Table 1: Inhibitors of Therapeutic Targets in Autophagy and Apoptosis  
Inhibitors of autolysosome 
formation   
Compound: Mechanism of Action 
(Hydroxy) Chloroquine Lysosomotropic drug 
Bafilomycin A1 
Specific inhibitor of vacuolar H+ ATPase (V-
ATPase) 
Concanavalin A 
Apoptosis induction/immunomodulating 
activity 
Concanamycin A Specific inhibitor of V-ATPase 
    
Inhibitors of caspase inhibitors   
AT- 406 
A Smac mimetic and an antagonist of the 
inhibitor of apoptosis proteins (IAPs) 
AEG35156  An antisense oligo of XIAP 
YM155 Inhibits Survivin promoter activity  
    
 Inhibitors of Bcl-2   
Obatoclax (GX15-070) Antagonist of Bcl-2  
ABT-263 (Navitoclax)  Potent inhibitor of Bcl-xL and Bcl-2  
AT101 Binds with Bcl-2, Bcl-xL  
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1.15.2 Figure 1. Apoptosis (the Yin) 
 
Apoptosis is an ATP-dependent, multi-step process which occurs in response to both 
internal (intrinsic) and external (extrinsic) signals and as part of normal cell development 
and homeostasis. The intrinsic apoptotic signaling pathway is dependent on the formation 
of the apoptosome, an interactome of apoptotic protease activating factor 1 (Apaf-1), 
(pro-) caspase 9, cytochrome C and (d) ATP. The extrinsic pathway utilizes 
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transmembrane death receptors (FasR, TNFR1, DR3, and DR4/DR5) (6), and their 
corresponding ligands (FasL, TNF-α, Apo3L, and Apo2L). Apoptosis takes place in four 
sequential stages: stimulus, signaling, regulation, and execution. Stimulus occurs in 
response to ligand-receptor interaction (extrinsic) or intracellular stress (intrinsic). 
Subsequently, regulatory proteins (p53, Bcl-2, IAPs) and apoptosomes fine tune this 
dynamic process. A group of caspases are then activated and used for cleaving proteins 
critical to cell survival and proliferation. 
1.15.3 Figure 2. Autophagy (the Yang), Conjugation Pathways. 
 
Autophagy uses two conjugation systems similar to the ubiquitin targeting system. The 
process of attaching LC3 to the membrane is accomplished through LC3 cleavage, 
lipidation and translocation. The LC3 designation is modified once cleavage has occurred 
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as well as when the protein is localized to the membrane. Under this nomenclature LC3-I 
refers to cytosolic localization following cleavage and LC3-II refers to a membrane 
bound LC3. During the elongation of the isolation membrane, the Atg5-Atg12-Atg16L 
complex localizes to the membrane to form a cup-shaped structure. LC3-II then localizes 
to the isolation membrane, while the Atg5-Atg12-Atg16L complex dissociates.  
1.15.4 Figure 3. Autophagy (the Yang), Autophagic flux. 
 
Autophagy has three major phases: initiation, elongation and completion.  Initiation 
involves the formation of a double membrane structure (autophagosome). The formation 
of this double membrane structure is a complex process involving many Atg proteins. 
LC3 is required for the formation of autophagosomal membranes. LC3 is recruited to the 
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isolation membrane, which ultimately develops into the autophagosome where cellular 
targets are sequestered in preparation for degradation. LC3 is the only protein that 
remains associated with the completed autophagosome. The autophagosome then fuses 
with endosomes/lysosomes to create the autolysosome where cellular targets are 
degraded. Following autolysosomal formation, the lysosomal hydrolases, including 
cathepsins, degrade the targeted proteins, while the cathepsins degrade LC3-II on the 
inner autophagosomal surface. Following target degradation, Atg4 is involved in 
separating outer membrane LC3-II from the autophagosome, although LC3-II is still 
present in late autophagic vesicles. Crosstalk between the regulatory proteins, such as 
ApoL6, ApoL1, and DRAM, can dictate the outcome of autophagic flux. 
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1.15.5 Figure 4. Similar Molecules Between Two Protein Degradation 
Pathways. 
 
Transient conjugation of LC3 to the autophagosomal membrane through an ubiquitin like 
system is essential for macroautophagy. Ubiquitin directs proteins targeted for 
degradation to the proteasome and is activated by an E1 enzyme. Following activation, 
E1 transfers the activated ubiquitin to E2 enzymes and then with E3 enzymes catalyzes 
the conjugation of ubiquitin to substrates. LC3 binding residues can function in an 
ubiquitin-like fashion and terms ubiquitin-like, E1-like, E2-like and E3-like are applied to 
these autophagic ubiquitin-like systems producing the conjugated proteins (LC3-II-PE 
and Atg5-Atg12-Atg16L). LC3 targeting system works with LC3 acting as the ubiquitin-
like protein that is transferred to phosphatidylethanolamine (PE), while Atg7 functions in 
the same manner as an E1 enzyme;  Atg3 like an E2 enzyme and the Atg12-Atg5-Atg16L 
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complex like an E3 ligase for the LC3-II–PE complex. Upstream of the LC3-II-PE 
linkage, Atg12 is conjugated to Atg5 to form a stable Atg12-Atg5 conjunction. This 
process is mediated by Atg7, E1-like activating enzyme, and Atg10, an E2-like 
conjugating enzyme. Atg16 then forms a complex with the Atg12–Atg5 conjugate. 
1.15.6 Figure 5. Biochemical reactions in Atg8 lipidation. 
 
Atg8 in budding yeast Saccharomyces cerevisiae shares significant homology with 
mammalian LC3. In yeast Atg8, residues Phe 77 and Phe 79 are located on one surface, 
and residues Tyr 49 and Leu 50 are on the opposite surface. It has been shown that Phe 
77 and Phe 79 recognize Atg4, an endopeptidase and a de-conjugation enzyme. Atg4 is a 
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specific cysteine protease belonging to the caspase family, initiates LC3 processing by 
post-translationally cleaving LC3’s C-terminal amino acid (arginine). This cleavage 
generates LC3-I. The newly exposed C-terminal glycine (Gly 116) is bound by 
phosphatidylethanolamine (PE), a lipidation conjugation reaction catalyzed by Atg12-5-
16L complex, which results in the formation of LC3-II.  
1.16 Dissertation Summary: Background  
The American Cancer Society estimates that in 2015, 73,870 new melanomas will be 
diagnosed and 9,940 people will die from their disease. 1The 5-year survival rate for stage 
IV melanoma also remains unchanged at only 15-20% but the incidence continues to 
rise.1 Once melanoma has metastasized the available treatment options all have 
significant challenges. Immunotherapy with IL-2 and IFN-α offers some patients 
complete and long-lasting remission, but has a very low percentage of responders. 
2,3Chemotherapy, including alkylating agents (dacarbazine, temozolomide), platinum 
analogs, and microtubular toxins 4 have a larger percentage of responders. 2,5 However, 
these agents used alone or in combination still have less durability.6 Advances in the field 
of melanoma have successfully identified targeted therapies including selective oncogene 
inhibitors. Activating mutations in the BRAF and NRAS proto-oncogenes are found in 
approximately 58% of primary melanomas (43% BRAF V600E; 15% NRAS Q61R) and 63% 
of melanoma metastases (48% BRAF V600E; 15% NRAS Q61R) .7 Long term effective 
treatments for invasive melanoma typically use targeted immunotherapy combined with 
therapeutics that target the critical MAPK pathway through the inhibition of BRAF. 2,8 
However, inhibition of these targets has not significantly increased patient survival, as 
tumors eventually develop resistance. 1,9 Recently, immunotherapy has shown 
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encouraging advances in metastatic melanoma treatment through the recognition of 
neoantigens and through deactivation of immune checkpoint blockades, such as CTLA-4 
antagonist-antibodies, and PD-L1.  These have shown an increase in ten month survival 
in phase I and II clinical trials. 10,11  While activating mutations in BRAF/NRAS are 
critical mediators of melanomagenesis 12–14 and the most common somatic alterations in 
melanoma, the mechanisms by which these mutations promote tumorigenesis are still 
under investigation.  One potential pathway that may provide a mechanism to support 
tumorigenesis is the metabolic pathway of autophagy. Autophagy, or self-eating, is a 
catabolic process that assists the removal of unnecessary or dysfunctional components, 
damaged proteins and organelles through lysosomal degradation.15,16 A tightly regulated 
process autophagy, plays a role in a wide variety of normal physiological processes 
including energy metabolism, stress responses, growth regulation, and aging17,18 and can 
be induced in response to nutrient deprivation.19 Macroautophagy, the most widely 
discussed type of autophagy (referred to hereafter as autophagy) involves the initial 
formation of a double membrane structure (isolation membrane) which encapsulates 
organelles and targeted elements in the cell, separating these targets from the rest of the 
cytoplasm and fusing them into a circular autophagosome.  The autophagosome then 
fuses with the lysosomes (autophagolysosome), which degrades or recycles the contents 
of the vesicles. 20 Autophagy has been shown to play a Janus role in cancer,21 suppressing 
the early stages of tumor formation 22,23 yet enhancing tumorigenesis in the later stages of 
development.24–28  Research has shown that while autophagy plays similar roles in tumor 
cells as in normal cells, tumor cells’ energetic needs are greater and they have a more 
hypoxic environment, so dependence on autophagy may be greater. 29–31 Conversely, 
 
 
48 
 
deficiencies in autophagy in normal cells can promote cancer through the accumulation 
of damaged mitochondria and other components that autophagy normally degrades or 
recycles. 32,33 Finally autophagy has been reported to control other processes relevant to 
the etiology of cancer, including oxidative stress 32 inflammation 18,34,35 and both innate 
and acquired immunity.21,35–38  Tumor cells have increased levels of DNA and protein 
synthesis and require a constant nutrient source; autophagy appears to promote tumor 
survival by providing energy to the hypoxic tumor environment or in response to 
chemotherapy. 30,39–41 Autophagy also localizes to hypoxic tumor areas that occur far 
from blood vessels and supports tumor cell survival.30 Importantly, the mechanism by 
which BRAF and NRAS influence autophagy remains to be elucidated. Recent evidence 
for metabolic resistance to BRAF inhibitors and the speculation that some cancers are 
“autophagy addicted” suggests that activating mutations in BRAF may generate tumors 
with this phenotype.42  There is thus a need to investigate the mechanism and extent to 
which mutations in oncogenes affect the rate of autophagic flux and ultimately sensitivity 
to inhibition of this process. 
1.17 Single Nucleotide Polymorphisms (SNPs): 
1.17.1 SNP Definition  
A single nucleotide polymorphism is a DNA (germline) sequence variation that occurs 
commonly within a population; in which a single nucleotide (adenine, thymine, cytosine, 
or guanine) is altered. There are many types of SNPs and the most commons are those 
that occur in between genes in introns (intronic). SNPs, in a majority of cases have no 
clear effect on human health or development but some act as biological marker that allow 
for the identification of disease associated genes. Even intronic SNPs may have on 
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impact if they are located in enhancers, super enhancers, promoters or introduce splice 
variants. 43–47Some SNPs occurring near or within genes potentially play a more direct 
role, effecting the functioning of an associated gene or protein stability and impacting 
risk, progression or disease specific  survival. 48 
There is evidence that autophagy related genes have SNPs which impact the function of 
both promoters as well as protein stability.49,50 The role of autophagy-related SNPs in 
melanoma progression and survival has not been investigated and may provide insight 
into the interactions between this disease and the autophagy pathway.  
1.18 Purpose and Hypotheses 
Invasive melanoma is a complex disease with an increasing incidence of 6% each year 
and few clinical treatment options. The American Cancer Society estimates that in 2015 
the 5-year survival rate for stage IV melanoma will remain unchanged at only 15%, even 
with new therapies. One emerging hallmark of cancer is the reprogramming of energy 
metabolism 51 which includes the role of autophagy.  
Autophagy is a cellular recycling pathway involved in normal physiological processes 
including nutrient and/or stress responses, antigen presentation, and aging. In cancer, 
autophagy appears to be an important energy source for nutrient depleted tumors.29 
Studies of solid tumors have shown autophagy’s role is biphasic as it initially suppresses 
the early stages of tumor formation 22 and inhibits metastasis by promoting anti-tumor 
inflammatory responses but later promotes metastasis by enhancing the tumor’s ability to 
respond to environmental stress. 15,52  However, the mechanisms supporting the Janus 
nature of autophagy remain to be elucidated. 
Studies have indicated that evaluated tumors differ in their sensitivity to chloroquine 
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(CQ), a potent inhibitor of autophagy.26,53 Currently, multiple clinical trials are underway 
using CQ and its derivatives to evaluate the effectiveness of these inhibitors in cancer 
therapies.54,55 In melanoma, basal levels of autophagy appear to vary by tumor stage, and 
higher levels of autophagic flux are associated with increased hypoxia and poor clinical 
prognosis.56 In 2010, Lazova and colleagues reported that melanoma cells contain high 
levels of autophagosomes, a cellular structure associated with autophagy, as measured by 
the proxy marker LC3, an autophagy related (ATG) protein.57 Ma et al. (2014) reported 
increased autophagy in BRAF inhibitor resistant cells.58 These findings suggest 
autophagy provides metabolic support for tumors.  
Other environmental and genetic factors also have an influence on autophagy. 
Ultraviolet-radiation (UVR) exposure increases autophagic flux59,60 and UVR is an 
established risk factor for melanoma. Furthermore, in oncogenic BRAF-mutated thyroid 
cancer a single nucleotide polymorphism (SNP) in a crucial ATG gene, ATG5, has been 
shown to have a positive association with cancer susceptibility and poor outcome.50 To 
date there are no studies examining ATG gene SNPs in melanoma outcomes, so the role 
of these variants is unclear, particularly in relation to the presence of BRAF/NRAS 
oncogenes. Variants identified in these patients could affect ATG gene expression and 
ultimately, influence the rate of autophagy.  
The objective of the present study is to determine whether in melanoma oncogene status 
and UV exposure are independently associated with levels of autophagy and if autophagy 
markers associate with increased melanoma survival. Our long term goal is to reduce 
mortality from melanoma by identifying novel targets for treatment using the autophagy 
pathway.  
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1.19 Rationale, Hypothesis, and Specific Aims:   
 
1.19.1 Rationale 
The rationale of the proposed research is that oncogene status in melanoma differentially 
suppresses apoptosis by modifying autophagic flux.  
 
1.19.2 Hypothesis 
Our hypothesis is that cutaneous malignant melanomas (CMM) with BRAF mutations 
may be autophagy-addicted while tumors with NRAS mutations may be less dependent 
on autophagy.  
 
I interrogated this hypothesis through the following specific and testable aims:  
 
1.19.3 Specific Aim 1  
Determine if BRAF/NRAS mutations alter autophagic flux at the cellular level in order to 
suppress apoptosis in melanoma.    
 
1.19.4 Specific Aim 2  
Determine if autophagic flux is associated with individual UV exposure and/or clinical 
stage and modified by oncogenic BRAF/NRAS in melanoma tumor. 
 
1.19.5 Specific Aim 3  
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Determine whether SNPs in ATG genes are associated with BRAF/NRAS mutations in 
melanoma patients.   
  
1.20 Overall Approach. 
In order to determine if BRAF/NRAS mutations alter autophagic flux to suppress 
apoptosis in melanoma, I used melanoma cell lines to quantify the complete process of 
autophagy (autophagic flux), beginning with the formation of an isolation membrane, 
autophagosome and eventually an autolysosome where unnecessary or dysfunctional 
cellular components are degraded. 61,62 The goal was to examine the model that metabolic 
stress caused by mutations in oncogenes leads to alterations in gene expression, as shown 
in tissue samples, increasing the rate of autophagy, and ultimately leading to melanoma 
progression. In addition, variants in autophagy genes may modify autophagic flux leading 
to melanoma progression. 
 Our long term goal is to reduce mortality from melanoma by identifying novel targets for 
treatment using the underexplored autophagy pathway. In six melanoma cell lines (e.g. 
SK-Mel 2, 19, 29, 94,103, and 147) containing BRAF or NRAS mutations, the sensitivity 
and cell viability associated with chloroquine (CQ) treatment were characterized by 
autophagic flux, to determine decreases in cellular viability caused by autophagy 
inhibition. Using quantification of LC3-II puncta and western blots, I evaluated the 
differential rate of autophagy by oncogene status. These two common CMM activating 
mutations, BRAF and NRAS, appear to have differential effects on the autophagy 
pathway. Our data indicate that the targeting of autophagy using CQ in the BRAF 
oncogenic cell lines increases apoptosis and leads to a significant decrease in viability 
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(Figure 1; Chapter 2).  In addition, BRAF cell lines appear to have higher basal protein 
expression of LC3-II (Figure 4; Chapter 2) and a higher number of basal LC3-II puncta 
when compared to NRAS cell lines (Figure 4; Chapter 2) indicating dependence on the 
autophagy pathway for survival.  Finally, the induction of autophagy through serum 
starvation results in differential LC3 expression as measured by number of puncta in the 
BRAF and NRAS cell lines (Figure 4; Chapter 2). These results indicate that BRAF mutant 
melanoma is more dependent on autophagy for survival than NRAS mutant melanoma 
and that oncogene status affects the sensitivity of melanoma cells to CQ by altering 
autophagic flux, subsequently increasing apoptosis. Ongoing experiments include the 
evaluation of autophagy in patient samples to quantify expression of known autophagy 
markers as well an evaluation of LC3-II expression correlated with oncogene status and 
autophagy SNPs.  These findings will be immediately translatable for patients who would 
benefit from CQ co-therapy, which is approved for clinical use. 
 
1.21 Significance of the Dissertation Study  
Long term survival remains a challenge for metastatic melanoma patients as there are few 
durable treatment options available. Melanoma treatment can be divided into four major 
types: surgery, chemotherapy, radiation therapy and biological therapy.63 Treatment of 
stage IV and recurrent melanoma may include the following: targeted therapy with 
ipilimumab or BRAF inhibitors (e.g. vemurafenib); biological therapy with interleukin-2 
(IL-2); chemotherapy including alkylating agents; or palliative therapy to relieve 
symptoms and improve the quality of life. 63,64 Unfortunately, in most cases, treatment 
fails to halt the advance of melanoma and patients do progress, typically within a few 
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months.9 Exciting immunotherapy treatment options including IL-2, 2,3,8 drugs that block 
Cytotoxic T lymphocytes (CTLs) inhibitory mechanism (CTLA-4) or Programmed cell 
death 1 (PD-1) boost the immune response against melanoma cells. These combinations 
which circumvent the tumor’s ability to evade immune destruction are resulting in tumor 
regression and increased survival, although there remains heterogeneity in responses to 
treatment.65–67 The Phase Ib study of MEDI4736 for a combinations of CTLA-4 and 
Programmed cell death ligand 1 (PD-L1) antagonist-antibodies have shown promising 
results while illuminating the relationship between melanoma progression and immune 
system.68  These results indicate that combining immunotherapy with oncogene (BRAF, 
NRAS)-targeted drugs may provide durable responses in melanoma for a larger number of 
patients.   
In addition to evading immune destruction, another hallmark of cancer is the 
reprogramming of pathways involved in energy metabolism to support continuous 
growth, development and progression of cancer using mechanisms including the 
autophagy pathway.51 Autophagy is often dysregulated in the hypoxic, low nutrient 
regions of tumors and can support cancer survival through its ability to provide tumors an 
energy source.15,18,29,34,69,70  Autophagy upregulation has been documented in lung, 
prostate and other cancer types but the mechanisms supporting its role in melanoma 
tumorigenesis have not been well characterized. In addition, the role of autophagy in 
modifying cancer cell death or survival remains controversial.71  Interestingly, it appears 
that oncogene status, an important contributor to cellular deregulation of proliferation and 
apoptotic pathways in melanoma also influences the rate of autophagic flux. BRAF V600E 
mutations have been reported to promote lung tumorigenesis by utilizing autophagy’s 
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ability to preserve mitochondrial function,72 and inhibition of autophagy in vemurafenib-
resistant melanoma decreases cell survival. The concept that oncogenes can directly 
influence autophagic rates has important implications for cancer development as well as 
the management of treatment options for this difficult disease. Furthermore, in non-
medullary thyroid cancers with activating BRAF mutations, a SNP in ATG5, a crucial 
ATG gene, has been shown to be associated with disease susceptibility and outcome. 73 
To date there are no studies examining ATG gene SNPs in melanoma progression or 
survival, so the role of these variants is unclear. Variants identified in these melanoma 
patients could affect ATG gene expression and ultimately influence the rate of autophagic 
flux.   
The significance of this proposal is that autophagy may represent a novel area for 
identifying biomarkers and potential targets for treatment in melanoma. Given that 
oncogenes influence autophagy and BRAFV600E melanoma cells appear to use late-stage 
autophagy to maintain an active metabolic state,57,74 the current study was designed to 
determine whether oncogenic mutations drive melanomas to become autophagy-addicted 
for survival and if inhibition of this pathway increases apoptosis in these cells. If this is 
so, we would anticipate finding that autophagy or oncogenically driven autophagy as an 
important factor in progression to metastasis and death.  Our study design is innovative as 
it combines both molecular epidemiology and molecular biology techniques allowing the 
proposed research to determine if oncogene status is an important modifier of autophagy 
in melanoma moving from bench to bedside.  Autophagy has been shown to promote 
tumor survival 21,58 and support survival of radiation and chemotherapy resistant tumor 
cells 54,57 thus highlighting the importance of investigating this process in melanoma. 
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Upon completion of the proposed aims, this research will clarify the relationships 
between autophagy, melanoma and oncogene status and will elucidate some of the 
molecular mechanisms/pathways contributing to this disease. This project has the 
potential to make a significant contribution because (i) it will characterize the cell death 
response to autophagy inhibition in the context of BRAF/NRAS oncogenic status; (ii) it 
will characterize the relationship at between autophagy and UV exposure in tissue 
sections and (iii) it is an important first step in identifying autophagy related SNPs that 
may influence autophagic flux and melanoma tumorigenesis. 
1.22 Limitations of Dissertation Study 
There are several limitations to this study.   
1.  While immortalized cells lines can provide some information about how metastasis in 
melanoma is facilitated, there are limitations to using them as a resource. Some of the 
strengths of cell lines are they often show similar allelic populations compared to the 
actual tumors and they provide a rich source of RNA which under other circumstances 
would be difficult to obtain. They also provide good model systems for evaluating 
invasion and the potential for the tumors to metastasize to distant sites. Weaknesses 
include an increase in chromosomal instability in many cancer cell lines as well as 
chromosomal gains and losses as the number of passages increase, which could affect 
experimental outcomes.  
2.  Problems with reliable labeling of autophagosomes have created controversies around 
using immunofluorescence.62,75 To address this potential issue, I used a proven 
colocalization experiment to identify the autolysosomes indicating true target degradation 
and autophagy completion. Staining protocols have been developed for quantitative 
 
 
57 
 
analysis using antibodies to LC3 (ATG8). In addition, quantitative fluorescent 
microscopy will be used to assess relative quantities of LC3 estimating the accumulation 
of autophagic vacuoles. Although my aims have little interdependence, this aim was 
limited by the reality that many cells use other mechanisms, such as methylation or 
acetylation, to regulate protein expression so LC3 may stay consistently expressed under 
variable conditions. Flow cytometry experiments have resulted in higher levels of cell 
death (Figure 2a-d Chapter 2), so I used an alternative method to examine cell death, 
Caspase activity, in order to obtain more definitive results. Furthermore, the use of the 
IHC could result in variable or incomplete staining and subjective quantification of 
protein expression. For this reason I developed a novel quantification method which 
removes the subjective component of IHC quantification. An alternative approach would 
be to use standard immunofluorescent techniques using anti-LC3 antibodies to quantify 
expression of tumor cells from tumor-associated melanophages. The immunofluorescent 
nature of melanoma samples makes this method a less desirable but still viable 
alternative.  
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CHAPTER TWO: 
Melanoma Cells Carrying BRAF V600E or NRAS Q61R Differ in Autophagy Status 
and Sensitivity   
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2.1 Abstract: Metastatic melanoma has no cure. Although mutations of BRAF or NRAS 
(BRAF* or NRAS*) are identified in 63 percent of melanomas, single inhibition of these 
targets has not increased survival. Recently, autophagy has been examined as a potential 
target for overcoming BRAF inhibitor resistance and there is evidence that survival of 
melanoma cells may be autophagy-dependent. Our study investigated whether BRAF or 
NRAS mutations alter autophagic flux to suppress apoptosis in melanoma, whether basal 
levels of autophagic flux differ based on oncogene status and whether chemical inhibitor 
of autophagy would differentially alter autophagy in BRAF* vs. NRAS* melanoma cells. 
Our study has shown that autophagy is upregulated in BRAF* melanoma cells compared 
to NRAS*. Interestingly, BRAF* melanoma cells demonstrated a four-fold decrease in 
cell viability following treatment with 20 µM chloroquine compared < 20 percent 
decreased in NRAS* cells.  In addition, knockdown of BRAF gene expression 
corresponded with a decrease in LC3 gene expression not seen in NRAS knockdown. Our 
research supports that BRAF* melanoma cell lines have a higher basal level of 
autophagic flux, are more sensitive to autophagy inhibition, and were less able to respond 
to autophagy induction than NRAS* melanoma cells. Findings from this study indicate 
that oncogene status influences autophagic flux and that BRAF mutant melanoma may be 
addicted to autophagy for survival while NRAS mutant melanoma may not be as 
dependent on this pathway.   
 
 
2.2 Keywords:  Autophagy; NRAS; BRAF; LC3; cell death; melanoma 
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2.3 Introduction: 
One of the emerging hallmarks of cancer is the reprogramming of pathways 
involved in energy metabolism to support continuous growth using mechanisms like 
autophagy.1  Autophagy, or self-eating, is a catabolic process that assists the removal of 
unnecessary or dysfunctional components, damaged proteins and organelles through 
lysosomal degradation.2 It is a tightly regulated process that plays a role in normal cell 
growth and development 3and  can be induced in response to nutrient deprivation.4 
Macroautophagy, the most widely discussed type of autophagy (hereafter referred to as 
autophagy), involves the initial formation of a double membrane structure (isolation 
membrane) which encapsulates cytoplasm, organelles and targeted elements in the cell, 
separating these targets from the rest of the cytoplasm and fusing them into a circular 
autophagosome.  The autophagosome is characterized by the microtubule-associated 
protein 1A/1B-light chain 3 (LC3) protein, which is proteolytically cleaved during 
autophagy and then the conjugated/ lipidated form (LC3-II) localizes to the 
autophagosome membrane. Subsequently, LC3-II can be used as a proxy marker for the 
rate of autophagy as Immunofluorescent punctate structures are visible using 
microscopy.5  The autophagosome then fuses with the lysosomes (autophagolysosome), 
which degrades or recycles the contents of the vesicles. 6 The dysregulation of autophagy 
has implications for many diseases including cancer. 3,7–11  
Autophagy has been shown to play a dual role in cancer11, suppressing the early 
stages of tumor formation12 yet having a pro-tumorigenic influence in the later stages of 
development. 13–16 Autophagic flux refers to the complete process of autophagy, 
beginning with the formation of an isolation membrane, autophagosome and eventually 
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an autolysosome where unnecessary or dysfunctional cellular components are degraded.17  
Autophagy is often upregulated in the hypoxic, low nutrient regions of tumors and can 
support cancer survival through its ability to provide tumors an energy source.18,19 This 
upregulation has been documented in lung, prostate and other cancer types but 
autophagy’s role in melanoma has not been well characterized.  
In addition, the rate of autophagic flux appears to vary by tumor type, and it has 
been reported that the effect of autophagy on cancer cells may be dependent upon the 
stage of the cancer.20 For example, in early primary melanomas, autophagy has been 
reported to play a role in suppression of melanoma tumorigenesis through the induction 
of senescence.21   
 Interestingly, it appears that oncogene status, an important contributor to cellular 
deregulation of proliferation and apoptotic pathways in melanoma also influences the rate 
of autophagic flux. BRAF V600E mutations have been reported to promote lung 
tumorigenesis by utilizing autophagy’s ability to preserve mitochondrial function.22 The 
concept that oncogenes can directly influence autophagic rates has important implications 
for cancer development as well as the management of treatment options for this difficult 
disease. 
Invasive melanoma is a complex disease with an increasing incidence and the 
cause of the majority of skin cancer deaths.  In 2015, the American Cancer Society 
estimates that 73,870 new melanomas will be diagnosed and 9,940 people will die from 
their disease. 23 The 5-year survival rate for stage IV melanoma also remains unchanged 
at only 15-20% but the incidence continues to rise, as it has for the past 30 years, at a rate 
of 6% every year. 24 Activating mutations in the BRAF and NRAS proto-oncogenes are 
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found in approximately 58% of primary melanomas (43% BRAF V600E; 15% NRAS Q61R) 
and 63% of melanoma metastases (48% BRAF V600E; 15% NRAS Q61R).25 Advances in the 
field of melanoma have successfully identified targeted therapies including selective 
oncogene inhibitors (BRAF/NRAS); however, single inhibition of these targets has not 
significantly increased patient survival, as tumors eventually develop resistance.26,27 
While activating mutations in BRAF are critical mediators of melanomagenesis28 and the 
most common genetic alterations in melanoma, the mechanisms by which these 
mutations promote tumorigenesis are still under investigation.  Importantly, many of the 
mechanism by which proto-oncogenes like BRAF influence autophagy are under 
investigation. 29,30 Recent evidence for metabolic resistance to BRAF inhibitors and the 
speculation that some cancers are “autophagy addicted” suggests that activating 
mutations in BRAF may generate tumors with this phenotype.31 These findings 
demonstrate the need to investigate the mechanism and extent to which mutations in 
proto-oncogenes affect the rate of autophagic flux and ultimately sensitivity to inhibition 
of this process.            
 Given that oncogenes influence the rate of autophagy and BRAF V600E -mutant 
melanoma cells, in particular, appear to use late-stage autophagy to maintain an active 
metabolic state,29,32,33  the current study was designed to determine whether proto-
oncogene mutations differentially drive metastatic melanomas to become autophagy-
addicted for survival.  
2.4 Materials and Methods: 
2.4.1 Cell Lines.  
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Six melanoma cell lines, authenticated using short tandem repeat loci profiling by ATCC 
(Table 1), were established from human metastatic melanomas at Memorial Sloan 
Kettering Cancer Center and were a generous gift from Dr. Paul Chapman  (SK-Mel 2, 
SK-Mel 19, SK-Mel 29, SK-Mel 94, SK-Mel 103, and SK-Mel 147) (Table1). Cells were 
maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% 
heat-inactivated fetal bovine serum (FBS), penicillin (250 units/ml), and streptomycin 
(250 μg/ml) (Pen-Strep) and referred to as normal media (NM) or DMEM without FBS 
referred to as serum free media (SFM) at 37°C and 5% CO2.  
2.4.2 In Vitro Cytotoxicity Assay: Cell lines were seeded at a density 1.20X106 in 25 
cm2 flasks. Twenty-four hours after plating, cells were treated with 20µM chloroquine 
(CQ) and incubated at 37˚C and 5% CO2 for a period of 24 hours Synthetic CQ was 
purchased from Sigma-Aldrich (C6628) and prepared in H2O (vehicle). Control cells 
were treated with equivalent volume of vehicle.  Following treatment, floating cells were 
collected; adherent cells were washed with PBS, trypsinized and mixed with the 
corresponding floating cells before staining. Cells were stained with 0.4% trypan blue 
and counted to estimate the number of live and dead cells. Cell viability is expressed as 
the percentage of live cells compared to the total number of cells counted.  Comparisons 
of percent viability in vehicle vs. treated cells were determined using one way ANOVA 
with a cut-off of P<0.01. 
2.4.3 Annexin 5/PI Staining – Flow Cytometry:  BRAF V600E mutant melanoma cell 
lines and NRAS Q61R mutant melanoma cell lines were trypsinized and incubated with 
FITC-conjugated Annexin V (BD Biosciences) and propidium iodide. Ten thousand 
events were analyzed by flow cytometry with CellQuest Pro software. Data is presented 
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as the average percentage of viable cells +/- SD that was quantified 24 hours post 
treatment with either vehicle or 20 µM CQ. Statistical significance was set at 1%.   
2.4.4 Caspase Activity: Caspase 3/7 activity was quantified using the Caspase-Glo assay 
kit (Promega, Madison USA) following the manufactures instructions. 24 hrs. following 
vehicle or CQ treatment, the plates containing cells were removed from the incubator and 
allowed to equilibrate to room temperature. 100 μl of Caspase-Glo reagent was added to 
each well; the plate was gently mixed and then incubated at room temperature for 1 hour. 
The luminescence of each sample was measured in a plate-reading luminometer 
(Infinite® Tecan). The experiments were performed in triplicate on two separately-
initiated cultures. 
2.4.5 Immunofluorescent Staining of Lysotracker Red:  Autophagic flux was assessed 
using immunofluorescence imaging of LC3 as an indicator of the steady state level of 
autophagosomes and co-staining with LysoTracker (red-Cy3 dye) to examine the co-
localization of lysosomal vesicles and autophagosomes in the cell.  Cells were grown in 
normal media (NM) or serum free media (SFM), fixed, and examined by microscopy for 
the presence of autophagosomes and autolysosomes visualized by autophagosome 
membrane fluorescent LC3 or LysoTracker.  LysoTracker Red was used to visualize 
lysosomes in vehicle and CQ treated cells. Cells were grown on coverslips as described 
below and once 70% confluence was reached, pre-warmed (37°C) media containing 
LysoTracker Red DND-99 at 50nM concentration was added. Cells were incubated for 
30 minutes under normal growth conditions (37°C, 5% CO2), and then the media was 
replaced with normal media prior to imaging to ensure sufficient lysosomal staining prior 
to fixation and co-staining. 
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2.4.6 Immunofluorescent Staining of Microtubule-associated Protein 1 Light Chain 
3 (LC3):  Monolayers of cells were grown on coverslips to 70%confluence prior to 
experimental treatments.  Cells were grown in NM or SFM media containing DMEM 
only.  Cells were then treated with vehicle, 20 µM CQ, 20nmol/L Bafilomycin A1 (BAF) 
(Wako) or 1 μM Rapamycin (RAP) (Sigma, St. Louis, MO). Following treatment 
conditions, cells were washed twice in cold 1X PBS then fixed with 4% 
paraformaldehyde for 10 min, washed with 1X PBS and incubated in blocking buffer at 
room temperature for 30minutes.  Cells were incubated with a selective antibody against 
LC3 (Microtubule-associated protein1A/1B-light chain 3; MBL, Woburn, MA) to 
evaluate autophagic flux following treatment with 20 µm CQ, 20nmol/L BAF or 1 μM 
RAP or vehicle for 24 hours. Cells were labeled with LC3 primary antibody in blocking 
solution for 1 hour. After 40 minutes, media containing DAPI was added to the coverslips 
for the final 20 minute incubation of LC3. After washing with 1X PBS, coverslips were 
incubated in anti-goat FITC-conjugated secondary antibody in blocking buffer (1:1000) 
in the dark for 1 hour at room temperature and then mounted on microscope slides using 
prolong gold (Life Technologies, NY). Autophagic flux was determined using the 
percentage of cells displaying LC3 punctate (rather than diffuse) fluorescence out of a 
100 total cells counted in three biological replicates for each cell line and treatment type 
grown in cell line  in either NM or a SFM for 2 hours.   Formation of acidic vesicular 
organelles as an indication of autophagic flux was monitored by LysoTracker DND-99 
(Cy3 –red) and 4',6-diamidino-2-phenylindole (DAPI) staining was used to visualize 
nuclei.   BAF treatment was used to inhibit lysosomal function, resulting in a decrease in 
autophagic flux.  Conversely autophagic rate was increased by treating with RAP and the 
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change in flux was measured. Cells were examined by Zeiss Axioskop 2MOT 
microscope, magnification × 620 oil immersion objective lens, and representative images 
of cells were taken. Co-localization of punctate Anti-LC3 FITC, LysoTracker (Cy3) and 
DAPI staining is shown by the pink and yellow color in a composite panel. One-way 
repeated measures ANOVA were used to compare means among the experimental groups 
and vehicle control.  Pair wise comparisons between treatment groups and vehicle control 
were performed after adjusting for multiple tests to evaluate the effect of each treatment.  
Statistical significance was set at 1%  
2.4.7 Quantification of Co-localized Puncta: SlideBook version 5.0 software, which 
analyzes the entire three-channel images by measuring the intensity of each label, was 
used to quantify the number of cells displaying autophagosomes.  The quantification of 
cells with higher levels of LC3 puncta per cell is represented by area in microns 
compared to background. Mask segments of the low- and high- FITC/Cy3 fluorescents 
were created in SlideBook using in both channel images and the background was 
corrected using the same threshold values for all images to be analyzed. The merged 
images were then statistically analyzed using cross-mask and cross-channel functions. 
The ratio of fluorescence was then calculated allowing for quantification of the number 
of fluorescently-labeled co-localized puncta in fixed cells.   
2.4.8 Cell Transfection and RNA Interference: For RNA interference experiments, 
cells were grown in 12-well plates at a density of 1 × 105 cells/well for 24. The cells were 
then transfections with siRNA using Lipofectamine 2000 (Thermo Fisher Scientific, 
Waltham, MA)  following the manufacturer's recommendations using a final 
concentration of 10 nM siRNA against BRAF (Origene SR300470)  or NRAS (Origene, 
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SR303236). siRNA transfected cells were collected 24, 48 and 72 hours following 
transfections. Efficiency of knockdown of the target mRNA was evaluated by real-time 
PCR. 
2.4.9 RNA Isolation and Real-Time PCR with SYBR Green Assay: Total RNA (1 μg) 
was isolated with RNeasy Mini Kit from Qiagen  (Valencia, CA) and  reverse transcribed 
in 50 μl at 48 °C for 2 h using High Capacity cDNA Archive Kit from Applied 
Biosystems (Foster City, CA, USA). Amplification of cDNA was carried out using the 
following primers and SYBR green PCR master mix in an Applied Biosystems 7900 
Real-Time PCR System. The primers used for amplification are: MAP1 LC3B forward 
primer (AGCAGCATCCAACCAAAATC) and reverse primer 
(CTGTGTCCGTTCACCAACAG). For both BRAF and NRAS gene expression pre-
designed KiCqStart™ SYBR green primers were purchased (Sigma St. Louis, MO). The 
threshold cycle (Ct) values, as defined by the default setting, were measured by an ABI 
Prism 7900 Sequence Detection System. B-actin was used as an internal control. 
Triplicate samples were measured and averaged. 
2.4.10 Western Blot Analysis of LC3 Protein Expression: Cells were washed twice 
with PBS and lysed for 30 min at 4°C in RIPA buffer (Sigma-Aldrich, France) prior to 
harvesting by scraping. After an ultra-centrifugation at 16,000 ×g for 10 min at 4°C, 
protein concentration was determined using the BCA Protein Assay Kit (Pierce, IL).  
Proteins were electrophoresed on a4-20% SDS–polyacrylamide gel for 45 minutes at 
200 V. Proteins were then transferred onto nitrocellulose membranes (30 min, 100 mA) 
(BioRad Laboratories, France). Membranes were blocked with 3% bovine serum albumin 
(BSA), 0.1% Tween 20 in 10 mM Tris–HCl pH 7.5, 0.1 M NaCl for 1 hour at room 
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temperature. Incubation was overnight at 4°C with primary polyclonal rabbit anti-human 
LC3 at 1:500 (Cell Signaling Technology, MA) and monoclonal anti-actin at 1:1,000 
(Sigma-Aldrich, France) (loading control).   Subsequently the membranes were washed 
and incubated with 0.02 μg/ml Horseradish peroxidase–conjugated secondary antibody 
(HRP)-conjugated IgG (Cell Signaling, MA) for 1 hour and visualized using Super Signal 
West Fempto Chemiluminescent Substrate System (Pierce Biotechnology, IL). The 
intensity of bands was analyzed by FluorChem™ R System and AlphaView Analysis 
Software (Protein Simple, California). Three biologic replicates were generated for each 
endpoint. LC3-I/LC3-II ratio has been previously used as a surrogate of autophagic flux. 
However, documented differences in across cell lines and tissue dependent expression 
levels of LC3-I and LC3-II as well as differences in antibody affinities for LC3-I and 
LC3-II have indicated that this type of analysis has produced false-positive or false-
negative results. Additionally, as LC3-II itself is subject to autophagic degradation at the 
lysosome, the current study is in agreement with the consensus to utilize overall levels of 
LC3-II normalized to loading control as a measure of autophagic flux (30). One-way 
repeated measures ANOVA were used to compare means among the experimental groups 
and vehicle control.  Pair wise comparisons between treatment groups and vehicle control 
were performed after adjusting for multiple tests to evaluate the effect of each treatment.  
Statistical significance was set at 1%.   
2.5 Results: 
2.5.1 In vitro Viability Assessments: Melanoma cell lines treated for 24 hours with 
CQ demonstrated a decrease in percent cell viability as measured by trypan blue 
exclusion (Figure 1). Further, differential sensitivity to this chemical inhibition of 
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autophagy appeared to be influenced by BRAF/NRAS status in these cell lines. When 
cultured in NM and treated with CQ, BRAF V600E cell lines (SK-MEL 2, 19 and 29) had 
significantly decreased viability when compared to cells treated with vehicle (SK-MEL 
19, P=0.00014; SK-MEL 29, P=0.0013; SK-MEL 94, P= 0.0008) (Figure 1A).  NRAS 
Q61R cell lines (SK-MEL 2, SK-MEL 103 and SK-MEL 147) treated with the same dose 
of CQ had a significantly less pronounced response with <20% decrease in viability 
compared to vehicle (SK-MEL 2, P= 0.003; SK-MEL 103, P= 0.937; SK-MEL147, 
P=0.005 (Figure 1B).  This data suggests that oncogenic status may influence the level of 
autophagic flux utilized by these cells.    
2.5.2 Characterization of Apoptotic Cell Death:  We used Annexin V/PI staining 
and a capase3/7 activity assay in order to characterize the type of cell death associated 
with the observed decrease in cell viability after treatment with CQ (Figure 2a-e; Figure 
3).  Overall, there was a high rate of cell death (15-20%) in the control samples 
potentially due to the adherent cell removal. Despite this baseline, following CQ 
treatment of BRAF cell lines, a significantly larger subpopulation of apoptotic cells was 
present when compared to vehicle treated cells (21.2% vs. 48.6%).  Conversely, the 
NRAS cell population was predominantly composed of viable cells subsequent to CQ 
treatment. Further, when compared to NRAS treated cells, BRAF treated cells had a 
greater percentage of cells undergoing apoptosis demonstrating that the decrease in cell 
viability seen following CQ treatment was a consequence of inhibiting autophagy rather 
than overt toxicity.  In addition, the activity of caspase 3/7 was over 5X greater in the 
cells with 20 μM CQ compared to untreated BRAF* cells, while there was no significant 
difference between the NRAS* treated or untreated cells (Figure 3) 
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2.5.3 Effect of Serum Starvation on Oncogenic BRAF and NRAS Melanoma Cells. 
Under nutrient-deprived conditions, autolysosomes become more acidic as demonstrated 
by an increase in Cy3-red lysosomal staining of the cells. Following incubation for 0.5 
hour in SFM, both NRAS and BRAF showed a marked increase in LC3-puncta co-
localizing with lysosomal staining, indicating an increase in the number of autolysosomes 
(Figure 4). Quantification by SlideBook software of LC3 positive puncta (~ 100 cells/ 
triplicate experiment) from either BRAF* and NRAS* melanoma cells grown in NM or 
SFM indicated that serum deprivation induces LC3 puncta to form large structures at 0.5 
hour in BRAF* cells (Figure 4a and c). Serum deprivation also induces LC3 puncta 
formation at 0.5 and at 2 hours in NRAS cells (Figure 4b and c).  Note that although 
serum starvation induces both autophagosomes (green) and autolysosomes (yellow) in 
BRAF* melanoma cells, indicating autophagic induction, the quantity of autolysosomes 
are inhibited at 2 hours of serum starvation. In addition, in BRAF* cells extended serum 
deprivation (2 hours) shows a decrease in LC3 size and number with continued starvation 
(Figure 4a). As shown in the quantification of LC3 immunofluorescence puncta, as a 
ratio of the percentage of cells displaying punctate fluorescence out of 100 cells, 
compared to control cells in an average of three independent experiments the attenuated 
response in BRAF* cells lines shortly after serum starvation suggesting an exhaustion of 
the autophagy pathway (Figure 4).  
2.5.4 Effect of Autophagy Inhibition and Induction on Oncogenic BRAF and 
NRAS Melanoma Cells. Following treatment with autophagy inhibitors (BAF or CQ) or 
an inducer of autophagy (RAP) BRAF* and NRAS* cells displayed differential 
autophagic responses to these chemical treatments (Figure5a-e). Following CQ or BAF 
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treatment BRAF cell lines reveal an up-regulation of LC3-II protein expression, 
indicating a higher rate of autophagy in these melanoma cell lines as indicated by the 
numerous, large LC3 puncta. These large LC3 puncta are indicative of impaired 
autophagic flux and demonstrate decreases co-localization with lysosomes (red) which 
represent a higher basal autophagic flux in BRAF* cells.  Conversely, in the NRAS* cells 
autophagic inhibition by CQ or BAF addition induces very few LC3 puncta to form large 
structures.  For autophay induction, RAP addition results in an increase in lysosome/LC3 
co-localization as well as LC3 puncta indicating autophagy induction in both types of cell 
lines. Figure 5a-e). BRAF* cells display a much higher basal level of autophagic flux as 
indicated by large number of autophagosomes (green) and autolysosomes (yellow) while 
RAP addition induced a substantial increase in lysosome/LC3 co-localization. The large 
statistical increase in NRAS autolysosomes following RAP induction confirms the 
capacity of these cells to utilize autophagy (Figure 5c) but indicates low levels of basal 
autophagy. 
2.5.5 Differential Rates of Autophagic Flux:  Differential rates of autophagic flux 
were validated using LC3 protein quantification and the LC3-II turnover assay by 
western blot (Figure 6 a-e). BRAF LC3-I and LC3-II protein levels were higher than the 
expression levels in represented in the NRAS cell lines. BRAF cell lines also demonstrated 
significantly increased level of LC3-II expression after CQ treatment, suggesting a break 
in autophagy flux.  A subsequent accumulation of LC3-II that would have otherwise been 
degraded following conjugation into the inner autophagosomal membrane during the 
completion of autophagic flux may explain the eventual increase in LC3-II levels. 
Conversely, NRAS cell lines demonstrated a negligible change in LC3-II expression 
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following inhibition of autophagy, suggesting that these cells are not as dependent on this 
process.   
2.5.6 Association of LC3 Gene Expression with NRAS/BRAF Expression: Gene 
expression experiments examining the relationship between NRAS, BRAF and LC3 using 
RT-PCR indicate a trend between BRAF expression and LC3 expression in our cell lines. 
LC3 gene expression decreased at 24, 48 and 72 hours following BRAF knockdown. 
While LC3 gene expression did decrease slightly at 24 hours following NRAS knockdown 
there was no continued trend with NRAS expression. 
2.6 Discussion. 
 
2.6.1 BRAFV600E or NRASQ61R Genotype Determines Melanoma Sensitivity to CQ 
Treatment. 
 In this study, our data demonstrated CQ attenuated cell viability in BRAFV600E cell 
lines when compared to NRAS Q61R cell lines treated with an equivalent dose. This data 
implies a variation in the basal levels of autophagic flux of these two oncogenic cell lines 
that are subsequently differentially affected by chemical inhibition.   
 Upregulation of autophagy related (ATG) genes results in the conjugation of 
cytosolic LC3 (LC3-I) to form LC3-II-PE which is recruited to the autophagosomal 
membranes.6  When the intra-autophagosomal components are degraded by lysosomal 
hydrolases, LC3-II-PE is also degraded.  Lysosomal turnover of LC3-II-PE reflects 
autophagic flux, and the detection of LC3 by immunofluorescence is a reliable method 
for monitoring autophagy.34   CQ disruption of lysosomal function causes a dysregulation 
in autophagosome turnover resulting in an increase in the number of autophagosomes 
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present in the cell.5,34  Similarly, a defect in autophagy turnover results when autophagy 
has been induced but there is limited autophagic flux.  Subsequently, this leads to a 
reduction in the overall rate of autophagic flux and an increase in type II cell death. Our 
data support that BRAF* cells are dependent on late-stage autophagy for maintenance of 
an active metabolic state and undergo apoptosis when treated with autophagy inhibiting 
agents such as CQ (Figures 1-5). 35,36 Some cancer cell types have been shown to rely on 
autophagy for survival as evidenced by an increase in autophagosome production and 
autophagic flux while under nutrient depleted conditions (Figure 4). 18,37,35 Further,  this 
dependence on autophagy for survival has been described as “autophagy-addiction”.31   
To that end, recent reports in the literature have revealed that tumor cells harboring BRAF 
V600E mutations develop an addiction to autophagy as a means to preserve mitochondrial 
function, as well as for glutamine metabolism, suggesting that oncogene mutation status 
may dictate basal levels of autophagy. 38 These findings suggest that inhibiting autophagy 
may be a powerful strategy for BRAF V600E -driven malignancies that develop resistance 
to selective inhibition. 
2.6.2 Oncogene status dictates melanoma CQ sensitivity, altering autophagic 
flux and increasing apoptosis.   Through in vitro assays we showed a significant 
decrease in cell viability following inhibition of autophagy in BRAF V600E melanoma cell 
lines which we then characterized as apoptotic cell death.  Supporting the idea that 
oncogene status alters autophagic flux, we observed a diminished effect on cell viability 
in NRASQ61R after CQ treatment. This phenomenon was evident as an 8-fold difference in 
the IC50 for CQ in BRAF
V600E melanoma cell lines compared to NRASQ61R was observed 
(Table 1; Figure 1). We verified that the reduction in cell viability following CQ 
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exposure resulted in a significant increase in apoptotic cell death in BRAF* cell lines 
following CQ inhibition compared to the NRAS* cell lines (Figure 2 and 3).   These data 
indicate that BRAF V600E melanoma cell lines are more sensitive to CQ induced inhibition 
of autophagy and that inhibition of autophagy in these cells as shown by our data 
(Figures 2 and 3) results in apoptotic cell death. While CQ is currently being investigated 
in cancer trials, without a clear understanding of the biological mechanisms underlying 
the mode of action for this treatment, we may be unable to appropriately target those 
patients who can benefit from this combination therapy. Our data indicate that only 
patients with BRAF* melanomas may be responsive to autophagy inhibition with CQ as a 
co-therapy (Figure 1-3; Figure 5). 
2.6.3 BRAF cells have more basal LC3 puncta and, following autophagy 
inhibition or induction, oncogenic cell lines display different rates of 
autophagic flux. In this study dysregulation is represented by higher basal expression of 
LC3-II puncta in the BRAF V600E cell lines compared to NRAS Q61R cell lines (Figure 4 
and 5).  Thus these data are consistent with the hypothesis that cell lines with BRAF V600E 
mutations may be more dependent upon autophagy for survival than NRAS Q61R cell lines. 
In addition, the inability of BRAF* cells to upregulate autophagy over 2 hours following 
serum starvation (Figure 4) reinforcing the elevated basal level maintained in these cells. 
The failure of these cells to have the capacity to increase autophagic degradation rates in 
response to serum deprivation suggests these cells have upregulated basal autophagy to 
threshold. 39 The data that NRAS*cells can increase autophagy following serum starvation 
as well as following RAP induction indicate that these cells can use the autophagy 
pathway to survive nutrient depletion but they are not dependent upon this pathway under 
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basal conditions. In addition, we demonstrated an increase size in LC3 puncta in CQ-
treated BRAF V600E cell lines (Figure 4), suggesting autophagosome accumulation as a 
consequence of lysosomal inhibition by CQ. By contrast, we did not observe the same 
level of LC3-II aggregation and autophagosome accumulation in the NRAS Q61R cell lines 
treated with the same dosage of CQ. Further, using the western assay, we showed a 
decrease in overall LC3-I and an increase in LC3-II protein expression following CQ 
treatment (Figure 6) in BRAF* cells but not a corresponding decrease in NRAS* cells 
indicating that autophagy is induced at higher basal levels in BRAF* than NRAS* 
melanoma cells. 
 To determine if BRAFV600E was associated with autophagy activation, we 
knocked down either BRAF or NRAS in melanoma cells and evaluated the corresponding 
change in LC3 gene expression (Figure 7). These results indicate showed knock-down of 
BRAF significantly decreased LC3 expression. These results are consist with the 
association of the BRAF* and increased rates autophagy. We did not see a corresponding 
consistent trend with NRAS knockdown providing evidence that, while BRAF* correlates 
with LC3 expression, NRAS* expression does not. Previously, a positive correlation 
between LC3 protein and levels of BRAF has been also reported lending further support 
to our conclusions.32  
 Currently, BRAF inhibition is accomplished clinically by treatment with 
vemurafenib, a specific BRAF V600E ATP-competitive, small-molecule inhibitor. Studies 
have reported the development of NRAS mutation in patients following vemurafenib 
treatment for BRAF melanoma.40 This important finding reiterates the significance of 
understanding the biological mechanisms underlying the induction of the autophagy 
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pathway, as BRAF inhibition resistant tumors might also lose their sensitivity to 
chloroquine following acquisition of NRAS mutations. BRAF is an amino acid sensor and 
has been shown to positively regulate autophagy in colon cancer cells. Under nutrient 
deprivation conditions or with constitutive activation of BRAF, MAPK is induced and 
results in the upregulation of autophagy. As part of the MAPK pathway, Extracellular 
Signal-regulated Kinase (ERK) regulates the maturation of autophagic vacuoles and 
constitutive activation of the MAPK.41 MAPK activation results in the inhibition of 
mTORC1/2, as well an increase in the expression of Beclin 1 (Atg6), a protein with a 
central role in autophagy initiation. Through these interactions we speculate that BRAF 
may be facilitating an increase in basal autophagic flux (Figure 8). This speculation is 
supported by recent data reporting that the use of combination BRAF and autophagy 
inhibitors promoted tumor regression in BRAF inhibition -resistant xenografts.42   
 Limitations of our study include the absence of the characterization of the rate of 
autophagic flux in a BRAF/NRAS wildtype cell line. However, as melanoma is a highly 
mutagenic cancer, even a cell line that that expressed wildtype NRAS and BRAF would 
have other mutations which might impact autophagy independently diminishing the 
relevance of this comparison.  
 In the current study we determined that autophagy was up-regulated in BRAFV600E 
melanoma cells when compared with NRASQ61R melanoma cells as measured by 
immunofluorescence and western blot analyses and that inhibition of autophagy resulted 
in apoptotic cell death specifically in the BRAF* cells. Finally we identified a trend in the 
gene expression of a proxy marker of LC3 and BRAF expression but no corresponding 
trend with NRAS expression. 
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 Despite the recent success of BRAFV600E specific inhibitors, chemo-resistance quickly 
occurs which suggests that other signaling mechanisms, like autophagy, may contribute to 
progression in this subtype of melanoma. Our findings implicate a positive association 
between the expression of BRAF V600E mutations in melanoma cells lines and the rate of 
autophagic flux. While both BRAF and NRAS mutations activate ERK/MAPK 
signaling,43 our research reveals that melanoma cells harboring BRAF V600E mutations 
utilize autophagy as a metabolic resource to a greater extent than NRAS* cells.  In 
addition, the BRAF* and NRAS* pathways, may have opposing effects on the rate of 
autophagic flux in melanoma. Our results indicate that BRAF* melanoma cells are 
addicted to autophagy and support BRAF activation of autophagy, potentially through 
Beclin1, 44,45 thereby promoting tumor survival (Figure 8). 30,43  
 In conclusion, BRAF* melanoma cancer cells are more susceptible to autophagic 
inhibition, while NRAS* melanoma cells appear less dependent on this pathway which 
implicates this process as a viable and attractive target for future therapies. The 
identification of an association of autophagy dependence and BRAF V600E melanoma 
suggests that drugs like CQ, that suppress this process, may also have therapeutic 
potential for aggressive tumor types and that there is differential activation of the 
autophagy pathway in BRAF* vs. NRAS* melanomas.  
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2.9 Tables and Figures 
 
2.9.1 Table 1: Oncogene status and gender summary for Memorial Sloan 
Kettering melanoma cell lines (SK-Mel). 
 
  
 
 
2.9.2 Figure 1: Cell Treatment with 20 µM CQ. Average percentage of viable cells 
(n=3) following treatment with vehicle or 20 µM CQ (A) BRAF V600E mutant melanoma 
cell lines (SK-Mel 2, 19, 29) (B) NRAS Q61R mutant melanoma cell lines (SK-Mel 94, 
103, 147) (mean ± SD *, P <0.01; **, P <0.001; ***, P <0.0001). 
 
Cell Line Gender p53 B-RAF N-Ras
19 Female WT V600E WT
29 Male WT V600E WT
94 Male WT V600E WT
2 Male WT WT Mut/Q61R
103 Male WT WT Mut/Q61R
147 Male WT WT Mut/Q61R
Table 1: Memorial Sloan Kettering Melanoma Cell 
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2.9.3 Figure 2a-d:  Annexin V/PI staining by flow cytometry. Flow cytometric 
analysis of melanoma cell apoptosis in culture. Untreated and CQ treated cells collected 
after 24 h of culture were stained with PI and FITC-labelled Annexin V. Two melanoma 
cell lines, one BRAF and one NRAS were treated either with vehicle (Figure 2a and c) or c 
20 µM CQ (Figure 2b and d) for 24 hours prior to staining with Annexin V and 
propidium iodide (PI). Viable cells with intact membranes were represented by the 
unstained portion (Annexin V and PI negative) in the lower left, while and Annexin V 
stained cells, indicating early apoptotic cells, are represented in the lower right (Annexin 
V positive/ PI negative). The upper left portion represents necrotic cells (Annexin V 
negative/PI positive) while cells with disrupted membranes are undergoing late apoptosis 
or are already dead are represented in the upper right (Annexin V positive/ PI positive).  
Insets represent the percentage of cells in each quadrant. 
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2.9.4 Figure 3a-b: Caspase activity luminescence assay. BRAF (SK-MEL19) or 
NRAS (SK-MEL 103) mutant cells were treated with either vehicle or 20μM  chloroquine 
for 24 h. Following treatment the caspase 3/7 activity of each triplicate group of cells was 
quantified by a luminescence assay. Data are mean ± SD of two sets of different triplicate 
experiments. * P < 0.005. 
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2.9.5 Figure 4a-c:  Immunofluorescent staining of melanoma cell lines before 
and after autophagy induction by serum starvation. (A-B) Autophagy was 
induced by serum starvation through culture in serum-free medium (SFM) for indicated 
time points. Control cells were cultured in normal media (NM) containing FBS and 
vehicle. Live cells were treated with lysotracker and then cells were fixed prior to 
additional staining with Anti-LC3 FITC and DAPI. Composite images of LC3 (green) 
with lysosomal (red) and nuclear stain (blue) or co-localization shown by yellow dual 
staining of LC3 (green) with lysosomal (red). Cells were examined by Zeiss Axioskop 
2MOT microscope × 620. *P < 0.05. A) BRAF mutant melanoma cells in NM or SFM. 
B) NRAS mutant melanoma cells in NM or in SFM. C) Histogram of quantification of 
LC3 immunofluorescence puncta as a ratio of the percentage of cells displaying punctate 
fluorescence out of 100 cells compared to control cells in an average of three independent 
experiments. *P < 0.05. 
* 
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2.9.6 Figure 5a-e: The effect of autophagic chemical inhibition by CQ or BAF 
treatment, or RAP induced autophagy, in melanoma cells.  
Oncogenic melanoma cells were treated with vehicle, (A) rapamycin (1 μM)(RAP), (D) 
cloroquine (CQ)(20 µM) or (D) bafilomycin A (BAF)(20nmol/L) for three hours. 
Quantification of autophagy induction (C) or inhibition (E). Control cells were cultured 
in normal media containing FBS and vehicle. Live cells were treated with lysotracker and 
then cells were fixed prior to additional staining with Anti-LC3 FITC (green) and DAPI 
nuclear stain (blue). Composite images of LC3 (green) with lysosomal (red) and nuclear 
stain (blue) or co-localization shown by yellow dual staining of LC3 (green) with 
lysosomal (red).  Cells were examined by Zeiss Axioskop 2MOT microscope. × 620. 
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2.9.7 Figure 6a-b: Western blot analysis of LC-3B.  
(A) Western blot and (B) Quantitative Analysis of (A). Relative LC3 protein expression 
in BRAF and NRAS mutant melanoma cell lines when treated with vehicle (-) or 20 µM 
CQ (+) for 24 hrs. (B) Protein quantification from Western blot using densitometry of 
LC-3B-II in BRAF or NRAS mutant melanoma following treatment with vehicle or 20 
µM CQ as indicated. Results are shown as arbitrary units (AU) normalized to β-Actin 
(mean ± SD; **, P < 0.01; ***, P < 0.001; n =3). 
 
A.       B 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.9.8 Figure 7: Suppression of BRAF or NRAS mRNA expression by siRNA.  
SK-Mel cells were transiently transfected with si-BRAF; si-NRAS or scrambled siRNA 
(Scramble). Twenty-four, forty-eight or seventy-two hours after siRNA or scramble 
treatment, total RNA was extracted from transfected cells and quantified using real-time 
PCR. Expression levels of BRAF and LC3 mRNA were significantly suppressed by si-
SK-MEL 103 SK-MEL 19  
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BRAF (A) and expression levels of NRAS mRNA were significantly suppressed by si-
NRAS (B) but had an insignificant influence on LC3 mRNA. Results are normalized to 
the expression level of B-actin mRNA and are expressed as the ratio of BRAF, NRAS or 
LC3 expression to scramble. Data are presented as mean ± SD of three replicate 
experiments. 
 
 
2.9.9 Figure 8: Melanoma cells with activating BRAF* or NRAS* have 
differential dependence on autophagy 
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CHAPTER THREE: 
Quantitative Analysis of Immunohistochemistry in Melanoma Tumors and LC3 
and Beclin 1 Expression in Melanoma Lesions: Association with UV Exposure 
and Prognostic Indicators.    
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Supplemental note: Due to the current subjective quantification of protein expression, in 
order to rigorously address whether autophagic flux is associated with UV exposure 
and/or clinical stage and modified by oncogenic BRAF/NRAS in melanoma tumors, I 
developed a novel quantification method which removes this aspect from the evaluation 
of proteins by IHC in melanoma.  
3.1 Abstract: 
Aims: Interpretation of protein expression, by immunohistochemistry (IHC), in 
melanoma tissue sections is difficult and subjective. Inter/intra-observer variability even 
among experienced dermatopathologists and inherent pigmentation, make diagnostic 
reproducibility challenging.  
Methods: We sought to identify a quantitative method for measuring IHC protein 
expression in melanoma tissues. In the current study, we used IHC HRP-DAB with an 
Azure counterstain, to develop a quantitative measurement of protein expression using 
spectral imaging technology. 
Results:  We examined the distribution of mean intensities from DAB-labeled protein in 
different participants using different Azure reference spectra to remove (unmix) melanin 
stain. We identified no significant differences in mean DAB intensities (p=0.73; Kruskal-
Wallis).  
Conclusions: To our knowledge, this is the first study to use spectral imaging to quantify 
IHC protein expression in melanoma lesions. Using this methodology, the absorbance 
spectra of the reference is not affected by overall label intensity, allowing IHC 
interpretation to be independent of high visual contrast chromogens.  This has important 
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implications particularly for pigmented tissue sections. This quantification method 
reduces the subjectivity of protein expression analysis and provides a valuable tool for 
accurate evaluation.   
Keywords: Immunohistochemistry; melanoma; spectral imaging 
 
3.2 Introduction: 
Immunohistochemistry (IHC) is an important technique to both researchers and 
clinicians1, and is used to identify the presence and location of protein2.  Most cancer 
research employing IHC utilizes formalin-fixed paraffin embedded (FFPE) tissues that 
have been sectioned and mounted onto slides. For clinicians, IHC is particularly 
important in the diagnosis of cancers, including melanoma, as it allows for identification 
of overexpressed proteins. These protein biomarkers, for example S100 and HMB-45 in 
melanoma, can predict disease progression and identify potential therapeutic targets. 
Standard IHC is a multi-step technique that has two major stages—antigen 
retrieval/staining and analysis.  The first step in the staining stage is deparaffinization and 
rehydration of the tissue section. The tissue section is incubated in a buffer under high 
heat to remove cross-links formed during the fixation process and “expose” proteins of 
interest. Antigen retrieval unmasks antigens within the tissue section for binding to 
antibodies, followed by a series of steps to block antibody binding to non-specific 
proteins and the removal of endogenous peroxidases.  Next, the tissue is incubated with a 
high affinity primary antibody specific to the protein of interest. Visualization of the 
protein is accomplished using a chromogen substrate and an enzyme, such as horseradish 
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peroxidase (HRP), is conjugated to either the primary antibody or a secondary antibody 
against the primary antibody.   
The addition of the chromogen bound to the substrate-conjugated antibody results in 
substrate cleavage, producing a colored stain at that location, and thereby indicating the 
presence of the target protein. The most commonly utilized substrate-chromogen 
combination is HRP (substrate) 3,3’-Diaminobenzidine (DAB) (chromogen), which 
results in a brown stain and there are a limited number of substrate-chromogen 
combinations available for IHC 3. 
 
Once the tissues are developed, they are dehydrated and mounted with a stabilizing 
mounting medium and coverslip for visualization. The stains are visualized using 
microscopy and quantified through a variety of methods. Current IHC analysis is semi-
quantitative; typically several readers use a subjective scoring system. The scores are 
subsequently compared in order to assess inter-reader variability4.  
 
The limitations of this semi-quantitative method have been particularly troublesome in 
melanoma, because the melanin pigment is brown, creating challenges for both 
researchers and clinicians to accurately differentiate between DAB staining and melanin, 
potentially impacting accurate diagnoses.  Given the importance of this tool, there is a 
need for a non-subjective quantitation method that can be applied to IHC in melanoma 
tissue sections. 
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In 1991, Kamino and Tam identified that Azure B, hereafter referred to as Azure, acts as 
an appropriate counterstain in melanoma sections5. They reported that Azure stains 
melanin green-blue, allowing for its identification in contrast to the surrounding tissue. 
However, this method was still quantified using the scoring system, and therefore relies 
on subjective interpretation.  
Azure, a cationic dye, is one of the major metabolites of methylene blue and is used in 
chromosomal tissue staining6. While the selective binding is not well characterized in the 
literature, we propose, as a provisionary mechanism, that the heterocyclic nitrogen in 
Azure functions as a base7 to deprotonate carboxylic acids found in melanin. This would 
allow for ionic interactions between melanin’s anion and the cations in Azure. Acidic 
interplay, in conjunction with hydrogen bonding, likely results in the preferential staining 
of the melanin (Supplemental Figure 1).  
With advances in imaging and associated software, we sought to identify a quantitative 
method for measuring protein expression in melanoma tissues. In the current study, we 
used IHC HRP-DAB staining in melanoma tissues, with Azure as a counterstain, to 
develop a quantitative measurement of protein expression using spectral imaging 
technology. 
 
3.3 Methods: 
3.3.1 Tissue samples: 
Melanoma tissue sections were obtained from two different sources:  University of 
California Surgical Pathology Laboratory and the University of New Mexico Hospital 
(UNMH) Surgical Pathology Laboratory. California Surgical tissues were selected from a 
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residual bio-repository of de-identified FFPE tumor blocks from patients diagnosed with 
malignant melanoma between 1990 and 1999 in Los Angeles County.  New Mexico 
tissues were selected from the University of New Mexico Ultraviolet Light Exposure and 
Immunosuppression in Melanoma bio-repository (INST 0815 HRRC 08-433).  
Non-pigmented control tissue was obtained from breast reduction mammoplasty surgery 
between November 2007 and January 2011 as previously described8. This sample was 
collected with IRB approval and was de-identified.  
3.3.2 Immunohistochemistry (IHC):  
All IHC protocols were performed according to the antibody manufacturer’s instructions. 
Briefly tissue sections were stained with antibody produced in rabbit and generated 
against a C-terminus peptide in G protein-coupled estrogen receptor 1 (GPER) (clone 
number 8073) at a dilution of 1:200 for one hour and fifteen minutes.  The GPER 
antibody was a generous donation from the laboratory of Dr. Eric Prossnitz.  Tissue 
sections were then incubated with 1:100 dilution of secondary goat anti rabbit-HRP 
antibody for one hour (Sigma, St. Louis, MO). 
HRP activity was visualized using the Liquid DAB Plus Substrate Kit (Life 
Technologies, Carlsbad, CA) according to manufacturer’s instructions. Following 
incubation with DAB, sections were stained with Azure for 10 minutes5. Tissue sections 
were then dehydrated and mounted with a coverslip using permount.  
3.3.3 Image Acquisition and Analysis: 
Brightfield, spectral images of IHC labeled sections were generated at the UNM Cancer 
Center Fluorescence Microscopy and Cell Imaging Shared Resource using a Nikon 
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TE2000 microscope (Melville, NY) in transmitted light mode, which had been adjusted 
for Koehler illumination. Images were obtained using a 60x oil objective, at 1.5x 
intermediate magnification, and a Nuance Spectral Imaging Camera and software (Perkin 
Elmer). The Nuance camera uses a liquid crystal tunable filter (LCTF), set to collect 
transmitted light in 20 nm bandwidths, at 10 nm step intervals, from 420 to 720 nm. The 
resulting spectral image cube consists of 16 separate images each acquired at a different 
wavelength range.  Each pixel in the resulting image cube has an absorbance spectrum 
that depends on the absorbing materials (labels) that are present at that pixel location.  
Nuance camera software controls both the LCTF and spectral image acquisition. Prior to 
imaging of the tissues, a 100% transmission reference image cube was acquired from a 
region of the slide with no tissue or other debris and was used to convert all images to 
optical density (OD) images. Spectral image cubes collected from melanoma sections 
labeled only with Azure or anti-GPER-DAB were used to generate pure absorbance 
spectra for each of these labels. These pure spectra were then used by the Nuance 
software to unmix (using a linear unmixing algorithm) image cubes acquired from slides 
labeled with both Azure and DAB, generating single component images of each label.   
Absorbance spectrum imaging and unmixing of IHC labeled sections has been previously 
described9. 
Three reference spectra (pure absorbance spectra) of Azure were generated from 3 
separate patient tumors, each labeled only with Azure.  A single reference spectrum of 
GPER-DAB was generated from a GPER-positive, non-pigmented tissue section labeled 
only with anti-GPER DAB.  To quantify the staining, we generated three spectral 
libraries, each consisting of two spectra: 1) GPER-DAB reference spectrum and Azure 
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spectrum from patient tumor section A; 2) GPER-DAB reference spectrum and Azure 
spectrum from patient tumor section B; 3) GPER-DAB reference spectrum and Azure 
spectrum from patient tumor section C.  
Additional tissue sections from the same three patient tumors were doubly labeled with 
GPER-DAB and Azure and spectral image cubes were acquired with the Nuance camera.   
These spectral image cubes were unmixed with each of the three spectral libraries 
described above. The Azure component images show location of the counterstain and 
tissue structure; GPER-DAB component images show GPER-expressing cells in the 
section.   
GPER-DAB component images were exported from the Nuance software as TIF images, 
imported into Slidebook software 6.0 (3i, Intelligent Imaging Innovations, Denver) and 
the GPER-DAB staining was quantified.  Component GPER-DAB images were inverted 
from absorbance to pseudofluorescence for analysis.  In the inverted images, higher 
pseudofluorescence intensity corresponds to higher absorbance (DAB concentration).  A 
segment mask was created by setting a threshold to eliminate background.  Intensity 
values above the threshold represent DAB labeling.  A single threshold level was 
determined by examination of multiple images and was used for quantifying all of the 
DAB component images. Segmentation masks were created on each doubly labeled 
patient section.  Utilizing the mask statistics function in Slidebook, we exported the mean 
intensity value of each masked region in the GPER-DAB component images for 
statistical analysis. 
3.3.4 Statistics:  
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Mean intensity of anti-GPER-DAB in the three sections stained with GPER-DAB and 
Azure was compared following unmixing with the three reference spectral libraries 
described above, generating three mean intensities of GPER-DAB staining for each of the 
participants. Since the distribution of mean intensities of GPER-DAB staining 
(distribution) might not meet normality assumptions, we used the Kruskal–Wallis one-
way analysis of variance (ANOVA) to compare the distributions. The null hypothesis 
was that the distributions for each of the participants would be equal. The alternative 
hypothesis is that the distribution for at least one of the participants is different from the 
distribution for other participants. 
3.4 Results:  
3.4.1 Azure reference spectra do not vary between tissue sections: 
Because the absorbance spectrum of melanin may vary from person to person, the 
spectrum of Azure bound to melanin may also vary from person to person, as the melanin 
pigment masked by Azure staining will be included in the absorbance spectrum. 
Additionally, we were concerned that the affinity of Azure to bind to melanin may also 
vary from person to person. To address these concerns, we compared Azure spectra 
across melanoma tissues samples from three different participants.  
Figure 1 shows the three Azure reference spectra (blue, green, and red lines) generated 
from melanoma tissues sections labeled with Azure only from three different participants.   
A GPER-DAB reference spectrum (brown line) was generated in a non-pigmented tissue 
section stained only with GPER-DAB. Importantly, the three Azure spectra overlap and 
are visually comparable (Figure 1). 
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3.4.2 Quantification of GPER-DAB staining in tissue sections with Azure 
counterstain: 
As described previously, from the spectra represented in Figure 1, we generated three 
spectral libraries which included one Azure spectra derived from the three different 
participants and the GPER-DAB spectra derived from the non-pigmented tissue section.  
Each of these spectral libraries is named A, B, or C (Figure 2 and Table 1) consistent 
with the participant (A, B, or C) from which the Azure spectra was derived. 
Melanoma sections stained with both GPER-DAB and Azure for each participant (A, B, 
and C) were imaged with the Nuance spectral camera, generating spectral image cubes, 
referred to in Figure 2 as Original Image. The Nuance software creates a single image 
representation of the spectral cube, using a lookup table that maps different patterns of 
absorbance to different colors which we refer to as the original image.  Although the 
original image appears to show good localization of label, accurate location information 
is obtained only after unmixing the original image, using a spectral library with reference 
spectra for each of the labels on the section.  The original image from participant A is 
shown in Figure 2. 
Using spectral library A, comprised of the Azure spectra from participant A and the 
spectra from the non-pigmented GPER-DAB tissue, we unmixed the original image from 
participant A. We also unmixed the original image from participant A using the spectral 
libraries that included Azure spectra generated from participants B and C.  As shown in 
Figure 2, these GPER-DAB component images appear nearly identical. 
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Similarly, we unmixed the original images from participants B and C with all three 
spectral libraries, resulting in three GPER-DAB component images per participant, and 
nine GPER-DAB component images total for participants A, B, and C. The component 
images for GPER-DAB are shown for participant A in Figure 2, and the mean intensities 
are reported for each of the nine GPER-DAB component images in Table 1.  
To compare the distribution of mean GPER-DAB intensities of participants compared to 
themselves but unmixed with different Azure reference spectra, we performed a Kruskal-
Wallis test and identified no significant differences (Table 1).  These results indicate that 
the reported mean intensities vary slightly depending on the Azure reference spectra. 
However, these differences are not significant for any of the patient samples (p=0.73 
p>0.05; One-way ANOVA with Kruskal-Wallis).  Importantly, this suggests that one 
Azure reference spectrum is sufficient to unmix dual-stained images from multiple 
participants, eliminating the need for a separately stained section and Azure reference 
spectrum for every individual. 
3.5 Discussion: 
We have shown that using Azure as a counterstain in pigmented tissue sections, such as 
melanoma tumors, allows for quantification of HRP-DAB staining using spectral imaging 
techniques. Acquisition of spectral images of IHC stained melanoma tissue samples and 
subsequent unmixing using reference spectra, allows DAB-labeled protein to be 
quantified without interference from highly pigmented melanin. Although not 
demonstrated here, this method also allows for the observation of co-localization and 
quantitative measurement of multiple staining components. Unmixing is based on the 
absorbance spectra of the labels, is not affected by overall label intensity and is non-
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subjective, meaning that IHC is no longer dependent on the chromogens showing a high 
visual contrast with pigmentation or other chromogens.  
Importantly, this method allows for elimination of inter-reader variability by using 
spectral imaging to evaluate highly pigmented tissues. This finding improves the current 
semi-quantitative method of IHC, and increases the utility of IHC for both researchers 
and clinicians. 
This study has many strengths. First, we have identified a non-subjective method to 
quantify protein expression in pigmented melanoma tissues.  Furthermore, it is likely that 
this method would also provide a non-subjective method for quantification of protein 
expression in non-pigmented tissues, along with tissues using multiple chromogens.  
Additionally, we used archival tissues to validate that this technique can be applied to 
stored samples. Stored samples serve as a valuable resource for biomarker validation 
studies, but are often limited by the quality of the specimen and the loss of antigenicity 
over time.   
The discovery that one Azure reference spectrum can be used for every participant has 
important implications. First, it will lessen the amount of time needed to image tissue 
sections by eliminating the need to image an Azure reference for every participant. This 
will also hasten the unmixing process, as each participant’s dual-stained image will be 
unmixed using the same spectral library, allowing for batch unmixing. Finally, this will 
reduce the number of tissue sections needed from each participant, thereby allowing 
precious samples to be used for additional biomarker testing. 
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In summary, to our knowledge, this is the first study to use spectral imaging to quantify 
protein expression in pigmented tissue sections. This quantification method reduces the 
subjectivity and hastens analysis of protein expression detected by IHC.  For clinicians, 
non-subjective quantification of protein expression in melanomas may impact the current 
diagnosis and staging standards. For researchers, quantification of protein expression may 
further inform melanoma etiology, progression and identification of therapeutic targets.  
Therefore, we expect that these findings will advance the field of melanoma. 
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3.8. Tables and Figures 
3.8.1 Figure 1: Azure Spectra do not vary between melanoma tissue sections 
 
 
 
3.8.2 Figure 2: Component images unmixed with different spectral libraries 
 
A:  
 
 
B.   
 
         
 
A: Original image: GPER-DAB and Azure in Melanoma (Participant A). This is a single image 
representation of a spectral image cube (containing 16 individual images). 
Azure  GPER 
 
Absorbance spectra of GPER ( 
) and Azure acquired from 
3 separate melanoma tissues (
). 
 
Original image A unmixed 
with Spectral Library A 
Original image A unmixed 
with Spectral Library B 
Original image A unmixed 
with Spectral Library C 
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B. Component images representing GPER-DAB in melanoma: Original image (Participant A) 
unmixed with three spectral libraries.  
3.8.3 Supplemental Figure 1: Proposed mechanism for Azure binding to 
melanin 
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3.9 Abstract  
LC3 and Beclin 1 Expression in Melanoma Lesions: Association with UV 
Exposure and Prognostic Indicators.  
 
Background: The activation of the autophagy pathway in BRAF melanomas is one 
proposed mechanism involved in progression. Autophagy, a catabolic process, has been 
shown to both inhibit and promote tumorigenicity. Autophagy inhibition is under 
investigation in melanoma treatment.  However, the melanoma risk factor, UV exposure, 
activates autophagy. Here we investigated UV exposure and autophagy by BRAF/NRAS 
status to test for differential contributions to melanoma prognostic factors and survival. 
 
Methods: Sections from n melanoma tumors and n benign nevi were analyzed for 
Beclin1 and LC3 expression, using immunohistochemistry. BRAF /NRAS status was 
determined by sequencing. Beclin1 and LC3 expression levels measured by IHC were 
correlated with UV exposure data. The effect of NRAS and BRAF pathways on autophagy 
proteins was evaluated. 
 
Results: We found that the autophagy pathway is activated with UV exposure in 
melanoma tumors compared to benign nevi. We observed critical proteins in the 
autophagy pathway associated with decreased Breslow depth (Beclin1) as well as 
decreased mortality (LC3). 
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Conclusions: The expression of Beclin1 and LC3 was not directly linked BRAF or NRAS 
mutations in melanoma; rather, autophagy was activated in response to UV exposure and 
associated with prognostic indicators and survival. These findings may have implications 
concerning the biology of melanoma and for ongoing autophagy inhibition clinical trials.
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3.10 Introduction:  
 Invasive melanoma has an increasing incidence of 6% each year but with new 
clinical treatment options for advanced melanoma. The American Cancer Society 
estimates that in 2015, 73,870 new melanomas will be diagnosed and 9,940 people will 
die from their disease.  Despite the introduction of new therapies, the 5-year survival rate 
for stage IV melanoma will remain unchanged at 15% to 20%.1  
 Autophagy is a cellular recycling pathway involved in normal physiological 
processes including nutrient and/or stress responses, antigen presentation, and aging.3–8 In 
cancer, autophagy appears to be an important energy source for nutrient depleted tumors. 
9–11 In melanoma, basal levels of autophagy appear to vary by tumor stage, and higher 
levels of autophagic flux are associated with increased hypoxia and poor clinical 
prognosis. 11–15 Mutations in BRAF and NRAS differentially regulate autophagy. 16–22 In 
2010, Lazova and colleagues reported that melanoma cells contain high levels of 
autophagosomes, a cellular structure associated with autophagic flux, as measured by the 
proxy marker microtubule-associated protein 1 light chain 3 (LC3), an autophagy related 
(ATG) protein.11 LC3 is integrated into the membrane of a critical structure in autophagy, 
called the autophagosome, in order to facilitate the recycling of products targeted for 
degradation. This integration creates a punctate LC3-staining pattern, which is used as a 
proxy marker for the rate of autophagy. 11  The role of LC3 and another critical protein in 
autophagy initiation, Beclin 1 (Becn1), may have a biphasic role in cancer. 3   LC3 levels 
have been shown to be elevated in the cytoplasm of cancer cells including 
gastrointestinal23 and pancreatic cancer.24 and have been reported to be associated with 
stress response, metastasis and poor clinical prognosis in melanoma.15,19,25,26  Becn1 has 
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been reported to be associated with increased stage27, lower relapse-free survival 28 and 
decreased 5-year survival in several cancers.29  Elevated levels of LC3 and Becn1 as well 
as other autophagic proteins correlated with  poor prognosis or cancer progression have 
prompted Phase I/II clinical trials to investigate autophagy inhibition as a co-therapy, 
particularly in melanoma.30–32  
Conversely, it also appears that there is an inverse relationship between expression of 
autophagy markers and malignant potential, so in some cancers lower levels of autophagy 
are associated with worse prognosis. This implies that defects in cellular autophagy may 
contribute to the development of cancer33 and that cancer cells may have lower basal 
autophagic activity. 34–37 Low levels of both Becn1 and LC3 have also both been reported 
to associate with poor clinical pathological markers and decreased survival 38–40 in 
melanoma, among other tumors.41,42 Becn1 in particular has been shown to exhibit anti-
oncogenic functions, has been found to be monoallelically deleted in breast, ovarian and 
prostate tumors.43–46 Finally, low levels of Becn1 have also been reported in nodular 
melanomas to be associated with increased risk of early death.47    The dual role of 
autophagy in the regulation and progression of melanoma require further investigation. 
The role of these two autophagy proteins (LC3 and Becn1) in melanoma may, in part, be 
influenced by their interaction with other factors including ultra-violet (UV) exposure. 
UV’s impact on progression and survival in melanoma is also complex and unclear. 48,49 
As autophagy appears to have a role in the resolution of double-stranded DNA 
breaks50,51, it may be that UV induces autophagy and  improves melanoma-specific 
survival at the same time that it is the major risk factor for melanoma. The impact of UV 
exposure on autophagic processes in skin has not been well characterized and there is a 
 
 
118 
 
need for in-depth evaluation of role of autophagy in a set of well-defined melanoma 
samples.52 
In the current study, we seek to determine whether autophagy differentially regulates 
prognostic characteristics and survival in melanoma depending on the timing of UV 
exposure. We evaluated autophagy in 51 melanoma and 17 benign nevus tissue sections, 
for LC3 and Becn1 protein expression, using immunohistochemistry (IHC) to determine 
if autophagic flux is associated with clinical stage in melanoma. For the same samples, 
using extensive questionnaire data, we evaluated the impact of estimated lifetime sun 
exposure on survival and correlated these data with prognostic factors as well as available 
information on autophagy levels. These results assessed whether autophagic flux is 
modified by UV exposure. We hypothesized that UV exposure is associated with levels 
of autophagy and autophagy markers are prognostic for clinical characteristics of 
melanoma survival. 
3.11 Material and Methods: 
3.11.1 Patient Characteristics:  
The New Mexico Tumor Registry and the University of New Mexico Cancer Center 
identified study participants in which a skin biopsy was taken to rule out melanoma.  
Study participants with melanoma or a benign skin biopsy (n=98) were interviewed using 
a validated questionnaire for UV exposure.48,53 Institutional Review Boards of all 
participating institutions approved the protocol and informed consent was obtained from 
each participant. 46 melanoma and 17 patients who had a benign nevi excised, were 
consented, enrolled and interviewed and selected based on availability of a tissue block 
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(see patient characteristics below, Table 1-2). Survival was determined using the National 
Death Index and provided by the Tumor Registry. 
3.11.2 IHC Staining of LC3 and Becn1: 
Formalin-fixed paraffin embedded (FFPE) control and melanoma sections were made 
using archival tissue blocks from patient biopsies. Expression of LC3 and Becn1 in these 
sections were measured as a proxy for levels of autophagy. Standard immunoperoxidase 
techniques for immunohistochemistry using anti-LC3 and anti-beclin1 antibodies (MBL, 
Woburn, MA; Cell Signaling Technology, Danvers, MA; 1:200; with citric acid/ antigen 
retrieval) was used to quantify expression in melanoma  cells (brown) compared to 
tumor-associated melanophages (azure). Azure B stains melanin green blue and is easily 
distinguished from the brown diaminobenzidine chromogen54. Original images were 
obtained using a Nikon Scope from the UNM Fluorescence Microscopy Shared 
Resource, equipped with a spectral imaging camera. Becn1 and LC3 staining intensity 
were quantified by Spectral imaging software.55  
 
3.11.3 BRAF, NRAS status:  
Genomic DNA was isolated from FFPE tumor sections using Qiagen QIAamp DNA 
FFPE kit (Qiagen, Inc., Valencia, CA). Patients’ BRAF/NRAS mutation status was 
evaluated using standard PCR technique to amplify the coding region of interest. All 
amplicons were directly sequenced on an ABI 3730xl DNA Analyzer (Applied 
Biosystems, Foster City, CA) using BigDye Terminators (Applied Biosystems) according 
to the manufacturer's specifications for sequencing. A 224 bp BRAF PCR product 
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(chr7:140453033-140453256) was amplified using the primers 5′-
TCATAATGCTTGCTCTGATAGGA-3′ and 5′-GGCCAAAAATTTAATCAGTGGA-3′ 
and a 272 bp NRAS PCR product (chr1:115256298-115256569) was amplified using the 
primers 5′- GGTGAAACCTGTTTGTTGGA-3′ and 5′- 
AACCTAAAACCAACTCTTCCCA-3′ in a  50 ml reaction containing the 10 μL 
(40ng/μl) DNA template, 5 μM of each primer, 2× Premix F (Epicentre, Madison, 
Wisconsin) and 0.5 U of Taq polymerase in a PCR reaction as described above. DNA 
template was denatured at 94°C for 4 min and cycled 26 times through steps of 
denaturing at 94°C for 1 min, annealing 63-0.5c and denaturation. An additional 10 
cycles of denaturing at 94°C for 1 min, annealing 50c and extension at 72°C; final DNA 
extension was at 72°C for 10:00 minutes. PCR products were purified using ExoSap 
(Affymetrix, Santa Clara, CA) according to manufacturer's instructions. 
Sequencing chromatograms were read with the aid of FinchTV software version 1.4.0 
(Geospiza, Inc., http://www.geospiza.com/Products/finchtv.shtml)  
3.11.4 Clinical Stage:  
Histopathology was characterized by a board-certified pathologist using Hematoxylin & 
Eosin (H&E) stained slides and clinical stage was determined including Breslow 
thickness, mitotic index and ulceration. Mitoses were defined as present or absent. 56 All 
cases were characterized using these variables. Patient vital status was obtained through 
linkage with the NM Tumor Registry, using an honest broker system with IRB approval 
(HRRC 08-433). 
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3.11.5 UV Exposure:  
Using extensive questionnaire data, participants were retrospectively evaluated for UV 
ambient exposure in the first decade of life and near the time of diagnosis.  Questionnaire 
data, which has been previously described,53 includes the following variables: daily sun 
exposure on weekdays and weekends at each decade; sun exposure at the site of the 
melanoma at each decade; and waterside recreational sun exposure at each decade.  
3.11.6 Data Analysis:  
Frequency tables were used to summarize the clinical distributions and UV exposures for 
controls and melanoma cases (Table 1-2).  Analysis of UV data with participant 
characteristics was correlated with oncogene status and levels of LC3 and Becn1 protein 
in melanoma tissue sections. Wilcoxon rank-sum tests and Pearson chi-squared tests were 
performed for pair-wise associations. ORs and 95% CIs were calculated from non-
parametric logistic regression models using data from cases and benign nevi controls to 
assess the association with LC3 and Becn1 expression. The Pearson’s coefficient was 
used to assess linear relationships. The relationship between categorical variables was 
analyzed by Chi-square test or Fisher’s exact test. Univariate and multivariate analyses of 
prognostic factors were performed by the Cox proportional hazards regression model. 
ORs and 95% confidence intervals estimated from coefficients were used to summarize 
the associations. For all tests, a two-sided P value <0.05 was considered statistically 
significant. 
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3.12 Results:  
In the overall population we identified 24 BRAF T1799A (V600E) point mutations in 16 
cases and 8 controls. Additionally, we found 6 cases with NRAS A182G (Q61R) 
mutations.  No controls had an NRAS mutation. There were 24 melanoma cases and 9 
controls without a mutation in BRAF or NRAS. Protein levels were evaluated in 48 
melanoma biopsies and 17 control tissues using the novel IHC quantification method we 
developed and is described previously in chapter 3 (Table 2; Table 4).  
After adjustments for age and sex, high Becn1 expression was associated with decreased 
Breslow thickness (p=0.05), whereas high levels of LC3 were correlated with decreased 
mortality among patients (p=0.02).  Furthermore, females were more likely to have 
tumors with high Becn1 expression (p=0.02) (Table 3).  Melanoma participants who 
reported ever having a blistering sunburn were more likely to have high Becn1 
expression (p=0.01) (Table 4). Becn1 expression was not associated with NRAS* or 
BRAF* status. Superficial spreading histology (Table 3) and report of blistering sunburns 
in early life had borderline associations with high levels of Becn1 and LC3 (P = 0.09, P = 
0.08, respectively) (Table 4). 
High LC3 expression was also positively associated with the expression of punctate LC3 
(p=0.0007) (Table 3).  High cytosolic LC3 expression correlated with NRAS WT 
genotype (p=0.01) when compared to NRAS mutant Table 3).  A lack of painful sunburns 
for two or more days (p=0.03) was associated with high LC3 expression (Table 4). High 
LC3 expression had a borderline significant associations with unprotected prolonged sun 
exposure (p=0.06), boating activities and any outdoor activity sun exposure (p=0.08) 
(Table 4). 
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3.13 Discussion: 
This study was designed to assess the association of oncogene status and UV exposure 
with protein levels of Becn1 and LC3 in cutaneous melanoma. UV is associated with 
both autophagy activation and melanoma incidence, and as both UV and autophagy are 
complex.  
Previously, it has been shown that Becn1 and LC3 protein levels are altered in several 
human cancer types including melanoma and our data supports the fact that protein levels 
vary between melanoma and control patient samples. 57 We also found that expression of 
autophagy markers varied by Clark’s level and survival status.  
High levels of Becn1 and LC3 are consistently inversely associated with poor prognostic 
markers and/or survival. High Becn1 expression was associated with decreased Breslow 
depth (the strongest prognostic indicator for melanoma) (p=0.05) (Table 3), whereas high 
levels of punctate LC3 indicating autophagosome formation, had an association with 
decreased mortality among patients (p=0.04) (Table 5).  Early autophagy, as represented 
by Becn1, was associated with lower stage at diagnosis, while late stage autophagy, as 
represented by lower punctate LC3 expression, and was associated with decreased 
mortality from melanoma (Table 5). Autophagy genes have previously been implicated 
both in tumor suppression and tumor development.44 Becn1 has multiple functions.  In 
addition to its role in autophagy initiation, it is implicated in both the differentiation and 
apoptosis of cancer cells.58,59 Lower Becn1 expression has been reported in both breast 
cancer,60 and melanoma42  and the loss of Becn1 has been correlated with poor prognosis 
in colon61  and liver50 cancer, lymphomas62 and squamous cell carcinoma.27 
Overexpression of Becn1 is also correlated with progression of gastric and colorectal 
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cancer63  and with poor prognosis in endometrial cancer. 29In our study the association of 
high Becn1 with decreased Breslow thickness might indicate that it is acting as a tumor 
suppressor in melanoma patients.  
In our study, the expression of the Becn1 protein and also of the autophagosome protein 
LC3 was found to be lower in melanomas with more aggressive prognostic indicators, 
similar to findings in ovarian cancer. 38The expression of Becn1 and LC3 could also be 
associated with UV in melanoma as both of these proteins were associated with UV 
exposure 
The relationship between UV and autophagy may have important implications for data 
describing the autophagy pathway in melanoma progression.17,26  While melanoma only 
accounts for approximately 2.4% of all cancer related deaths, it is the one of the most 
common cancers in young adults, age 25-29, particularly in young women. This is of 
particular importance as the mean survival rate of patients diagnosed with metastatic 
melanoma is six months, with five year survival rates of less than 5%.  UV exposure 
causes DNA damage and can induce the activation of autophagy. 
Extensive studies of the role of UV in survival with melanoma have been based on 
careful measurement of UV and melanoma risk,53 and  sun exposure and survival with 
melanoma.48,64  We evaluated sun exposure at three times in life:  early life up to the age 
of 10, in the 10 years prior to diagnosis, and averaged over the lifetime.  Studies have 
shown that an individual’s lifetime sun exposure is well represented by the sum of their 
exposures at each decade (e.g., 10, 20) of age. 65  We also evaluated sunburns and water-
related activities.  While not significant our study identified an association between water 
activities and boating activities and increased Becn1 expression (Table 3). 
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Previously it has been reported that the only significant UV predictors of melanoma 
survival are UVB dose up to the age of 10 and sunburns in the decade prior to diagnosis. 
48 Strangely, UVB dose up to the age of 10 increased the risk of dying from melanoma, 
yet any sunburns in the decade prior to diagnosis decreased the risk of dying from 
melanoma, even after adjusting for clinical characteristics.  As autophagy acts as a 
cytoprotective mechanism against ultraviolet (UV)-induced apoptosis, Becn1 and LC3 
expression may be upregulated following DNA damage from sun exposure.66  
UV-radiation is an established risk factor for melanoma and increases autophagic flux. 67 
UV exposure triggers defense mechanisms, including an increase in DNA repair 
capacity,49,68 and autophagy has an established role in DNA repair by removing products 
of DNA damage. 67 Some researchers have found evidence that high levels of sun 
exposure prior to diagnosis were associated with better melanoma survival.64  However, 
contradictory evidence indicates high levels of UV exposure in childhood are associated 
with worse survival and that high levels of UV exposure prior to diagnosis are associated 
with better overall survival but not with better melanoma-specific survival. 48 In our study 
we identified that UV exposure is independently associated with levels of autophagy as 
shown by the high LC3 protein expression in individuals with decreased sunburns or no 
participation in water sports (Table 4). 
Our study is limited by the possibility that cells use other mechanisms, including post 
translational modifications, to regulate protein expression so LC3/Beclin1 may stay 
consistently expressed under variable conditions.   In addition, our small sample size may 
not really be representative of a larger population-based sample. 
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In our study, high level of Beclin 1 and LC3 expression in tumors, correlated with less 
aggressive histopathological markers including Breslow thickness, as well as better 
overall survival of the patients.  The present data support the idea that while autophagy is 
associated with melanoma tumors, low level of autophagy favors cancer progression and 
that autophagy may support more indolent melanoma phenotype. Understanding the 
relationships between autophagy status, UV exposure and melanoma progression will 
help to elucidate the molecular mechanisms that contribute to this disease. 
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3.16 Tables: 
3.16.2 Table 1. Demographic and pathological summary of participants. 
N=68 Overall Control Case 
Age at diagnosis/Presentation No.  59.5 54.9 60.7 
 
No. % No. % No. % 
Gender 
      Male  48 51.1 11 61.1 37 48.7 
Female 44 46.8 6 33.3 38 50 
Oncogene Status             
NRAS* 7 7.4 . . 7 9.2 
BRAF* 25 26.6 1 5.6 24 31.6 
Wild-type 45 47.9 9 50 36 47.4 
Breslow thickness (mm)  
 
 
    0.01-1.00 30 31.9 . . 30 39.5 
> 1.00 32 34 . . 32 42.1 
LC3 Punctate              
Absent 30 31.9 6 33.3 24 31.6 
Present 39 41.5 11 61.1 28 36.8 
Anatomic site   
 
 
    Trunk/pelvis 15 16 . . 15 19.7 
Scalp/neck 6 6.4 . . 6 7.9 
Face/ears/other 13 13.8 . . 13 17.1 
Upper extremities 20 21.3 . . 20 26.3 
Lower extremities 17 18.1 . . 17 22.4 
Histological subtype              
SSM 38 40.4 . . 38 50 
NM 19 20.2 . . 19 25 
LMM 9 9.6 . . 9 11.8 
Other 2 2.1 . . 2 2.6 
Mitosis       
Absent 21 30.8 . . 21 41.2 
Present 29 42.7 . . 29 56.9 
Regression  
      Absent 28 29.8 . . 28 36.8 
Present 26 27.7 . . 26 34.2 
Ulceration  
 
 
    Absent 13 13.8 . . 13 17.1 
Present 44 46.8 . . 44 57.9 
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Clark's Level       
    Level  2 21 22.3 . . 21 27.6 
Level  3 8 8.5 . . 8 10.5 
Level  4 23 24.5 . . 23 30.3 
Level  5 7 7.4 . . 7 9.2 
Vital Statistics 
      Death from melanoma*  68 72.3 6 33.3 62 81.6 
Alive or death from other causes  12 12.8 . . 12 15.8 
3.16.3 Table 2. Summary of participants UV exposure. 
   Overall Control Case 
 No. % No. % No. % 
UV exposure        
Sunlamp Use 
      Never 64 68.1 13 72.2 51 67.1 
Ever 24 25.5 5 27.8 19 25 
Missing 6 6.4 . . 6 7.9 
Sun exposure without any protection             
Get a severe sunburn with blistering 13 13.8 3 16.7 10 13.2 
Have a painful sunburn for a few days 
with peeling 
34 36.2 5 27.8 29 38.2 
Get mildly burnt followed by some 
tanning 
27 28.7 7 38.9 20 26.3 
Go brown without any sunburn 11 11.7 3 16.7 8 10.5 
Don't Know 1 1.1 . . 1 1.3 
Missing 8 8.5 . . 8 10.5 
Repeatedly exposed to bright sunlight             
Go very brown and deeply tanned 11 11.7 2 11.1 9 11.8 
Get moderately tanned 39 41.5 10 55.6 29 38.2 
Get mildly or occasionally tanned 24 25.5 4 22.2 20 26.3 
Get no suntan at all or only get 
freckled 
11 11.7 2 11.1 9 11.8 
Don't Know 2 2.1 . . 2 2.6 
Missing 7 7.4 . . 7 9.2 
Ever Sunburn 
      Never 16 17 3 16.7 13 17.1 
Ever 72 76.6 15 83.3 57 75 
Missing 6 6.4 . . 6 7.9 
Sunburn at age 10y 
      No 26 27.7 6 33.3 20 26.3 
Yes 62 66 12 66.7 50 65.8 
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   Overall Control Case 
 No. % No. % No. % 
Missing 6 6.4 . . 6 7.9 
Ever Blister 
      No 47 50 13 72.2 34 44.7 
Yes 41 43.6 5 27.8 36 47.4 
Missing 6 6.4 . . 6 7.9 
Blister at age 10y             
No 59 62.8 14 77.8 45 59.2 
Yes 29 30.9 4 22.2 25 32.9 
Any occupational sun exposure             
No 35 37.2 8 44.4 27 35.5 
Yes 53 56.4 10 55.6 43 56.6 
Occupational sun exposure             
None 35 37.2 8 44.4 27 35.5 
<P50 29 30.9 6 33.3 23 30.3 
>=P50 24 25.5 4 22.2 20 26.3 
Any beach or waterside activities             
Never 55 58.5 10 55.6 45 59.2 
Yes 33 35.1 8 44.4 25 32.9 
Any outdoor poolside activities             
Never 37 39.4 6 33.3 31 40.8 
Yes 51 54.3 12 66.7 39 51.3 
Other sunbathing             
Never 23 24.5 4 22.2 19 25 
Yes 64 68.1 14 77.8 50 65.8 
Boating Activities             
Never 31 33 3 16.7 28 36.8 
Yes 57 60.6 15 83.3 42 55.3 
Any Water Activity             
Never 7 7.4 . . 7 9.2 
Yes 81 86.2 18 100 63 82.9 
Missing 6 6.4 . . 6 7.9 
 
* Death from melanoma recorded during 2 years of follow-up. 
Abbreviations: SSM, Superficial spreading melanoma; NM, Nodular 
melanoma; LMM, Lentigo maligna melanoma; UV, ultraviolet radiation 
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3.16.4 Table 3: Characteristics of Control and Melanoma Participants Analyzed for Demographic, Clinical Characteristics by LC3 and Beclin1 
 
LC3 Protein Expression Beclin 1 Protein Expression 
 
All Control Case   All Control Case 
 
  No. Mean No. Mean No. Mean 
P-
value 
No. Mean No. Mean No. Mean 
P-
value 
All 68 1543 17 1587 51 1528 0.67 59 2524 14 326 45 3207  
Age at 
Presentation 
            0.07             0.02 
Gender 21 1552 17 1587 4 1403   18 930 14 326 4 3045 0.02 
Male 23 1580 - - 23 1580   18 3040 - - 18 3040 
 
Female 24 1499 - - 24 1499   23 3366 - - 23 3366 
 
Clinical  Characteristics: 
   
  
      
 
Death from 
Melanoma 
44 1610 5 1908 39 1572 0.03 12 670 10 191 2 3065  
Alive or death 
from other causes 
10 1383 - - 10 1383   37 2991 4 663 33 3273 
 
Breslow Thickness             0.17             0.05 
< 1 20 1497 - - 20 1497   17 2986 - - 17 2986 
 
≥ 1 27 1538 17 1587 10 1455   23 1442 14 326 9 3179 
 
BRAF and NRAS              0.01             0.56 
WT 43 1567 9 1697 34 1532   37 2703 6 504 31 3128 
 
NRAS+ 6 1317 - - 6 1317   6 2868 - - 6 2868 
 
BRAF+ 24 1512 8 1465 16 1536   21 2188 8 192 13 3416 
 
Punctate LC3             >0.01             0.84 
Absent 38 1641 11 1763 27 1592   34 2366 10 391 24 3189 
 
Present 26 1550 17 1587 9 1478   22 1374 14 326 8 3209 
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Table 4. Characteristics of Control and Melanoma Participants Analyzed for UV Exposure,  LC3 and Beclin1 
 
      
 
 
LC3 Protein Expression Beclin 1 Protein Expression 
 
All Control Case  All Control Case  
UV Exposure: No. Mean No. Mean No. Mean 
P-
value 
No. Mean No. Mean No. Mean 
P-
value 
Repeated Sun Exposure Without 
Protection 
    
0.06 
      
0.46 
Go Very 
Brown/Deeply 
Tan 
28 1597 10 1613 18 1588   24 2270 8 389 16 3210   
Moderately Tan 18 1539 3 1786 15 1489   16 2990 2 301 14 3374   
Get Mildly Tan 6 1279 2 934 4 1451   5 1932 2 208 3 3082   
No Suntan/Only 
Freckled 
1 1556 - - 1 1556   1 3203 - - 1 3203   
Don't Know 4 1608 - - 4 1608   3 2831 - - 3 2831   
Missing 10 1519 2 1816 8 1445   9 2437 2 217 7 3072   
Painful Sunburn  (2 or 
more days) 
     
0.03 
      
0.5 
No 52 1494 14 1518 38 1485   45 2544 11 346 34 3256   
Yes 4 1608 - - 4 1608   3 2831 - - 3 2831   
Missing 12 1734 3 1914 9 1674   11 2354 3 253 8 3143   
Ever Blistering Sunburn 
     
0.32 
      
0.02 
No 28 1464 4 1378 24 1479   24 2976 3 194 21 3374   
Yes 4 1608 - - 4 1608   3 2831 - - 3 2831   
Any Beach/ Waterside 
Activities 
     
0.69 
 
     
0.93 
Never 26 1554 7 1471 19 1585   23 2529 6 502 17 3245   
Ever 4 1608 - - 4 1608   3 2831 - - 3 2831   
 
Subjects consisted of 68 participants from a New Mexico tissue collection.  OR values are adjusted for age as a continuous 
variable. Abbreviations:  CI = confidence limit; NM = nodular melanoma; HR = Hazard ratio; SSM = superficial spreading 
melanoma; SD = standard deviation; Death from melanoma recorded during 2.5 years of follow-up. *Statistical significance 
was set at 5%. **Unless noted otherwise odds ratios (OR) are for a one unit increase. 
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3.14.6 Table 5. Univariate Logistic Regression for Melanoma Specific Mortality 
Correlated with Histopathological Characteristics, UV Exposure and LC3/ Beclin 1 
Expression 
 
OR (95% CI)** p-value* 
Age at Diagnosis 1.00 (0.95-1.05) 0.95 
Sex (Female) 1.00 (0.29-3434) 0.99 
Clinical  Characteristics: 
  Breslow thickness (continuous) 1.5 (1.11-2.01) 0.01 
Breslow Thickness ≥ 1 5.33 (1.03-27.8) 0.05 
Clark (Per Stage Increase) 1.87 (0.90-3.92) 0.1 
Mitoses  1.31 (1.03-1.67) 0.03 
Moles  0.94 (0.84-1.05) 0.24 
Ulceration  (Absent vs. Present) 13.67 (2.48-75.27) 0.003 
Regression (Absent vs. Present) 0.25 (0.05-1.4) 0.12 
Oncogene Status:   
NRAS (heterozygous vs wt.) 35,0 (3.21-381.59) 0.004 
BRAF (heterozygous vs wt.) 0.63 (0.12-3.44) 0.6 
Autophagy Markers: 
  LC3  Expression (log-transformed) 0.004 (0.001-0.77) 0.04 
LC3 Punctate Expression 0.25 (0.06-1.08) 0.06 
Beclin1 Expression (log-transformed) 1.35 (0.38-4.72) 0.64 
Histological Sub-type:   
SSM 0.15 (0.04-0.64) 0.01 
NM 2.60 (0.69-9.8) 0.16 
LMM 8.39 (1.81-38.98) 0.01 
Melanoma in situ 1.03 (0.23-4.61) 0.97 
UV Exposure:   
Weekly Sun Hours Age 10 (per 8 hour 
increase) 
0.94 (0.45-1.92) 0.86 
Weekly Sun Hours at Diagnosis (per 8 hour 
increase) 
1.08 (0.68-1.73) 0.73 
Sunlamp Use 1.92 (0.48-7.67) 0.36 
Painful Sunburn  (2 or more days) 0.77 (0.14-4.17) 0.76 
Early Sunburn  (by age 10) 0.88 (0.20-3.81) 0.87 
Decades with Sunburn (per 1 decade increase) 0.76 (0.39-1.48) 0.42 
Ever Had a Blistering Sunburn 0.88 (0.23-3.34) 0.85 
Early Blistering Sunburn (by age 10) 1.21 (0.31-4.76) 0.78 
Decades with Blistering Sunburn (per 1 decade 
increase) 
0.62 (0.26-1.49) 0.28 
Any Occupational Exposure to Sunlight 0.95 (0.24-3.71) 0.94 
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Total Weekly Occupational Exposure to 
Sunlight (per 1 hour increase) 
1.01 (0.98-1.05) 0.47 
Total Occupational Exposure to Sunlight 1.22 (0.54-2.77) 0.64 
Activities: 
  Any Beach/Waterside Activity 2.93 (0.74-11.53) 0.12 
Swimming Pool Activities 2.05 (0.485-8.67) 0.33 
Sunbathing Other than Beach or Pool 0.76 (0.17-3.32) 0.72 
Boating Activities 1.57 (0.37-6.69) 0.54 
Any Outdoor Activity Sun Exposure 0.96 (0.10-8.97) 0.97 
Number  of Outdoor Activities (per 1 activity 
increase) 
1.42 (0.7-2.88) 0.34 
 
Subjects consisted of 68 participants from a New Mexico tissue collection.  OR values are adjusted for age 
as a continuous variable. Abbreviations:  CI = confidence limit; NM = nodular melanoma; OR = odds ratio; 
SSM = superficial spreading melanoma; SD = standard deviation; Death from melanoma recorded during 
2.5 years of follow-up. *Statistical significance was set at 5%. **Unless noted otherwise odds ratios (OR) 
are for a one unit increase 
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CHAPTER 4 
Variants in Autophagy Related Genes and Clinical Characteristics in Melanoma: 
A Population-Based Study 
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4.1 Abstract  
Autophagy has been linked with melanoma, but polymorphisms in autophagy related 
(ATG) genes have not been investigated for association with survival or histopathological 
features known to be important in melanoma survival. We examined 5 ATG gene single 
nucleotide polymorphisms (SNPs) in a multicenter population-based case-control study 
of melanoma. DNA from 911 melanoma patients was genotyped for SNPs with suspected 
impact on autophagic flux. While no association was identified with survival, several 
associations with prognostic features were noted. A decreased Breslow thickness (p = 
0.03) and earlier stage at diagnosis (OR 0.47, 95% CI 0.27-0.81, p = 0.02) was identified 
with the minor allele for an ATG16L polymorphism (rs2241880) and the heterozygous 
genotype was associated with younger diagnosis age (p = 0.02). In addition, two SNPs in 
ATG5 (rs2245214 and rs510432) were associated with increased stage of melanoma (OR 
1.84 95% CI 1.12-3.02, p=0.05; OR 1.47 95% CI 1.11-1.94, p=0.03).  Finally, although 
not significant at the global p-value, we identified an inverse association between the 
minor alleles of ATG5 (rs2245214) and scalp or neck melanomas (OR 0.20, 95% CI 
0.05-0.86, p= 0.03); ATG10 rs1864182 (OR 0.42, 95% CI 0.21-0.88, p= 0.02) and brisk 
TILs, and non-brisk TILs and ATG5 rs510432 (OR 0.55 95% CI 0.34-0.87, p= 0.01). In 
summary, our data suggest ATG SNPs might be associated with prognostic characteristics 
although not with survival and that the direction of the ATG SNPs may be differential 
due to low.  It may be informative to evaluate these and other SNPs in the larger 
population as these associations may be helpful to understand the role of autophagy in 
melanoma.  
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4.2 Introduction: 
The American Cancer Society estimates that in 2015, 73,870 new melanomas will be 
diagnosed and 9,940 people will die from their disease.1 The long term prognosis for 
melanoma patients has not improved at the same rate as other cancers.2 One mechanism 
of tumorigenesis that is under intensive investigation is autophagy. Autophagy  is a 
catabolic process that assists the removal of unnecessary or dysfunctional cellular 
components, including damaged proteins and organelles through lysosomal degradation.3 
Macroautophagy (hereafter referred to as autophagy) is tightly regulated and plays a role 
in a wide variety of normal physiological processes including energy metabolism, stress 
responses, growth regulation, and aging4,5 and can be induced in response to nutrient 
deprivation.6 Accumulating evidence indicates that autophagy is involved in cancer 
progression.5 In addition, the idea of melanoma addiction to autophagy7–11  has important 
implications for cancer development as well as treatment options.12 There are clinical 
trials ongoing at the National Institutes of Health to target inhibition of the autophagic 
pathway in multiple cancer types including melanoma.13 However, the extent to which 
the autophagy impacts melanoma progression and/or survival remains to be elucidated. 
Single nucleotide  polymorphisms (SNPs) have been implicated in the pathogenesis of 
many types of cancers14 including melanoma.15–17 Relevant data from the current 
literature suggests that the frequency of variants in autophagy-related (ATG) genes may 
be altered in cancer patients.18  Autophagy gene variants have been associated with risk 
prognosis and/or  survival in autoimmune diseases, including Crohn’s disease, 
tuberculosis19 and gastric, breast and thyroid cancers20–24. To our knowledge, there are no 
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studies examining the relationship between ATG gene SNPs and histopathological 
markers or survival in melanoma.  
In this study, we analyzed germline DNA for variants (i.e. SNPs) in ATG genes from a 
large population-based cohort of melanoma patients from Australia and the US. The 
SNPs investigated were chosen having been identified as significantly associated with 
disease outcomes and≥10% minor allele frequency in Caucasians.  Our goal was to 
determine whether SNPs in ATG genes were associated with factors associated with 
tumor characteristics and survival in melanoma patients. We hypothesize that ATG gene 
variants are associated with histopathological markers of melanoma progression.  
4.3 Materials and Methods 
4.3.1 Patient Characteristics:  
Over four years, 3,579 individuals from 9 study sites including eight population-based 
cancer registries in the United States (New Jersey, North Carolina, California), Australia 
(New South Wales, Tasmania), Canada (Ontario, British Columbia), and Italy (Turin), 
and one hospital center in Michigan were enrolled in the Genes, Environment and 
Melanoma (GEM), a large international population-based case control study. GEM 
recruitment procedures and data collection have been previously described.25 The 
Institutional Review Boards of all participating institutions approved the protocol and 
informed consent was obtained from each participant. GEM is a population-based 
international consortium studying risk for melanoma development and progression and 
survival. From this study of a population of 1,206 individuals with multiple primary 
melanoma and 2,373 with single primary melanoma, 911 genomic DNA samples were 
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chosen based on tumor availability (previously reported; Thomas et. al 2015)(see patient 
characteristics below, Table 1)26 and genotyped to compared ATG SNP frequencies with 
histopathological data.  
4.3.2 Clinical Stage:  
Histopathology slides were reviewed as previously described27 and clinical stage was 
determined based on pathology reports and includes Breslow thickness, mitotic index and 
ulceration. Mitoses were defined as present or absent. TIL grade was scored as absent, 
nonbrisk, or brisk using a previously defined grading system.27 All cases were 
characterized using the T classification which describes the state of the primary tumor in 
the AJCC TNM (tumor, regional nodes, and distant metastasis) melanoma staging 
system. 
4.3.3 Selection of SNPs and Genotyping:  
5 SNPs in three critical ATG genes were selected from those identified with functional 
SNPs in the literature or that were associated with cancer or disease outcomes (see Figure 
1). 18,19,21,28,29 Taqman Real-Time PCR Assays (ThermoFisher Scientific, Grand Island, 
NY) were used to identify SNPs in ATG genes performed with a 7900HT Fast Real-Time 
PCR System (ThermoFisher Scientific, Grand Island, NY) following manufacture 
recommendations. DNA was isolated from buccal cells as previously described.25,30 A 
Nanodrop 2000 spectrophotometer (ThermoFisher Scientific, Grand Island, NY) was 
used for quantification of DNA. The ratio of fluorescence in amplification during the 
logarithmic phase was quantified to identify specific alleles in genes of interest using a 
commercially available Taqman primer assay on a 7900HT Applied Biosystems qPCR 
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machine. Genomic DNA samples were chosen from those samples with sufficient DNA 
and tumor availability to allow for somatic analysis in future studies. 26 The genotyping 
call rate for the 911 chosen samples ranged from 96% to 99% and biological replicates 
were generated for 10% of the samples with 100% concordance. 
4.3.4 Data Analysis:  
Frequency tables were used to summarize the genotype distributions for each ATG SNP.  
To assess the genotyping quality, we calculated the genotype call rates and tested the 
departure from Hardy Weinberg Equilibrium for each SNP in all subjects. The 
association between SNPs and histopathological features were tested under the general 
genotypic inheritance (co-dominant) model.  No assumptions were made on the model of 
inheritance, and the genotypes for each SNP were treated as a three-level nominal 
variable.  Using a genotypic model to simultaneously compare heterozygous genotype 
versus wildtype, and homozygous minor genotype versus wildtype, we report a global p -
value representing the overall significance of the two comparisons for our analysis. 
Linear regression analyses were performed to assess the association between ATG gene 
SNPs and log transformed Breslow thickness, which was non-normally distributed. To 
evaluate the association between ATG SNPs and histopathological features, we conducted 
logistic regression analyses for binary outcomes (mitosis, ulceration), ordinal logistic 
regression analysis for ordinal outcome (stage), and polytomous logistic regression 
analyses for nominal outcomes (histology and tumor subtype). The exponentiated 
regression coefficient modeled Breslow thickness representing Breslow thickness 
increases per mm. ORs and 95% confidence intervals estimated from the regression 
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models were used to summarize the associations. Wald tests were used to assess the 
significance of the association and statistical significance was two-sided at 5%.  
4.4 Results: 
Five SNPs within ATG genes that have been previously reported associated with disease 
outcomes were genotyped and similar allele frequencies were identified in males and 
females (data not shown). GEM minor allele frequencies are presented in Table 2 and 
genotypes do not deviate from Hardy Weinberg Equilibrium (HWE) (data not shown). 
After adjustment for age, sex, status (single or multiple primaries) and study center, three 
ATG SNPs (rs2241880, rs510432, rs2245214) were significantly associated with 
melanoma prognostic indicators. An analysis of all 5 ATG gene SNPs with Breslow 
thickness, the most important prognostic marker in melanoma, revealed a significant 
association between the minor allele (A) of rs2241880 (ATG16L) (Table 3a) and a 
decrease in Breslow thickness (p= 0.02). A significant association was also identified 
between the rs2241880 (ATG16L) minor allele and an earlier stage at diagnosis (OR 0.47 
95% CI 0.27-0.81, p = 0.02) when defined as a binary variable of Stage T1a/T1b/T2a 
versus T2b and higher (Table 4). Finally, presence of heterozygous (AG) of rs2241880 
was significantly associated with a younger age of melanoma diagnosis (p = 0.02) (Table 
3b).  
In addition, two ATG5 SNPs (rs2245214 and rs510432) were found significantly 
associated with increased stage of melanoma (OR 1.47, 95% CI 1.11-1.94, p=0.03; OR 
1.84, 95% CI 1.12-3.02, p=0.05) (Table 4).  The minor allele (CC) of rs510432 had a 
borderline association with increased stage. Interestingly, only the heterozygous (CG) of 
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rs2245214 was associated with this increase in stage when it was defined as a continuous 
variable (Supplemental Table S1), while the other two SNPs (rs2241880, rs510432) did 
not retain significance in this analysis 
No associations between the 5 autophagy SNPs and mitosis, ulceration, histological 
subtype or melanoma specific survival (Table 5; Supplemental Table S1) were identified.  
Of interest, while they were not significant at the level of the global p-value, a decrease in 
OR (OR 0.42 95% CI 0.21-0.88, p=0.02) was identified between the presence of brisk 
TILs and the minor allele of SNP rs1864182, and the presence of non-brisk TILs and the 
minor allele of rs510432 (OR 0.55 95% CI 0.34-0.87, p=0.01). Finally, while not 
significant at the global p-value, an inverse association between the minor allele of 
rs2245214 and scalp/neck melanomas was also identified (OR 0.20 95% CI 0.05-0.86, 
p=0.03). 
4.5 Discussion:  
There are clear associations between autophagy and cancer and the role of germline SNPs 
in melanoma progression and survival has remained unexplored. Autophagy in cancer is 
context dependent, acting as both a tumor suppressor and as a tumor promoter depending 
on the stage of development of the tumor. While a recent GWAS study reported no 
association between melanoma susceptibility31 and ATG gene SNPs, we know of no other 
study addressing the associations between common genetic variants in ATG genes and 
melanoma development and survival. 
In the current study, five SNPs were selected for analysis based on their association with 
other diseases.  The SNPs investigated in this study are located in genes that are critical 
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to the early stage of the autophagy pathway (Figure 1) and necessary for the formation of 
the autophagosome.3 As shown in Figure 1 ATG10 is essential for ATG12 conjugation to 
ATG5 and ultimately to ATG16L.  
Previously, variants in ATG genes have been associated with risk, prognosis or survival 
in cancer18,28,29 and autoimmune conditions.32–35  In the current analysis, we examined 
one SNP (rs2241880) in ATG16L which increases risk and is associated with poorer 
prognosis in disease and might contribute to progression in melanoma.  A 
nonsynonymous polymorphism in ATG16L, rs2241880 (T300A), has been extensively 
studied because its variant allele has been linked with increased risk of Crohn’s disease.23 
This ATG16L SNP (AA) creates a caspase 3- and caspase 7- cleavage site and reduces the 
stability of the protein resulting in decreased autophagy; clinically, presence of this 
variant is associated with decreased survival and increased risk for ileal Crohn’s disease 
in adults. 23 While this SNP is associated with increased susceptibility, it is also 
associated with childhood (early) onset of this disease.36As illustrated in Figure 1, 
ATG16L is essential for the formation of the autophagosome. Through its noncovalent 
interaction with ATG12–ATG5, it facilitates the conjugation of other critical ATG 
proteins. Other studies have identified a genetic association for rs2241880 and another 
SNP in ATG5 (rs2245214) with nearly two-fold susceptibility to non-medullary thyroid 
cancers 18 as well as an increase in disease severity associated with rs2241880.28  This 
SNP (rs2241880) has also been shown to be associated with almost double the risk of 
developing colorectal cancer.37  
ATG5 is part of an ubiquitin-like conjugation pathway which links ATG5 with ATG16L 
(ATG5-ATG16L). Specifically, ATG5 membrane binding is activated through its 
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conjugation with ATG16L.  Membrane binding by the ATG12–ATG5-ATG16 exerts an 
E3 enzyme-like function and this binding is critical for the correct formation of the 
autophagosome (Figure 1). Importantly, both rs1864182 and rs1051423, located in 
ATG10, have been reported associated with a decreased risk of breast cancer.29 
In the current study, three SNPs were associated with melanoma prognostic indicators. 
One SNP, in a critical autophagy gene (ATG16L), had multiple associations in our 
analysis. A significant association was identified between the minor allele for rs2241880 
and a decrease in Breslow thickness (p = 0.03) and an earlier stage at diagnosis (OR 0.47 
95% CI 0.27-0.81, p = 0.02). This SNP (rs2241880) also showed an association between 
the heterozygous variant and a younger age at melanoma diagnosis (p = 0.02). This SNP 
is also associated in the literature with decreased autophagy and may mediate melanoma 
progression through the accumulation of protein aggregates and damaged organelles in 
patients.38,39There is evidence in the literature that decreased autophagy may inhibit 
melanoma tumorgeneis.7,8 Further, this ATG16L SNP has been reported in the literature 
to be associated with increased IL-1β production in primary cells.23 Metastatic melanoma 
cells spontaneously secrete active IL-1β40 and the association between melanoma and this 
ATG variant warrants further investigation.  
In ATG5, we identified a positive association with increased stage between two SNPs, 
rs510432 minor allele (CC) (defined as a Stage T1a/T1b/T2a vs. T2b and higher OR 1.26 
95% CI 0.81-1.95, p = 0.05) and rs2245214 heterozygous genotype (CG) (defined as 
categorical stage OR 1.47 95% CI 1.11-1.94 p = 0.03), and increased stage in melanoma. 
SNP rs510432 had a borderline association when it was. Interestingly, rs510432 is in the 
5′ untranslated region (UTR) upstream of its first exon in the promotor region. In 
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addition, this SNP (rs510432) (C) has a reported positive association with asthma (p= 
0.003) 21 and is reported to confer increased promoter activity of this gene.  As we also 
identified a positive association with increased stage and rs510432 (C) in our population, 
further studies exploring the functional role of this SNP in the rate of autophagy and 
melanoma progression may elucidate ATG5 promoter activity in these participants, 
leading to more advanced melanoma stage. 
In addition, ATG5 has functions independent of autophagy, including critical roles in 
apoptosis, mitotic catastrophe and regulation of the β-Catenin signaling pathway41,42. As 
ATG5 is often down-regulated in primary melanomas,43 the association of two SNPs in 
this critical ATG gene with increased melanoma stage is significant as they have the 
potential to become new markers of melanoma risk, progression and/or therapeutic 
targets. 
Our study identified no association between the 5 ATG gene SNPs and melanoma 
specific survival. There were also no significant associations identified between the SNPs 
and ulceration, mitosis, or histological subtype.   
While they were not significant at the global p-value, a decrease in OR (0.42 95% CI 
0.21-0.88, p = 0.02) was identified between the presence of brisk TILs and the minor 
allele of SNP rs1864182, and non-brisk TILs and the minor allele of rs510432 (OR 0.55 
95% CI 0.34-0.87 p = 0.01). The association of TILs with autophagy variants is 
significant as increased number of TILs, particularly brisk TILs, in primary melanomas 
are associated with improved melanoma-specific survival.44 TIL absence in melanoma is 
associated with higher stage then either the presence of non-brisk or brisk TIL. The 
presence of non-brisk TILs is also associated with a 30%  decrease in melanoma death 
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(HR 0.7; 95% CI  0.5 to 1.0) while there is a 50% decrease associated with brisk TILs 
(HR 0.5 95% CI 0.3 to 0.9).44  
Finally, while not significant at the global p-value, an inverse association between the 
minor allele of rs2245214 and scalp/neck melanomas was also identified (OR 0.20 95% 
CI 0.05-0.86 p=0.03). As it has been previously documented that individuals with 
scalp/neck melanomas have poorer outcomes than patients with melanomas on other 
sites, 45 this inverse relationship warrants further studies to determine if there is a 
functional significance for ATG5 and this anatomic site. 
Autophagy has had a role in cancer; however the relationship between genetic variants in 
autophagy genes and cancer development, progression and survival remains under 
explored. In the present study, we assessed the impact of variants in ATG genes necessary 
for autophagic flux in relationship to melanoma prognostic indicators and survival. Drugs 
targeting the autophagy pathway are being investigated as effective therapy for many 
cancers including melanoma. SNPs that alter autophagic rates may affect the 
effectiveness of current treatment strategies and have clinical significance.9,46–49 In silico 
analysis of results from multiple studies, and/or coordination of large studies, will have to 
assess the reproducibility of these ATG gene interactions in melanoma. 
This study is limited by the knowledge that alteration of autophagy might not be due to 
variants in ATG genes but possibly due to other signaling pathways that regulate 
autophagy or post-translational modifications. In addition, there are other probably other 
functional genetic variants not included in the current study, as there are approximately 
38 ATG genes specifically required for autophagy in Saccharomyces cerevisiae.50 We 
found no direct association between any of the 5 ATG gene SNPs and survival although 
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this may be due to insufficient sample size. Enlarging the number of samples and 
incorporating functional studies may help to establish if an association with survival 
exists.  Our analyses did not control for multiplicative significance and false discovery 
rate but employed a more stringent global p-value to reduce type 1 errors. These 
limitations must be addressed in future experiments by screening for SNPs in other 
relevant genes potentially using alternative technologies including deep sequencing.  
In conclusion, while we found no association with survival, we have identified three ATG 
gene SNPs as a genetic factors affecting melanoma progression, which, in melanoma 
patients, may cause changes in ATG protein levels and alter autophagy regulation, 
affecting melanomagenesis. These findings emphasize the significance of the autophagy 
pathway in melanoma. As the role of autophagy in melanoma is complex and context 
dependent, the reported associations may provide important insight into how SNPs in 
critical autophagy genes impact melanoma progression. 
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4.7 Figure and Tables: 
4.7.1 Figure 1: Overview of the Autophagy related (ATG) conjugation pathway 
focusing on the gene variants investigated in this study, including those in the ATG5, 
ATG 10 and ATG 16L genes. 
 
* Five variants from three autophagy related genes were selected for either an association 
with or functional impact on risk or progression of disease.  Two SNPs were chosen from 
ATG10, two from ATG5 and one from ATG16L. From our analysis a significant 
association was identified between the ATG16L polymorphism (rs2241880) and a 
decrease in Breslow thickness (p = 0.03), younger age (p = 0.02) and earlier stage at 
diagnosis (OR 0.47, 95% CI 0.27-0.81, p = 0.02).   In addition, two SNPs in ATG5 
(rs2245214 and rs510432) were associated with increased stage of melanoma (OR 1.84 
95% CI 1.12-3.02, p=0.05; OR 1.47 95% CI 1.11-1.94, p=0.03).  We identified an 
inverse association between the ATG5 SNP rs2245214 and melanomas on the scalp or 
neck (OR 0.20, 95% CI 0.05-0.86, p= 0.03); rs1864182 (ATG10) (OR 0.42, 95% CI 0.21-
0.88, p= 0.02), and with brisk TILs. Finally, we identified an association between non-
brisk TILs and the ATG5 SNP rs510432 (OR 0.55 95% CI 0.34-0.87, p= 0.01) although 
not significant at the global p-value. 
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4.7.2 Table 1.   Clinicopathologic characteristics among 911 melanoma cases* 
Characteristics 
 
No.  % 
Age at diagnosis 60 
 
 
Breslow thickness, median , mm 0.8 
 
 
 
Gender  Male 534 59 
  
Female 377 41 
Breslow thickness (mm) 0.01-1.00 547 60 
 
1.01-2.00 212 23 
 
2.01-4.00 108 12 
 
> 4.00 44 5 
Status  SPM 603 66 
 
MPM 308 34 
Anatomic site Trunk/pelvis 394 43 
 
Scalp/neck 56 6 
 
Face/ears/other 116 13 
 
Upper extremities 172 19 
 
Lower extremities 173 19 
Histological subtype  SSM 610 67 
 
NM 92 10 
 
LMM 116 13 
 
Other 93 10 
 
Missing 0 0 
Ulceration  Absent 794 92 
 
Present 73 8 
Mitosis  Absent 454 52 
 
Present 415 48 
AJCC stage  T1a 397 46 
 
T1b 124 14 
 
T2a 183 21 
 
T2b 16 2 
 
T3a 73 8 
 
T3b 32 4 
 
T4a 21 2 
 
T4b 21 2 
 
   
AJCC stage (T1a/T1b/T2a vs. T2b+) T1a/T1b/T2a 704 81 
 
T2b+ 163 19 
TIL grade Absent 194 22 
 
Non-Brisk 563 65 
 
Brisk 111 13 
Growth phase Absent 255 29 
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Present 614 71 
Death from melanoma*  
 
76 8 
Alive or death from other causes  
 
835 92 
 
  
 
*Subjects comprised 911 participants from the GEM study from Australia and the United States.  OR 
values are adjusted for age as a continuous variable. Abbreviations:  AJCC= American Joint Committee on 
Cancer; CI = confidence limit; Mpm= Multiple primary melanoma; NM = nodular melanoma; OR = odds 
ratio; SSM = superficial spreading melanoma; SD = standard deviation; TIL= Tumor infiltrating 
lymphocytes; Spm=Single primary melanoma.  Death from melanoma recorded during 7.5 years of follow-
up. 
4.7.3 Table 2. Allele frequencies of ATG genes in melanoma patients 
ATG SNP Genotype Number of patients (%) 
ATG5 
  
rs510432  CC 190 (0.22) 
 
CT 425 (0.48) 
 
TT 266 (0.30) 
ATG5 
  
rs2245214  CC 331 (0.38) 
 
CG 427 (0.49) 
 
GG 110 (0.13) 
ATG16L 
 
 
rs2241880  AA 198 (0.23) 
 AG 418 (0.490 
 
GG 245 (0.29) 
ATG10 
  
rs10514231  CC 116 (0.13) 
 
CT 403 (0.47) 
 
TT 345 (0.40) 
ATG10 
  
rs1864182 AA 238 (0.28) 
 AC 424 (0.49) 
 CC 200 (0.23) 
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4.7.4 Table 3. Relationship between ATG genotype, Breslow thickness and age of 
diagnosis in melanoma 
4.7.4a Table 3a. Relationship between ATG genotype and Breslow thickness in 
melanoma 
                                                         Breslow thickness (Continuous) 
ATG gene SNP Genotype  Coeff (95% CI) p-value* Global p-value* 
rs10514231 TT 1.00 
 
0.18 
 
CT 1.09 (0.98-1.22) 0.09 
 
 
CC 0.99 (0.84-1.16) 0.91 
 
rs1864182 CC 1.00  
0.72 
 
AC 1.05 (0.92-1.19) 0.46 
 
 
AA 1.05 (0.9-0.82) 0.50 
 
rs2241880 GG 1.00  0.03 
 
AG 1.04 (0.92-0.85) 0.55 
 
 
AA 0.87 (0.97-0.99) 0.06 
 
rs22445214  TT 1.00  
0.28 
 
CG 1.09 (0.98-1.22) 0.11 
 
 
CC 1.06 (0.9-1.26) 0.49 
 
rs510432 TT 1.00  
0.30 
 
CT 1.05 (0.94-1.19) 0.37 
 
  CC 1.12 (0.97-1.3) 0.12   
Genotypic model adjusted for age (continuous) sex, study center and status.  Abbreviations: CI, 
confidence interval; Coeff, coefficient 
4.7.4b Table 3b.  Age at diagnosis by genotype status among melanoma cases 
 
 
 Age at diagnosis, y 
 
  ATG gene SNP Genotype n Coeff (95% CI) p-value* Global p-value* 
rs10514231 TT 864 1.00  
0.71 
 
CT  0.22 (-1.95-2.39) 0.84 
 
CC  1.33 (-1.84-4.50) 0.41 
rs1864182 CC 862 1.00  
0.70 
 
AC  0.72 (-1.67-3.11) 0.55 
 
AA  -0.26 (-3.09-2.57) 0.86 
rs2241880 GG 861 1.00  0.02 
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AG  -3.25 (-5.60--0.91) 0.01 
 
AA  -2.04 (-4.83-0.74) 0.15 
rs2245214 TT 868 1.00  
0.75 
 
CG  -0.59 (-2.77-1.58) 0.59 
 
CC  -1.17 (-4.43-2.09) 0.48 
rs510432 TT 881 1.00  
0.75 
 
CT  0.43 (-1.86-2.73) 0.71 
 
CC  -0.55 (-3.33-2.23) 0.70 
Genotypic model adjusted for sex, study center and status. 
4.7.5 Table 4. Relationship between ATG genotype and AJCC stage in melanoma 
 
                                          Melanoma Stage    
ATG gene SNP Genotype  ≥ Stage  T2b vs. Stage T1a/T1b/T2a p-value* 
Global p-
value* 
rs10514231 TT 1.00  
0.46 
 
CT 1.18 (0.80-1.76) 0.41 
 
CC 0.84 (0.46-1.54) 0.57 
rs1864182 CC 1.00  
0.52 
 
AC 1.22 (0.79-1.89) 0.38 
 
AA 0.98 (0.57-1.66) 0.93 
rs2241880 GG 1.00  
0.02 
 
AG 0.88 (0.59-1.33) 0.55 
 
AA 0.47 (0.27-0.81) 0.01 
rs2245214 TT 1.00  
0.14 
 
CG 1.46 (0.98-2.17) 0.06 
 
CC 1.05 (0.57-1.92) 0.88 
rs510432 TT 1.00  
0.05 
 
CT 1.26 (0.81-1.95) 0.30 
 
CC 1.84 (1.12-3.02) 0.02 
Genotypic model adjusted for age (continuous) sex, study center and status.  Abbreviations: 
AJCC, American Joint Committee on Cancer 
4.7.6 Table 5. Relationship between ATG Genotype and melanoma-specific survival 
ATG gene SNP Genotype HR (95% CI) 
p-
value 
Wald p-
value 
rs10514231 TT 1 [Reference]  0.72 
 
CT 1.24 (0.74-2.07) 0.42 
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CC 1.12 (0.54-2.35) 0.76 
rs1864182 CC 1 [Reference]  
0.18 
 
AC 1.83 (0.93-3.59) 0.08 
 
AA 1.89 (0.90-3.98) 0.10 
rs2241880 GG 1 [Reference]  
0.85 
 
AG 1.04 (0.60-1.80) 0.89 
 
AA 0.86 (0.43-1.72) 0.67 
rs22445214  TT 1 [Reference]  
0.80 
 
CG 0.86 (0.52-1.43) 0.56 
 
CC 0.82 (0.37-1.81) 0.63 
rs510432 TT 1 [Reference]  
0.13 
 
CT 0.68 (0.40-1.17) 0.16 
  CC 1.19 (0.67-2.12) 0.55 
Survival analysis adjusted for age, sex, study center, status (Spm vs. Mpm) and time dependent crossover 
in a genotypic model.  Abbreviations: HR, hazard ratio; CI, confidence interval
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4.7.7 Supplemental Table S1a. Clinicopathologic characteristics by genotype status among melanoma cases* 
Anatomic Site 
ATG gene SNP Genotype 
Scalp/neck vs. 
Trunk/pelvis 
p-value* 
Face/ears/ other vs. 
Trunk/pelvis 
p-value* 
Upper extremities vs. 
Trunk/pelvis 
p-value* 
Lower extremities vs. 
Trunk/pelvis 
p-value* 
Wald 
p-value 
rs10514231 TT 1.00 
 
1.00 
 
1.00 
 
1.00 
 
0.73 
 
CT 0.74 (0.39-1.39) 0.34 1.06 (0.65-1.74) 0.80 0.8 (0.53-1.2) 0.28 0.97 (0.63-1.47) 0.87 
 
CC 0.46 (0.15-1.4) 0.17 1.36 (0.71-2.62) 0.35 0.76 (0.41-1.42) 0.39 0.97 (0.52-1.82) 0.92 
rs1864182 CC 1.00 
 
1.00 
 
1.00 
 
1.00 
 
0.22 
 
AC 1.56 (0.77-3.14) 0.22 1 (0.58-1.71) 0.99 0.79 (0.5-1.24) 0.31 0.68 (0.25-1.81) 0.44 
 
AA 0.83 (0.52-1.33) 0.44 1.33 (0.72-2.47) 0.37 0.94 (0.55-1.62) 0.83 1.26 (0.73-2.17) 0.41 
rs2241880  GG 1.00 
 
1.00 
 
1.00 
 
1.00 
 
0.70 
 
AG 1.68 (0.83-3.4) 0.15 0.9 (0.53-1.52) 0.68 0.96 (0.62-1.5) 0.87 0.99 (0.62-1.59) 0.97 
 
AA 0.88 (0.34-2.27) 0.79 1.18 (0.65-2.16) 0.59 0.96 (0.57-1.63) 0.88 1.09 (0.63-1.89) 0.75 
rs2245214  TT 1.00 
 
1.00 
 
1.00 
 
1.00 
 
0.51 
 
CG 0.73 (0.4-1.33) 0.31 0.9 (0.56-1.45) 0.66 0.73 (0.49-1.1) 0.14 0.84 (0.55-1.28) 0.41 
 
CC 0.20 (0.05-0.86) 0.03 0.88 (0.44-1.77) 0.72 0.68 (0.37-1.26) 0.22 0.72 (0.38-1.37) 0.32 
rs510432  TT 1.00 
 
1.00 
 
1.00 
 
1.00 
 
0.20 
 
CT 0.65 (0.35-1.23) 0.18 0.67 (0.41-1.11) 0.12 1.27 (0.82-1.98) 0.28 1.23 (0.78-1.95) 0.38 
  CC 0.45 (0.19-1.07) 0.07 0.68 (0.37-1.24) 0.21 0.88 (0.51-1.52) 0.65 0.98 (0.56-1.71) 0.94 
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Histological sub-type 
      ATG gene SNP Genotype NM vs. SSM p-value LMM vs. SSM p-value Other vs. SSM p-value Wald p-value 
  rs10514231 TT 1.00 
 
1.00 
 
1.00 
 
0.36   
 
CT 1.21 (0.70-2.07) 0.50 1.08 (0.68-1.73) 0.74 0.95 (0.59-1.54) 0.83 
  
 
CC 1.78 (0.90-3.52) 0.10 1.10 (0.57-2.13) 0.77 0.46 (0.19-1.14) 0.09 
  rs1864182 CC 1.00 
 
1.00 
 
1.00 
 
0.46   
 
AC 1.58 (0.85-2.94) 0.15 1.52 (0.90-2.57) 0.12 1.00 (0.59-1.71) 0.99 
  
 
AA 1.63 (0.81-3.27) 0.17 1.12 (0.59-2.11) 0.73 0.80 (0.41-1.56) 0.52 
  rs2241880  GG 1.00 
 
1.00 
 
1.00 
 
0.54   
 
AG 1.63 (0.92-2.88) 0.09 1.31 (0.78-2.19) 0.30 0.89 (0.53-1.51) 0.66 
  
 
AA 1.18 (0.60-2.36) 0.63 1.18 (0.65-2.15) 0.59 0.74 (0.39-1.42) 0.36 
  rs2245214  TT 1.00 
 
1.00 
 
1.00 
 
0.26   
 
CG 1.59 (0.95-2.67) 0.08 0.88 (0.56-1.39) 0.59 1.41 (0.84-2.37) 0.20 
  
 
CC 0.76 (0.31-1.85) 0.54 0.80 (0.40-1.60) 0.53 1.40 (0.68-2.90) 0.36 
  rs510432  TT 1.00 
 
1.00 
 
1.00 
 
0.96   
 
CT 1.03 (0.60-1.78) 0.91 0.88 (0.54-1.43) 0.60 0.89 (0.53-1.49) 0.65 
    CC 1.33 (0.71-2.49) 0.38 0.98 (0.54-1.78) 0.94 0.93 (0.49-1.76) 0.83 
  All genotypic analyses were adjusted for age (continuous), sex, study center and status (Spm/ Mpm/ crossover)                                                                             
*Bold significance set p= 0.05    
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Ulceration 
 
    
ATG gene SNP Genotype Ulceration present vs. absent p-value 
Wald p-
value 
  rs10514231 TT 1.00  
0.82 
  
 
CT 1.04 (0.60-1.81) 0.90 
  
 
CC 0.80 (0.35-1.86) 0.61 
  rs1864182 CC 1.00  
0.61 
  
 
AC 1.23 (0.66-2.29) 0.52 
  
 
AA 0.90 (0.41-1.95) 0.78 
  rs2241880  GG 1.00  
0.41 
  
 
AG 0.94 (0.53-1.68) 0.84 
  
 
AA 0.61 (0.28-1.31) 0.20 
  rs2245214  TT 1.00  
0.29 
  
 
CG 1.33 (0.77-2.28) 0.31 
  
 
CC 0.70 (0.27-1.78) 0.45 
  rs510432  TT 1.00  
0.36    
CT 1.27 (0.68-2.37) 0.45 
  
  CC 1.68 (0.83-3.43) 0.15 
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Mitosis 
 
    
ATG gene SNP Genotype Mitosis present vs. absent p-value Wald p-value 
  rs10514231 TT 1.00  
0.84   
 
CT 1.09 (0.81-1.48) 0.56 
  
 
CC 1.02 (0.65-1.58) 0.95 
  rs1864182 CC 1.00  
0.50   
 
AC 0.95 (0.68-1.33) 0.77 
  
 
AA 1.17 (0.79-1.74) 0.43 
  rs2241880  GG 1.00  
0.49   
 
AG 1.06 (0.76-1.48) 0.73 
  
 
AA 0.86 (0.58-1.27) 0.44 
  rs2245214  TT 1.00  
0.17   
 
CG 1.33 (0.98-1.79) 0.07 
  
 
CC 1.30 (0.83-2.03) 0.25 
  rs510432  TT 1.00  
0.34   
 
CT 1.18 (0.86-1.63) 0.31 
    CC 1.33 (0.90-1.96) 0.15     
 
 
 
 
 
TIL Grade 
 
    
ATG gene SNP Genotype Non Brisk vs. Absent p-value Brisk vs Absent p-value 
Wald p-
value 
rs10514231 TT 1.00  
1.00 
 0.88 
 
CT 0.98 (0.68-1.41) 0.91 0.92 (0.54-1.59) 0.78 
 
CC 1.15 (0.67-1.98) 0.62 0.80 (0.34-1.86) 0.6 
rs1864182 CC 1.00  
1.00 
 
0.14 
 
AC 1.12 (0.74-1.68) 0.60 0.87 (0.49-1.58) 0.66 
 
AA 0.81 (0.51-1.29) 0.37 0.42 (0.21-0.88) 0.02 
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rs2241880  GG 1.00  
1.00 
 
0.42 
 
AG 0.91 (0.61-1.35) 0.63 1.02 (0.55-1.90) 0.96 
 
AA 0.89 (0.55-1.43) 0.62 1.53 (0.76-3.08) 0.23 
rs2245214  TT 1.00  
1.00 
 
0.97 
 
CG 0.93 (0.65-1.34) 0.70 0.86 (0.50-1.49) 0.59 
 
CC 0.91 (0.53-1.57) 0.74 1.01 (0.46-2.22) 0.98 
rs510432  TT 1.00  
1.00 
 
0.12 
 
CT 0.74 (0.49-1.11) 0.15 0.99 (0.54-1.79) 0.96 
 
CC 0.55 (0.34-0.87) 0.01 0.72 (0.36-1.45) 0.36 
 
 
Melanoma Stage (continuous) 
 
  
ATG gene SNP Genotype  OR (95% CI) p-value 
Wald p-
value 
rs10514231 TT 1.00  
0.32 
 
CT 1.18 (0.90-1.56) 0.23 
 
 
CC 0.92 (0.61-1.38) 0.69 
 
rs1864182 CC 1.00  
0.90 
 
AC 1.07 (0.79-1.46) 0.65 
 
AA 1.06 (0.74-1.53) 0.74 
rs2241880  GG 1.00  
0.14 
 
AG 1.01 (0.75-1.37) 0.93 
 
AA 0.74 (0.52-1.06) 0.10 
rs2245214  TT 1.00  
0.03 
 
CG 1.47 (1.11-1.94) 0.01 
 
CC 1.23 (0.82-1.85) 0.32 
rs510432  TT 1.00 
 
0.14  
CT 1.30 (0.97-1.75) 0.08 
  CC 1.37 (0.96-1.95) 0.09 
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4.8 Supplemental research to chapter 4 manuscript: 
4.9 Introduction: 
The importance of the autophagy pathway, particularly in cancer, has been previously 
described in this chapter. In addition, it has been reported that knockout of autophagy 
related genes results in multiple disease states including neurodegenerative disease, 
autoimmunity, and cancer. Cells dependent on this catabolic pathway with decreased 
autophagic capacity to recycle nutrients will undergo programmed cell death which can 
result in tissue damage and inflammation. 1 Inflammation has an important and emerging 
role in cancer and has particular significance for melanoma. Melanoma inflammatory 
cells, including tumor-infiltrating macrophages, have prognostic implications.2 The 
presence of TILs in vertical growth phase of cutaneous melanomas has been reported to 
be associated with a better prognosis 3,4 Conversely, high levels of an inflammatory 
marker, C-reactive protein is a poor prognostic indicator.5 Cytokines, chemical 
messengers of the immune system, have a dynamic range of expression patterns in 
melanoma that changes with cancer progression. A variant in one SNP previously 
described in this chapter, autophagy related 16-like 1 (T300A) (Chapter 4.4), enhances 
the degradation of the ATG16L protein by caspase 3.1 Under certain conditions ATG16L  
is critical for negative regulation  of  inflammatory cytokines9  and the T300A  variant 
impacts IL-1β and IL-6  production. 10 
Characterizing the correlation of this SNP, which can directly impact the rate of 
autophagy in cells, with the two major oncogenes in melanoma BRAF and NRAS, should 
allow us to elucidate the role of autophagy in these important subtypes melanoma. For 
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this analysis, I used only single primary samples which had been genotyped for 
BRAF/NRAS status from GEM participants. In order to determine whether SNPs in ATG 
genes are associated with BRAF/NRAS mutations in melanoma patients, I used the 
procedures and premises listed in the previous part of this chapter to investigate 5 SNPs 
in 3 autophagy related genes in melanoma. 
4.10 Materials and Methods: 
4.10.1 Patient Characteristics:  
From the study of a population of  2,373 participants with single primary melanomas, we 
chose  602 genomic DNA samples were based on tumor availability (previously 
described in 4.3.1 and previously reported) 3 and compared ATG SNP frequencies with 
oncogene status.  
4.10.2 Clinical Stage:  
Previous described in 4.3.2 and summary characteristics were previous reported 3 
4.10.3 Selection of SNPs and Genotyping:  
5 SNPs in three critical ATG genes were selected from those identified with functional 
SNPs in the literature or that were associated with BRAF and NRAS status as previously 
described. DNA was isolated from buccal cells as previously described in 4.3.3.4,5 SNPs 
in ATG genes were characterized using Taqman Real-Time PCR Assays (ThermoFisher 
Scientific, Grand Island, NY) on a 7900HT Fast Real-Time PCR System (ThermoFisher 
Scientific, Grand Island, NY) following manufacture recommendations as previously 
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described in 4.3.3. The identification of ATG gene alleles were identified using the ratio 
of amplification fluorescence during the logarithmic phase generated from a 
commercially available Taqman primer assay on a 7900HT Applied Biosystems qPCR 
machine as previously described 4.3.3. Genomic DNA samples were chosen from those 
samples for single primary melanoma with sufficient DNA and tumor availability to 
allow for somatic analysis in future studies. 3  The genotyping call rate for the 602 chosen 
samples ranged was 98 to 100% and biological replicates were generated for 10% of the 
samples with 100% concordance. 
4.10.4 Data Analysis:  
Frequency tables were used to summarize the genotype distributions for each ATG SNP 
(see Table 2).  The association between SNPs and oncogene status were tested under the 
general genotypic inheritance (co-dominant) model allowing for simultaneous 
comparison of the heterozygous genotype versus wildtype, and homozygous minor 
genotype versus wildtype.  No assumptions were made on the model of inheritance, and 
the genotypes for each SNP were treated as a three-level nominal variable.  From this 
analysis we report a global p -value which represents the overall significance for our 
analysis as described previously. To evaluate the association between ATG SNPs and 
BRAF or NRAS status, we conducted logistic regression analyses. ORs and 95% 
confidence intervals estimated from the regression models were used to summarize the 
associations. Wald tests were used to assess the global significance of the association and 
statistical significance was two-sided and set at 5%.  
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4.11 Results: 
Five SNPs within ATG genes that have been previously reported associated with disease 
outcomes were genotyped and the result correlated with oncogene status. After 
adjustment for age, sex and study center, none of the 5 ATG gene SNPs were 
significantly associated with BRAF or NRAS status in melanoma participants. However 
the "A" allele of one SNP in ATG10 (rs1864182) showed a positive correlation with 
BRAF status although it did not retain significance at the global p-value (AC) (OR 1.79 
95%CI 1.12-2.87, p= 0.02) (AA) (OR 1.82 95%CI 1.06-3.12, p= 0.03).  This may be due 
to insufficient sample size as our power calculation was originally based on 795 samples. 
I was unable to obtain DNA for all 795 participants and information on BRAF NRAS 
status was unavailable for some tumors, resulting in decreased sample size.  
4.12 Discussion:  
In this study a SNP in ATG10 (rs1864182), while not significant at the global level, 
correlated with BRAF status in our melanoma participants. Of interest, the significance of 
both allelic specific models, one which examines the relationship between the 
heterozygous genotype versus wildtype, and homozygous minor genotype versus 
wildtype were both below .05 (p=0.02; p=0.03 respectively). Elevated expression of 
ATG10 in colon cancer has been shown to be associated with increased lymph node 
metastasis6 and previously this SNP has showed to be associated with increased IL-8 
production (p = 0.04).7 
Melanoma cells express a variety of cytokines, and their level of expression changes as 
melanoma progresses. 6 Early stage melanoma with lesions less than 1 mm Breslow 
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thickness exhibit low levels of cytokines including IL-8. 7 More advanced stage is 
associated with increased expression of pro-inflammatory cytokines IL-1α, β, IL-6, and 
IL-8. 7 The expression of IL-6 in particular has been associated with melanoma 
malignancy and its production has been associated with defective autophagy.8  Of 
interest, this particular SNP in ATG10 (rs1864182) was also previously reported to be 
associated with decreased breast cancer risk.8 Induced autophagy in breast cancer cells 
has been shown to result in autophagic regulated cell death.9 The impact of this SNP in 
the function of ATG10 remains to be elucidated. Analysis of the rate of autophagy 
associated with this SNP would provide insights into its association both with BRAF 
oncogene status as well as correlations with melanoma progression and survival. 
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4.14 Tables: 
4.14.1 Table 1: BRAF/ NRAS status by SNP genotype among melanoma cases* 
ATG SNP Genotype 
BRAF/ NRAS 
status 
OR (95% CI) p-value 
Wald 
p-value 
rs10514231 TT wt. 
 
1 [Reference] 
0.36 
rs10514231 CT BRAF* 1.36 (0.90-2.06) 0.15 
rs10514231 CC BRAF* 1.39 (0.77-2.50) 0.26 
rs10514231 CT NRAS* 1.37 (0.79-2.37) 0.27 
rs10514231 CC NRAS* 0.81 (0.34-1.92) 0.62 
rs1864182 CC wt. 
 
1 [Reference] 
0.09 
rs1864182 AC BRAF* 1.79 (1.12-2.87) 0.02 
rs1864182 AA BRAF* 1.82 (1.06-3.12) 0.03 
rs1864182 AC NRAS* 1.09 (0.61-1.95) 0.77 
rs1864182 AA NRAS* 0.78 (0.38-1.62) 0.51 
rs2241880 GG wt. 
 
1 [Reference] 
0.94 
rs2241880 AG BRAF* 0.97 (0.62-1.53) 0.90 
rs2241880 AA BRAF* 0.90 (0.53-1.53) 0.61 
rs2241880 AG NRAS* 1.17 (0.64-2.12) 0.70 
rs2241880 AA NRAS* 0.91 (0.45-1.86) 0.80 
rs2245214 TT wt.  
1 [Reference] 
0.57 
rs2245214 CG BRAF* 1.12 (0.75-1.68) 0.57 
rs2245214 CC BRAF* 0.89 (0.47-1.69) 0.73 
rs2245214 CG NRAS* 0.71 (0.41-1.21) 0.20 
rs2245214 CC NRAS* 0.93 (0.43-2.02) 0.86 
rs510432 TT wt.  
1 [Reference] 
0.38 
rs510432 CT BRAF* 1.12 (0.72-1.73) 0.63 
rs510432 CC BRAF* 1.03 (0.59-1.78) 0.93 
rs510432 CT NRAS* 0.86 (0.47-1.55) 0.61 
rs510432 CC NRAS* 1.51 (0.78-2.93) 0.22 
Genotypic model adjusted for age (continuous) sex, and study center. *Bold significance 
set p= 0.05 Abbreviations: OR, odds ratio; CI, confidence interval 
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4.14.2 Table 2: Power calculation for detecting oncogene status in 795 melanoma 
patients 
                                    Minimum detectable per-allele OR 
SNP Minor allele NRAS vs wt. BRAF vs wt. 
rs510432 0.447 1.75 1.53 
rs2241880 0.471 1.75 1.53 
rs10514231 0.359 1.76 1.55 
rs2245214 0.367 1.76 1.55 
    * sample size of 795 , 80% power and  5% significance level 
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5.1 Conclusions:   
My research offers insight into the interactions between BRAF/NRAS status, autophagy 
and melanoma. Despite new treatment options and therapies the long term survival rate 
for melanoma is stilllow.1  A common hypothesis has been that the autophagy pathway is 
upregulated early in tumorigenesis, suppressing cancer progression, but then the pathway 
is subverted and in later stages promotes tumorigencity.2,3 However, I have demonstrated 
at the cellular level that, particularly in late stage melanoma, oncogene status influences 
autophagy regulation. 
My research involves a broad approach. Starting with cell lines from metastatic 
melanoma patients, moving to melanoma and benign nevus tissues of patients in a pilot 
study, and finally to a larger study of melanoma patients at the population level, I have 
examined the complex relationship between melanoma, autophagy and the oncogenes 
that characterize a majority of melanoma tumors. Using this broad approach, I have 
identified dependence in metastatic BRAF* mutant cell lines on autophagy. In addition, in 
NRAS* cell lines I identified that these cells have the ability to utilize the autophagy 
pathway in response to serum starvation or chemical induction but they are not 
upregulating this process for survival under basal conditions. In addition, the data 
supporting the concept that BRAF* melanoma cancer cells are more susceptible to 
autophagic inhibition suggest that constitutively activated BRAF* selectively upregulated 
autophagy. The way in which autophagy is upregulated beyond the activation of the 
MAPK pathway remains to be elucidated, but this research suggests there is an important 
connection between the tumorigenicity of BRAF* melanoma and autophagy. My research 
also identifies the important but subtle finding that NRAS* melanoma cells appear less 
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dependent autophagy for survival at later in later stage. This differential activation of the 
autophagy pathway suggests that these two oncogenes, which mutually signal through the 
MAPK pathway, are interacting with other proteins to regulate autophagy. This finding is 
not counter intuitive as the uncoupling of mutant NRAS signaling from BRAF, and 
subsequent preferential signaling through CRAF has been previously reported.4 Still the 
role of autophagy in NRAS mutant melanoma etiology presents an area for additional 
research.  
The relationship between autophagy regulation and melanoma was also investigated in 
melanoma and control tissue sections showing that high Beclin1 expression was 
associated with decreased Breslow thickness potentially implying a tumor suppressive 
effect.  LC3 levels correlated with decreased melanoma specific mortality.  Of note my 
research also identified a gender specific association in the melanoma patients. Females 
in our sample population were more likely to have high Beclin1 expression in their tumor 
tissue sections.  This is a particularly stimulating observation as female melanoma 
patients exhibit longer survival over male melanoma patients with similar stage.5 If 
Beclin1 is acting as a tumor suppressor in melanoma, the higher levels of this protein 
may also have prognostic implications. 
Further, evaluation of UV exposure in melanoma tissue sections identified that certain 
outdoor activities, indicated consistent UV exposure, and were associated with 
upregulated autophagy. Melanoma participants reporting blistering sunburn were more 
likely to have elevated Beclin1 expression while high LC3 was associated with a lack of 
blistering sunburns. At first this finding may seem counter intuitive for a potential role 
for Beclin1 as a tumor suppressor. However, previous studies have shown an inverse 
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correlation between sunburn and death from melanoma.6 If Beclin1 is acting to suppress 
tumorigenesis following UV exposure this interaction may help to clarify the complex 
between relationships between sun exposure and melanoma progression. 
Interestingly, Beclin1 expression was not associated with NRAS mutant or BRAF mutant 
status in our analysis. While there may be no direct relationship between Beclin1 
expression and these oncogenes, another possible reason I did not identify a relationship 
between Beclin1 expression and BRAF or NRAS status might be due to low statistical 
power. We did see a borderline significance with the melanoma histological subtype, 
superficial spreading melanoma, that is more commonly associated with BRAF mutant 
melanoma but additional investigations will be necessary to clarify this relationship. 
LC3 expression is generally accepted as a proxy marker for the rate of autophagy and, 
interestingly, in our sample population high LC3 was correlated with decreased 
melanoma specific mortality. When I examined the interactions between mortality and 
LC3 compared to the interaction of mortality with either Beclin1 or Beclin1 combined 
with LC3, it was clear that LC3 protein expression alone in this model is associated with 
decreased mortality. As punctate LC3 in cases was significantly associated with LC3 
expression in cases, this potentially indicates an increase in the number of 
autophagosomes present in these patients. To add to the complexity, while BRAF and 
NRAS status were not significantly associated with LC3 expression, high cytosolic LC3 
expression correlated with wildtype status in our population genotype. The presence of 
high levels cytosolic of expression, coupled with the lack of punctate LC in these 
participants potentially indicates deacetylation of  LC3, which has been reported to 
increase LC3s expression in the cytoplasm.7 This would indicate that LC3 has been 
 
 
191 
 
primed for autophagy induction in the tissue of our non-oncogenic samples but that 
autophagosome formation may be impaired or inhibited as indicated by the absence of 
punctate LC3. The reasons for this association remain unclear and require additional 
investigation. In addition, while not significant, high LC3 expression was also associated 
with prolonged sun exposure on unprotected skin, boating activities and any outdoor 
activity sun exposure. This indicates a role for UV exposure with autophagy activation as 
evidenced by the high LC3 expression.   Ultimately my results indicated that autophagy 
proteins vary by tumor stage and their expression is associated with UV exposure. My 
research  also indicate that the expression of Beclin1 and LC3 could be beneficial as 
prognostic indicators and that elevated level of these two proteins may support the 
maintenance of a more indolent melanoma phenotype. 
In the final study of this project, I identified SNPs associated with markers of 
melanoma progression. To date, there are no other studies investigating the impact of 
ATG gene SNPs in melanoma progression and survival. While the association between 
oncogene status and these SNPs was not significant at a global p level, the linear 
correlation between BRAF status and a SNP in ATG10 was significant for the allelic 
model. This analysis could benefit from additional studies using increased sample size to 
ensure sufficient power in order to adequately evaluate this correlation. In addition, I 
identified three ATG SNPs (rs2241880, rs510432, rs2245214) that were associated with 
prognostic indictors in melanoma. The SNP in ATG16L (rs2241880) creates a cleavage 
site that results in the degradation of ATG16L and an overall decrease in the rate of 
autophagy. This variant was associated with better prognostic indicators including 
Breslow thickness, decreased stage and a younger age of melanoma diagnosis. This may 
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indicate that reduced levels of ATG16L are associated with less aggressive melanoma. In 
addition, two other SNPs in another autophagy related gene ATG5 (rs2245214 and 
rs510432) were associated with increased stage of melanoma. Of particular interest, the 
rs510432 SNP located in the ATG5 promoter has been associated with an increased rate 
of autophagy.8 This data would appear to suggest that increased levels of ATG, 
potentially resulting in increased rates of autophagy, is associated with more aggressive 
stage in melanoma. The apparent contrary nature of these two findings implies that, 
beyond the impact of these genetic factors that could be modulating disease severity, 
other factors are regulating autophagy potentially including UV exposure.  Throughout 
this study, several important interactions have been elucidated implicating the 
interactions between oncogenes and the autophagy pathway as impacting melanoma 
progression and survival. Overall, my results support the literature indicating the dual 
role of autophagy, acting tumor suppressive in earlier stages and tumor promoting, 
particularly in mutant BRAF melanomas as the tumor progresses. Autophagy, as 
represented by the proxy marker LC3, is upregulated in mutant BRAF melanoma cells 
compared to NRAS. This is also consistent with high levels of autophagy being associated 
with late stage BRAF tumor cells.  
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As shown at the individual level in melanoma tissue sections, and supported by the 
literature, high levels of autophagy are associated with earlier prognostic indictors 
suggesting that autophagy may be tumor suppressive in earlier stages of melanoma 
development. This is particularly true as Beclin1, which was associated with many 
positive prognostic indicators in my study, has tumor suppressive roles in many cancers. 
Finally at the population level my results indicated that decreased lifelong autophagy, 
resulting from the degradation of an important autophagy related protein (Atg16L), was 
associated with better prognosis, while increased autophagy, resulting from upregulation 
of the promoter of an important ATG gene (ATG5), was associated with increased 
melanoma stage.  
Overall my results indicate that dysregulation of autophagy can impact melanoma 
progression. 
 
5.2 Future studies: 
My research has broad implications for melanoma and cancer research as a whole. 
With a demonstrated but context specific impact of UV exposure and oncogene status on 
autophagic regulation, coupled with interactions with SNP in ATG genes potentially 
modifying melanoma progression and survival, this data builds knowledge applicable to 
the many autophagy associated diseases.  This knowledge suggests several future 
directions. 
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The differential activation of the autophagy pathway suggests that these two 
oncogenes, BRAF and NRAS, which mutually signal through the MAPK pathway, are 
interacting with other proteins to regulate autophagy. This finding is not counter intuitive 
as the uncoupling of mutant NRAS signaling from BRAF, and subsequent preferential 
signaling through CRAF has been previously reported.4 NRAS mutant cell lines have the 
ability to use the autophagy pathway in response to nutrient deprivation but mutant NRAS 
signaling of MAPK preferentially through CRAF appears to occur without the support of 
the autophagy pathway at least under basal condition. The cyclic AMP pathway (cAMP), 
which is inhibited in NRAS- mutant melanomas compared to BRAF oncogenic 
melanomas, has been reported to have a role in autophagy.4 BRAF signaling through 
cAMP has been reported to upregulate the autophagy initiating protein Beclin 1. Further 
characterization of this interaction, including the impact of oncogenic BRAF on Beclin1 
as well as the role of cAMP in autophagy and how these interaction impacts melanoma 
progression would help to clarify the biological regulation of autophagy. As I have stated 
the importance of Beclin1 warrants further investigation in melanoma. It has already been 
reported that the generation of Vitamin D3, following UV exposure, enhances the 
expression of Beclin-1 resulting in increased autophagy. 9 This interaction between UV 
exposure and a potential tumor suppressive role for Beclin1 could be characterized using 
clinical markers for sun exposure including serum Vitamin D levels and histopathological 
data from patients whose BRAF NRAS status has been established.  
In addition, there is data implicating high rates of autophagy as a mechanism of 
acquired resistance to BRAF mutant inhibitors including vemurafenib.10 This data 
supports the need for clinical studies in which autophagy inhibition is combined with 
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oncogene specific therapies in order to overcome resistance. However the effect of these 
combinations on different stages of melanoma is not clear. As our data have shown there 
remains a complex balance between the tumor suppressive effects of autophagy, 
particularly by Beclin 1, and the tumorigenic metabolic support provide by this pathway. 
Functional studies are needed in order to further characterize the anticipated outcome of 
these combination therapies.  The use of cell lines to characterize these interactions 
further would allow for some clarification of these relationships. Ultimately, the use of 
animal models would be beneficial for determining how the modulations of these 
proteins, as well as the impact of UV exposure, has on autophagy and melanoma 
progression and would allow for refinement in our understanding of these complex 
systems. 
In addition, in order to further investigate the correlations we identified in this study, 
autophagy SNPs should be functionally evaluated and it should be established what, if 
any linkage disequilibrium is present between these and other SNPs. At the present time, 
many novel and exciting therapies are in clinical trials and some, including CTLA-4 and 
PD-1/PD-L1 blockade, are showing promise for durable  impact on survival and 
ATG16L and ATG5 have both been shown to impact cytokine production in disease.8,11–
13 It is also important to note that focused my investigation on 5 SNPs in 3 genes. There 
are currently 38 ATG genes identified and the impact of variants in any of the other 
critical autophagy genes has not been established for melanoma progression or survival.  
Research characterizing deep sequencing and epigenetic changes including methylation 
patterns, could help to characterize the impact of the SNPs identified in this research. 
Finally, functional studies designed to evaluate the impact of the SNPs investigated in 
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this study as a well other ATG gene SNPs on cytokines production and autophagy 
regulation will provide insights into the relationship between autophagy and melanoma 
progression. 
5.3 Overall conclusions and perspectives: 
 
This dissertation has presented data suggesting that the relationships between 
autophagy, melanoma and oncogene status are complex and that careful examination of 
these interactions will be pivotal in the successful application of autophagy inhibitors for 
melanoma co-therapy. In particular, the dependence of BRAF mutant cell lines on 
autophagy to suppress apoptosis as well as the relationship between SNPs and melanoma 
clinical characteristics has important implications for understanding the etiology and 
progression of this disease. Factors impacting the rate of autophagy including SNPs and 
UV exposure interact with oncogenic differences to impact the melanoma progression 
and survival.   
These findings have important repercussions in beyond melanoma. First, there are 
other diseases where the autophagy pathway plays a critical role including in 
cardiovascular, neurodegenerative, infectious, and metabolic diseases and the data 
present in this research may inform biological mechanisms in those diseases as well.  
In addition, epidemiological studies can be used to identify unique interactions 
between independent and complex variables, including autophagy and UV exposure, in 
order to provide insights into melanoma. The use of large population studies when 
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properly modelled, allows for the statistical power to examine interactions between 
multiple SNPs, exposure variables and clinical characteristics. 
 Importantly, these results have implications for the interaction of the autophagy 
pathway in disease, particularly, where oncogenes have a critical developmental role. 
Overall, this data indicates that while BRAF cells may be dependent on autophagy for 
survival, and that the expression of Beclin1 and LC3 may support a more indolent 
melanoma phenotype. This suggests that the role of autophagy, as well as its interactions 
with other mitigating factors, should be carefully considered before inhibition of 
autophagy is used universally in melanoma treatment. 
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